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Chapter 1 
General introduction,  







Sudden cardiac death, mainly caused by ventricular arrhythmias (VA) in a population with 
coronary artery disease, is a major cause of mortality in the western world. In the United States 
alone, the annual incidence of sudden cardiac death varies from 200.000 to 450.000 of which 
most fatal events occur outside the hospital.1 Since the prevention of these events has always been 
difficult, Mirowski and co-workers developed the implantable cardioverter defibrillator (ICD) 
and in 1980 the first ICD was implanted in a human.2 Initially, the ICD was thought to be a 
treatment of last resort for the prevention of sudden cardiac death. Soon it became clear that, if it 
would be possible to identify patients at risk, it would be the treatment of choice for patients at 
high risk for life-threatening arrhythmias.3 In 1984, 4 years after the first human implant, the first 
ICD was implanted in the Netherlands at the University Medical Centre Utrecht.  
The first ICDs were large (8 cm x 11.5 cm, 170 cm3) and heavy (280 g). These devices 
required open chest surgery and the device was implanted in the abdomen. Needless to say that 
these procedures were associated with a high rate of complications.4 Algorithms for the detection 
of potentially life-threatening VA were limited and the occurrence of inappropriate device 
therapy was frequent.5 At that time, ICD therapy was not generally accepted and considered 
unethical and even in-human by many. Despite the high failure rate of drug therapy, many 
physicians preferred treating their patients with antiarrhythmic drugs. Large secondary and 
primary prevention trials demonstrating the efficacy of ICD therapy were necessary to stimulate a 
wider use and to increase patient's acceptance. Furthermore, first generation devices were rather 
bulky and many improvements in size and weight, arrhythmia discrimination, battery technology, 
shock waveform and output, monitoring capabilities, and defibrillator electrode technology were 
necessary to allow the current large scale yearly implantations. However, the first human 
implants marked the start of a new way of treating patients at risk of dying suddenly. In other 




Major secondary and primary prevention trials 
Initially, to be eligible for ICD treatment, patients had to survive at least one episode of life-
threatening VA such as ventricular fibrillation (VF) or ventricular tachycardia (VT) (secondary 
prevention). In other words, all patients treated with ICD therapy were out of hospital cardiac 
arrest survivors. In the 1990s three large trials proved the effectiveness of ICD therapy for the 
secondary prevention of arrhythmic death: the Antiarrhythmics Versus Implantable Defibrillator 
study (AVID),6 the Canadian Implantable Defibrillator Study (CIDS)7 and the Cardiac Arrest 
Study Hamburg (CASH) (Table 1).8 The AVID trial enrolled patients who had survived a cardiac 
arrest or with documented sustained VAs. Patients were randomized to either amiodarone therapy 
or ICD treatment and the primary endpoint was all-cause mortality. The results showed a 
reduction in all-cause mortality of 28% in the defibrillator group.6 The CIDS trial had a similar 
design and showed a 20% reduction in mortality in the ICD group, compared with amiodarone 
treatment.7 Finally, the CASH trial enrolled patients who survived an episode of cardiac arrest 
and randomized to either ICD therapy or antiarrhythmic drug therapy, showing a mortality 
reduction of 23% in the ICD group.8 A meta-analysis of these three trials by Connolly et al., 
demonstrated a significant 28% reduction in all-cause mortality in the ICD treated group. The 
results of these studies led to the acceptance of ICD therapy for the secondary prevention of 
sudden arrhythmic death.9 However, acceptance rate in Europe was much lower than in the 
United States. 
 Since the survival rate of an episode of cardiac arrest is at best only 8%, the impact of 
secondary prevention ICD therapy on population mortality will be low.10 Therefore focus shifted 
from secondary prevention to the identification of patients at risk of life-threatening VAs without 
a prior arrhythmic event. Large randomized trials tested the hypothesis that ICD treatment was 
beneficial in selected patients, prior to cardiac arrest or sustained VT (primary prevention) (Table 




Table 1. Clinical features and results of 3 major secondary prevention ICD trials  
Trials	   AVID6	   CIDS7	   CASH8	  
Sample	  size	   1016	   659	   288	  
Design	   ICD	  vs	  
antiarrhythmic	  drugs	  
ICD	  vs	  amiodarone	   ICD	  vs	  amiodarone	  
vs	  metoprolol	  
Patients	   Resuscitated	  from	  	  
near-­‐fatal	  VF	  or	  
postcardioversion	  	  
from	  sustained	  VT	  




Survivors	  of	  cardiac	  




Follow-­‐up	  (months)	   18	   36	   57	  
Primary	  end	  point	   All-­‐cause	  mortality	   All-­‐cause	  mortality	   All-­‐cause	  mortality	  
Results	   	   	   	  
Risk	  reduction	  with	  
ICD	  
28%	  (P	  =	  .0.02)	   20%	  (P	  =	  .14)	   23%	  (P	  =	  .08)	  
AVID = Antiarrhythmics versus Implantable Defibrillators; CASH = Cardiac Arrest Study 
Hamburg; CIDS = Canadian Implantable Defibrillator Study; ICD = implantable cardioverter 
defibrillator; VF = ventricular fibrillation; VT = ventricular tachycardia. 
 
 
Trial (MADIT). This study enrolled patients with a prior myocardial infarction, left ventricular 
ejection fraction (LVEF) less than 35%, documented nonsustained VT and inducible, non-
suppressible VT on electrophysiological study. Patients were randomized to receive either 
amiodarone therapy or an ICD and, after the inclusion of 196 patients and with 27 months follow-
up, the study demonstrated a 54% reduction in mortality in the ICD group.11 Despite these 
findings, controversy about the study design remains. There was no registry of screened patients 
as in AVID, a high percentage discontinued taking amiodarone and the ICD treated population 
showed a disproportionately higher use of β-blockers. The prevailing consensus was that more 
data were needed to support the MADIT findings. Therefore, the results of this study were not 
adopted in the guidelines until the results of the Multicenter Unsustained Tachycardia Trial 
(MUSTT) were published.12 MUSTT enrolled patients with coronary artery disease, LVEF less 
than 40%, documented nonsustained VT and inducible, non-suppressible VT on 
electrophysiological study and the survival rate was comparable with MADIT. Further analysis of 




an LVEF of less than 26%.13 These and other observations from the MADIT trial resulted in a 
simplified design and a new study. The MADIT II trial randomized patients with a history of 
myocardial infarction and an LVEF less than 30% to either ICD therapy or no ICD without the 
requirement of additional electrophysiological testing and reported a 31% reduction for mortality 
in patients treated with an ICD.14 A meta-analysis of 10 primary prevention trials by 
Nanthakumar et al., demonstrated a significant 25% reduction in all-cause mortality in the ICD 
treated patients. Consequently, these findings led to the inclusion of primary prevention ICD 
treatment in the current guidelines (Table 3). 
 
 
 Table 2. Clinical features and results of 4 primary prevention ICD trials  
Trials MADIT11 MUSTT12 MADIT II14 SCD-HeFT37 
Sample size 196 704 1232 2521 




EP-guided therapy vs 
placebo 
ICD vs optimal 
pharmacologic 
therapy 
ICD vs optimal 
pharmacologic 










Coronary disease, EF 
≤0.40, nonsustained 
VT, inducible VT at 
EPS 








27 39 20 46 




54% (P = .001) 51% (P = .001) 31% (P = .02) 23% (P = .007) 
EP = electrophysiology; EPS = electrophysiology study; ICD = implantable cardioverter 
defibrillator; MADIT = Multicenter Automatic Defibrillator Implantation Trial; MI = myocardial 
infarction; MUSTT = Multicenter Unsustained Tachycardia Trial; nsVT = nonsustained 
ventricular tachycardia; SCD-HeFT = Sudden Cardiac Death in Heart Failure Trial; VT = 





Table 3. Guidelines for implementation of implantable cardioverter defibrillators. 
	   Class	  1	   	  
1.	   ICD	  therapy	  is	  indicated	  in	  patients	  who	  are	  survivors	  of	  cardiac	  arrest	  
due	  to	  VF	  or	  hemodynamically	  unstable	  sustained	  VT	  after	  evaluation	  to	  
define	  the	  cause	  of	  the	  event	  and	  to	  exclude	  any	  completely	  reversible	  
causes.	  
LoE:	  A	  
2.	   ICD	  therapy	  is	  indicated	  in	  patients	  with	  structural	  heart	  disease	  and	  
spontaneous	  sustained	  VT,	  whether	  hemodynamically	  stable	  or	  unstable.	  
LoE:	  B	  
3.	   ICD	  therapy	  is	  indicated	  in	  patients	  with	  syncope	  of	  undetermined	  origin	  
with	  clinically	  relevant,	  hemodynamically	  significant	  sustained	  VT	  or	  VF	  
induced	  at	  electrophysiological	  study.	  
LoE:	  B	  
4.	   ICD	  therapy	  is	  indicated	  in	  patients	  with	  LVEF	  less	  than	  or	  equal	  to	  35%	  
due	  to	  prior	  MI	  who	  are	  at	  least	  40	  days	  post-­‐MI	  and	  are	  in	  NYHA	  
functional	  Class	  II	  or	  III.	  
LoE:	  A	  
5.	   ICD	  therapy	  is	  indicated	  in	  patients	  with	  nonischemic	  DCM	  who	  have	  an	  
LVEF	  less	  than	  or	  equal	  to	  35%	  and	  who	  are	  in	  NYHA	  functional	  Class	  II	  or	  
III.	  
LoE:	  B	  
6.	   ICD	  therapy	  is	  indicated	  in	  patients	  with	  LV	  dysfunction	  due	  to	  prior	  MI	  
who	  are	  at	  least	  40	  days	  post-­‐MI,	  have	  an	  LVEF	  less	  than	  or	  equal	  to	  30%,	  
and	  are	  in	  NYHA	  functional	  Class	  I.	  
LoE:	  A	  
7.	   ICD	  therapy	  is	  indicated	  in	  patients	  with	  nonsustained	  VT	  due	  to	  prior	  MI,	  
LVEF	  less	  than	  or	  equal	  to	  40%,	  and	  inducible	  VF	  or	  sustained	  VT	  at	  
electrophysiological	  study.	  
LoE:	  B	  
ARVD/C = arrhythmogenic right ventricular dysplasia/cardiomyopathy; DCM = dilated 
cardiomyopathy; HCM = hypertrophic cardiomyopathy; ICD = implantable cardioverter 
defibrillator; LoE = Level of Evidence; LVEF = left ventricular ejection fraction; LV = left 
ventricular; MI = myocardial infarction; NYHA = New York Heart Association; SCD = sudden 



















Table 3. Guidelines for implementation of implantable cardioverter defibrillators. 
	   Class	  IIa	   	  
1.	   ICD	  implantation	  is	  reasonable	  for	  patients	  with	  unexplained	  syncope,	  
significant	  LV	  dysfunction,	  and	  nonischemic	  DCM.	  
LoE:	  C	  
2.	   ICD	  implantation	  is	  reasonable	  for	  patients	  with	  sustained	  VT	  and	  normal	  
or	  near-­‐normal	  ventricular	  function.	  
LoE:	  C	  
3.	   ICD	  implantation	  is	  reasonable	  for	  patients	  with	  HCM	  who	  have	  1	  or	  more	  
major†	  risk	  factors	  for	  SCD.	  
LoE:	  C	  
4.	   ICD	  implantation	  is	  reasonable	  for	  the	  prevention	  of	  SCD	  in	  patients	  with	  
ARVD/C	  who	  have	  1	  or	  more	  risk	  factors	  for	  SCD.	  
LoE:	  C	  
5.	   ICD	  implantation	  is	  reasonable	  to	  reduce	  SCD	  in	  patients	  with	  long-­‐QT	  
syndrome	  who	  are	  experiencing	  syncope	  and/or	  VT	  while	  receiving	  beta	  
blockers.	  
LoE:	  B	  
6.	   ICD	  implantation	  is	  reasonable	  for	  non	  hospitalized	  patients	  awaiting	  
transplantation.	  
LoE:	  C	  
7.	   ICD	  implantation	  is	  reasonable	  for	  patients	  with	  Brugada	  syndrome	  who	  
have	  had	  syncope.	  
LoE:	  C	  
8.	   ICD	  implantation	  is	  reasonable	  for	  patients	  with	  Brugada	  syndrome	  who	  
have	  documented	  VT	  that	  has	  not	  resulted	  in	  cardiac	  arrest.	  
LoE:	  C	  
9.	   ICD	  implantation	  is	  reasonable	  for	  patients	  with	  catecholaminergic	  
polymorphic	  VT	  who	  have	  syncope	  and/or	  documented	  sustained	  VT	  
while	  receiving	  beta	  blockers.	  
LoE:	  C	  
10.	   ICD	  implantation	  is	  reasonable	  for	  patients	  with	  cardiac	  sarcoidosis,	  giant	  
cell	  myocarditis,	  or	  Chagas	  disease.	  
LoE:	  C	  
ARVD/C = arrhythmogenic right ventricular dysplasia/cardiomyopathy; DCM = dilated 
cardiomyopathy; HCM = hypertrophic cardiomyopathy; ICD = implantable cardioverter 
defibrillator; LoE = Level of Evidence; LVEF = left ventricular ejection fraction; LV = left 
ventricular; MI = myocardial infarction; NYHA = New York Heart Association; SCD = sudden 
cardiac death; VT = ventricular tachycardia; VF = ventricular fibrillation. 
 
 
Cardiac Resynchronization Therapy-Defibrillator 
Congestive heart failure (CHF) is associated with decreased hemodynamic function, exercise 
tolerance and quality of life due to poor left ventricular systolic or diastolic function. 
Furthermore, patients with CHF are at increased risk for sudden cardiac death (SCD). As already 
discussed, ICD treatment in CHF patients resulted in improved outcome and a reduction in all-
cause mortality.15 In a significant number of patients, left ventricular failure is associated with 
conduction disturbances causing mechanical dyssynchrony. Ventricular dyssynchrony further 
contributes to the already impaired left ventricular function. Electrical cardiac resynchronization 




electrical disturbance. Recent years, numerous randomized and observational studies 
demonstrated that CRT may improve functional status, quality of life and may even lower 
mortality.16 It was therefore a logical step to combine CRT with ICD therapy (CRT-D). The first 
CRT implantations in the Netherlands were performed in Utrecht by thoracic surgeon Dr. Bakker 
and her team. In 1994, Cazeau et al were the first to report on the benefit from CRT in CHF 
patient. This study tested the safety and efficacy of multisite pacing in patients with heart failure. 
Significant improvements in exercise tolerance, New York Heart Association (NYHA) class and 
quality of life were noted. In 2003, the COMPANION trial was the first to randomize between 
optimal medical therapy, optimal medical therapy and CRT and optimal medical therapy and 
CRT-D. CRT-D reduced mortality with 36% in comparison with standard therapy, whereas CRT 
alone resulted in a 20% reduction in mortality.15 Other studies (CARE-HF) demonstrated that 
CRT alone had the same effect on mortality as CRT-D in the COMPANION trial. Recently, the 
Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy 
(MADIT-CRT) enrolled patients with NYHA class I or II, QRS duration ≥ 130 ms and LVEF ≤ 
30%. Patients were randomized to ICD therapy alone or to ICD therapy with CRT. The primary 
end-point was a composite of all-cause mortality and nonfatal heart failure and during follow-up 
17% in the CRT-D group and 25% in the ICD group reached the primary end-point. It was 
concluded, that the incidence of all-cause mortality and nonfatal heart failure was significantly 
reduced when CRT was added to ICD therapy.16   
 
The Device  
The first ICD, developed in the 1970s, was large and heavy, could not be programmed, used 
epicardial patch electrodes, had no telemetry capabilities and required a thoracotomy for the 
implantation of the epicardial lead system. ICD implantation procedures were major surgical 




years, many improvements have been made. Current devices are relatively small, can be 
implanted subcutaneously in the majority of cases and are connected to an endocardial lead 
system. Furthermore, more and more functions became available and most modern devices can be 
connected to a telemonitoring system allowing remote follow-up. Nevertheless, the basic 
components of current generation ICDs do not differ from the first generation ICDs. 
Improvements were made in battery, capacitor, leads, microprocessors and resulted in a rapid 
evolution of ICD technology.17 Furthermore, reductions in size and weight were made, whereas 
former devices were large and heavy, current devices are small and light (about 113 gr, < 5 cm 
wide and a thickness of 1,25 cm) (Figure 1 and 2). 
 
 





Figure 2: Example of pectoral implanted CRT-D system in 42-year old male 
 
 
Components and function  
An ICD contains a battery, a capacitor to store and deliver charges, a microprocessor and 
integrated circuits for electrogram sensing, data capture, storage and control of therapy delivery, a 
header to connect the endocardial leads used for sensing-, pacing, and defibrillation (Figure 3). 
Furthermore, the devices have extensive telemetry function for device programming and data 
retrieval. All these components together are called a pulse generator and are encased in a titanium 
can. The collaboration of these components results in the essential features of ICD function, 
including sensing, detecting and classification of tachyarrhythmias, delivering therapy 
(ventricular defibrillation or antitachycardia pacing), monitoring heart rhythm after therapy, and 
storage of episodes. In this process, the sensing function determines the depolarization sequences 
of each atrial and ventricular depolarization and the detecting function classifies the rhythm by an 






Figure 3: Exploded view of an ICD. 
 
 
The device implanted in the 1980s, called the automatic implantable cardiac defibrillator, 
was designed only to recognize and terminate VF by delivering a high energy shock.2 These early 
devices could not detect unstable VTs which could degenerate into VF, and because these devices 
lacked programmability, separate pacemakers were required to allow backup bradycardia pacing, 
leading to dangerous interactions.18 Development of second generation devices facilitated 
bradycardia pacing capabilities and were (minimally) programmable. Especially the bradycardia 
pacing capability was important as it ended the need for separate pacemakers. Additionally, these 
devices had a limited telemetry function used to test battery strength and simply note the number 
of delivered shocks. For this telemetry function, an external monitoring device was needed. In the 
next decade, many improvements were made and in the early 1990s the first so-called third 




well as low energy shocks for terminating VTs, extensive programmability and telemetry 
functions.19 Current devices can be programmed into 3 or even 4 different cycle length related 
zones and different schemes of antitachycardia pacing, shock or a combination of both can be 
programmed. With these advancements in third generation devices programmability, current 
devices exhibited improved arrhythmia discrimination.  
 
Battery and capacitor 
First generation devices used capacitor and battery technology originally developed for camera 
flashes. The device contained cylindrical aluminum electrolytic capacitors and silver vanadium 
pentoxide batteries for rapid charge time and the delivery of high voltage shocks.17 Nowadays, 
Lithium-silver vanadium manganese oxide batteries are used which resulted in an increase of the 
service life of an ICD. Some models use two batteries connected in series to minimize the time 
between arrhythmia detection and therapy and thereby reducing the charge time by a few seconds 
and improving patient safety. However, this reduction in charge time is accompanied with an 
undesirable increase in ICD size, since the sizes of the battery and capacitor are the major 
determinants of the size of the ICD. Additionally, the capacitor charge time will expand and 
worsen during service life. Therefore, it is important to develop capacitors which require a 
minimum of stored energy but still deliver enough energy for defibrillation without affecting the 
ICD service life.20 
 
Leads  
The large first generation devices were implanted abdominally and needed thoracotomy to place 
the lead system. The lead system which was used contained a spring patch and apical cup. The 
second generation devices eliminated thoracotomy by the introduction of transvenous leads in 




transformed from open chest surgery to a procedure performed in the electrophysiology 
laboratory.21 Further research evaluated the safety and efficacy of subcutaneous ICD implantation 
performed entirely by electrophysiologists and demonstrated a high success rate, low 
complication occurrence, and short implantation time and made subcutaneous ICD implantation 
in the electrophysiology laboratory the method of choice.  
Besides improvements in the implantation procedures, improvements were made in the 
construction of the leads. Technical improvements in the construction are important for the 
efficient detection and termination of arrhythmias. Two different kind of leads are implanted, the 
coaxial lead design (Figure 4, left) in the first and second generation devices and the multilumen 
lead design (Figure 4, right) in third generation devices.22 The coaxial lead has a layered design 
composed of a tip conductor, ring conductor and defibrillation conductor and an insulation layer 
between each conductor. The multilumen lead construction is based on parallel running 
conductors through a single insulating body. Tip and ring conductors are used for pacing and 
sensing, a defibrillation conductor for the coil located in the right ventricle and a defibrillation 
conductor for the coil located in the superior vena cava. The insulating body contains extra 
lumens to increase lead’s resistance to compression forces. The major advantage of multilumen 
over coaxial leads is the fact that more conductors will fit into overall smaller leads.22 
Besides improvements in the implantation procedures and in the construction of leads, 
lead failure occurs frequently. Due to the different design and materials which are used, longevity 
of current implanted leads may differ significantly. Borleffs et al. evaluated the survival and 
failure rate in a large number of defibrillation leads implanted over a 16-year period.23 The 
implanted leads were produced by different manufacturers and different lead diameters were 
used. Defibrillation leads characterized by a small diameter body have several alleged 
advantages: it simplifies the implantation procedure, it maintains the venous blood flow and 




among different groups and showed an overall 10 years lead survival rate of 73%. Based on these 
findings it is important to carefully select the type of leads which are used for each patient and to 
optimize future lead performance.23   
 
 
Figure 4: Cross section of coaxial lead construction of a single coil defibrillation lead with true 




Since the first implantation in 1980, worldwide implantation rates have increased and, therefore, 
the number of ICD replacements is expected to increase dramatically. Most of the replacements 
are due to end of service life (battery depletion) and every implantation or replacement brings a 
substantial risk of complications and negatively influences patients’ quality of life. The major 
determinant of ICD longevity is the capacitor and therefore the ICD size. Hauser compared the 
cumulative survival of patients implanted with an ICD with ICD longevity. The probability of a 
patient living 4, 5 and 6 years after implantation was 79%, 75% and 68% respectively. 
Furthermore, the study suggested that if an ICD had 10 service years, the majority of patients 




batteries with longer service life. However, this will impact patients acceptance and possibly 
cause more pocket related problems due to the larger volume of the devices. Furthermore, 
because of the fast development of new ICD features it will sometimes be questionable if it is 
really desirable to implant devices with a projected longevity of 10 or more years. Replacement 
of the currently used Lithium-silver vanadium oxide batteries with large-capacity batteries can 
increase service life by 2.3 years.24 These large-capacity batteries increase the size and weight of 
the device and are in conflict with downsizing the device as the market forces.  
 
Algorithms and rhythm discrimination  
First generation devices were designed to detect VF only by wave-form analyses. The standard 
wave-form analyses used to identify cardiac rhythm was the rate of R waves. Due to the 
limitations of wave-form analyses only, inappropriate therapy occurred frequently, since episodes 
of supraventricular tachycardia with fast ventricular response could be classified as VT or VF and 
cause inappropriate shocks.5 The first detection criterion in all current devices is the signal rate 
recorded by the right ventricular lead. In order to confirm a ventricular tachyarrhythmia, a 
specified number of sensed events must occur at a higher rate than the cut-off rate.   
To improve specificity in discriminating between VT or supraventricular tachycardia, 
various algorithms have been developed. As mentioned previously, current ICDs can be 
programmed into 3 different cycle length related zones and the discriminative detection 
algorithms can be programmed in the 2 lowest zones. The highest programmable zone is meant 
for detection of fast VT or VF without any further discrimination to avoid unnecessary therapy 
delivery delay. Single chamber devices use algorithms to discriminate rhythms, comparing 
morphology of the arrhythmia with the morphology of baseline sinus rhythm, the rate of onset of 
arrhythmia and rhythm regularity. Dual chamber devices can use additional information retrieved 




All currently available algorithms have some known limitations like false positive and 
false negative therapy delivery decisions but by combining some of these algorithms, the amount 
of inappropriate inhibition or therapy delivery can be further reduced. The complexity and 
combination of algorithms which can be used depends on power requirements of the ICD. Since 
downsizing the ICD is an important goal, larger batteries which can provide the power 
requirements for complex algorithms are not used. These constraints reduce the use of more 
complex algorithms and despite advances in algorithms, inappropriate therapy still occurs.25  
 
Future developments 
Many marked improvements were made since the first implantation in 1980.2 Despite 
developments in sophisticated algorithms the inappropriate shock rate is still high. Patients with 
inappropriate shocks experience diminished quality of life, can even develop symptoms such as 
“phantom shocks”, and inappropriate therapy can initiate new arrhythmias which may even be 
life threatening.26 Technologies that eradicate the occurrence of inappropriate shocks are not 
developed yet.  
 
Need for clinical follow-up 
Normally, patients are clinically followed-up every 3 to 6 months, although the majority of these 
visits involve data collection only and do not require any further action to be undertaken. To 
decrease office time, a mechanism for intensive device surveillance without the consequent 
increase in office time was desired. To this purpose, telemonitoring was introduced in 2001.27 
Telemonitoring provides everyday wireless information about device function and diagnostic 
data, and facilitates potentially dangerous events to be sent to the physician without patient 
intervention. Telemonitoring may reduce hospitalization by early detection of potentially 




Subcutaneous ICD system 
In January 2005, the subcutaneous implantable defibrillator system was tested. A device that can 
be implanted entirely subcutaneously and positioned based on anatomical markings. The absence 
of leads in the heart might decrease implantation procedural time and risk for complications.29 
Besides these advantages, disadvantages are the positioning in the axilla of the pulse generator 
with a subcutaneous lead tunneled into a parasternal position, a higher amount of shock energy 
and the lack of pacing capabilities. The question is whether these advantages will counterbalance 
the disadvantages. 
 
Four-pole ICD connector 
Another improvement in device technology is the four-pole ICD connector, with high voltage and 
low voltage connectors inline, thus eliminating the bulky bipod or tripod of pace/sense connector 
and the connector(s) of the shock coil(s). The four-pole ICD connector uses a smaller pulse 
generator and thinner leads and, therefore, may simplify the implantation procedure and reduce 
complications. The device is attractive for patients who require CRT-D which uses three leads 
and requires multiple electrical contacts.30  
 
ICD cost-effectiveness  
With the inclusion of primary prevention ICD treatment in the current guidelines, worldwide 
implantation rates have increased significantly. With the increasing implantation rates of these 
expensive devices, high costs burdens are put on the health care systems, therefore warranting 
assessment of cost-effectiveness of ICD therapy. Sanders et al. assessed the cost-effectiveness of 
ICD therapy in 8 large primary prevention trials (MADIT, MADIT II, MUSTT, DEFINITE, 
COMPANION, SCD-HeFT, DINAMIT, CABG patch trial). The study demonstrated that 




years (QALY) and the cost-effectiveness ranged from $34.000 to $70.200 per gained QALY. The 
upper limit of the cost-effectiveness was relatively high because of the inclusion of two negative 
trials (DINAMIT the CABG patch trial).31 Cowie et al. also analyzed the cost-effectiveness of 
ICD therapy in 6 large primary prevention trials (AMIOVERT, CAT, DEFINITE, MADIT, 
MADIT II, SCD-HeFT). In this analysis, prophylactic single-chamber ICD implantation added 
1.88 QALY and the incremental cost-effectiveness was $29.530 per gained QALY.32 Smulders et 
al. demonstrated that a cost-effectiveness ratio below €40.000 per gained QALY was assumed 
acceptable according to the current Dutch economic threshold.33 In both studies the mean costs 
per gained QALY was below the acceptable cost-effectiveness ratio and therefore indicating that 
ICDs are cost-effective in primary prevention.  
 Another way of evaluating the cost-effectiveness of ICD therapy is by evaluating the 
number needed to treat (NNT). Camm et al. evaluated the NNT in 4 major primary prevention 
trials and in 1 secondary prevention trial. The evaluated primary prevention trials were MUSTT, 
MADIT, MADIT II, SCD-HeFT and a NNT of 3 at 5 year follow-up, 4 at 2.4 year follow-up, 11 
at 3 year follow-up and 14 at 5 year follow-up were found, respectively. The NNT in the 
secondary prevention trial (AVID) was 9 at 3 year follow-up. Additionally, the NNT for optimal 
medical therapy was ranging between 20 and 37.34 The review clearly demonstrates a higher NNT 
for optimal medical therapy compared with the primary and secondary trials. However, since the 
NNT is dependent on the time window over which the benefit is assessed, it is difficult to 
compare different trials and medications with different follow-up durations. 
 
Current risk stratification for SCD 
Although the beneficial effect of ICD treatment has been proven in selected patients, the majority 
of cases of SCD occurs in patients who are still not eligible for ICD implantation.35 In other 




ventricular arrhythmia. Primary prevention trials have established depressed LVEF as the single 
most important risk stratification tool to identify individuals at high-risk for SCD. The Maastricht 
circulatory arrest registry clearly shows that LVEF alone will not adequately identify high-risk 
patients of SCD. In the circulatory arrest registry 57% of the SCD victims had an LVEF >30% 
and 20% had an LVEF >50% showing the poor sensitivity of LVEF.10 Additionally, the MUSST 
trial demonstrated that approximately half of mortality occurred suddenly in patients with an 
LVEF <30% and the other half in patients with an LVEF >30%, hereby suggesting that the 
degree of left ventricular systolic failure did not predict the mode of death.36 As a perfect risk 
stratification tool should have a good sensitivity and specificity, one could say that LVEF as the 
single most important risk stratification tool alone is not the optimal tool to identify individuals at 
risk of SCD nor to identify patients at low risk.  
 
Aim and outline of the thesis 
Although the beneficial effect of ICD treatment has been proven in selected patients, the 
population assessed in large clinical trials does not reflect the population with ICDs in the real 
world. The aim of the current thesis is to give better insight in these patients at risk for life-
threatening arrhythmias by studying a large population of patients treated with an ICD, outside 
the setting of a clinical trial. 
 In part I, the actual need for defibrillator backup during long-term follow-up is evaluated. 
Chapter 2 describes differences in mortality and the occurrence of ventricular arrhythmia between 
patients receiving an ICD as primary vs. secondary prevention of SCD. The actual need for 
device replacement after an event-free first battery service-life is studied in Chapter 3. 
 In part II, an attempt is made to improve risk stratification by evaluating currently 
available parameters and the additive value of novel parameters. In Chapter 4 all classic baseline 




prevention ICD recipients with ischemic heart disease. Chapter 5 demonstrates the importance of 
atrial fibrillation in patients with ICD or CRT-D. Chapter 6 shows that usage of a risk model can 
predict the risk of non-benefit (death, prior to first ventricular arrhythmia) which might have 
important clinical consequences. In Chapter 7 the spatial QRS-T angle is evaluated in the 
prediction of ventricular arrhythmia. Chapter 8 demonstrates the risk of lead failure in small 
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Aims: The beneficial effects of implantable cardioverter defibrillators (ICDs) in primary and 
secondary prevention patients are well established. However, data on potential differences 
between both groups in mortality and ICD therapy rates during long-term follow-up are scarce. 
The aim of the study was to assess differences in mortality and ICD therapy between secondary 
and primary prevention ICD recipients. 
Methods and results: With exception of patients with congenital monogenetic cardiac disease, 
all patients treated with an ICD, regardless of the underlying cardiac pathology, from 1996 to 
2008 at the Leiden University Medical Center were included in the current analysis. The study 
population was grouped by type of prevention (secondary or primary) for sudden cardiac death. 
Primary end-point was all-cause mortality. Secondary end-point was the occurrence of device 
therapy (appropriate or inappropriate). A total of 2134 (80% men, mean age 63±12 years) ICD 
recipients were included. Thirteen-hundred-and-two (61%) patients received an ICD for primary 
prevention of sudden cardiac death and 832 (39%) patients for secondary prevention. During a 
mean follow-up of 3.4±2.8 years, 423 (20%) patients died. The 5-year cumulative incidence of 
mortality was 25% (95%CI 21-29%) for primary prevention patients and 23% (95%CI 20-26%) 
for secondary prevention patients. Secondary prevention patients exhibited a 74% increased risk 
for appropriate therapy as compared to primary prevention patients (HR 1.7, p<0.001). 
Comparable risk for inappropriate shocks was observed (HR 1.0, p=0.9).  
Conclusion: During long-term follow-up primary prevention patients exhibited a lower risk of 
appropriate therapy but comparable mortality rates were observed between both groups. Both 





Sudden cardiac death, mainly caused by ventricular arrhythmias (VA) in a population with 
coronary artery disease, is a major cause of mortality in the Western world. In the United States, 
the annual incidence of sudden cardiac death varies from 200.000 to 450.000 subjects.1-4 Initially, 
large trials proved the effectiveness of implantable cardioverter defibrillator (ICD) treatment in 
survivors of life-threatening VAs such as ventricular fibrillation or ventricular tachycardia 
(secondary prevention).5-7 Since survival rates of VA, prior to ICD implantation, are low, focus 
shifted to the identification of patients at risk of VA (primary prevention).1 Randomized trials 
tested the hypothesis that ICD treatment was beneficial in a population characterized by 
depressed left ventricular ejection fraction (LVEF) without prior cardiac arrest and demonstrated 
a reduction in all-cause mortality.8-11 Not only did the implementation of these results in the 
international guidelines dramatically increase the number of implantations worldwide, it also 
changed the ICD-treated population from VA survivors to patients characterized by decreased 
LVEF and symptomatic or asymptomatic heart failure.12 It is therefore important in follow-up 
studies to clearly describe the population currently receiving ICD treatment and to assess 
differences between secondary and primary prevention ICD recipients. Previous studies have 
clearly shown a higher occurrence of VA, causing appropriate device therapy, in secondary 
prevention ICD patients as compared to primary prevention ICD patients. However, data on 
potential differences in mortality and inappropriate ICD shocks during long-term follow-up are 
scarce. 
 Since 1996, all ICD recipients in the Leiden University Medical Center have been 
assessed and followed-up. This cohort allows the evaluation of the long-term outcome in these 






Since 1996, all patients who received an ICD in the Leiden University Medical Center have been 
registered in the departmental Cardiology Information System (EPD-Vision®, Leiden University 
Medical Center). Characteristics at baseline and data of all follow-up visits are recorded. 
Eligibility for ICD implantation is based on the international guidelines which, due to evolving 
guidelines, may have changed over time.4, 12 For the current study all ICD treated patients up to 
January 2008 were included. Patients with congenital monogenetic cardiac disease, such as 
hypertrophic obstructive cardiomyopathy, long-QT syndrome, Brugada syndrome and idiopathic 
ventricular fibrillation, related to an increased risk of cardiac arrhythmia were excluded.13 
The study population was grouped by type of prevention (secondary or primary) for 
sudden cardiac death. Prevention was defined secondary after survival of an episode of cardiac 
arrest, occurrence of VA with loss of consciousness or VA lasting longer than 30 seconds.5, 6 
Prevention was considered primary in case of depressed LVEF without prior sustained VA.8, 9, 11, 
12 
 
Device implantation and programming 
All implantations were carried out in the catheterization laboratory and all devices were 
implanted transvenously without thoracotomy. Ventricular and atrial (pacing and shock) leads 
were positioned conventionally. For implantation of a cardiac resynchronization therapy - 
defibrillator, a coronary sinus venogram was obtained using a balloon catheter, followed by 
insertion of the LV pacing lead into one of the posterolateral veins through an 8Fr guiding 
catheter. During implantation, sensing and pacing thresholds were tested and defibrillation 




Germany), Medtronic (Minneapolis, MN, United States), Boston Scientific (Natick, MA, United 
States, formerly CPI, Guidant [St. Paul, MN, United States]) and St. Jude Medical/Ventritex (St. 
Paul, MN, United States). All devices were programmed with three consecutive zones: a monitor 
zone (150-188 bpm), an antitachycardia pacing (ATP) shock zone (188-210 bpm) and an initial 
shock zone (≥210 bpm). In the monitor zone, no therapy was programmed unless slow VA was 
detected during follow-up. In the ATP-shock zone, arrhythmias were initially attempted to be 
terminated by two bursts of ATP and, if arrhythmia continued, defibrillator shocks were used. In 
case of VA faster than 210 bpm, device shocks were the initial therapy. Furthermore, atrial 
arrhythmia detection was set to >170 bpm with supraventricular tachycardia discriminators 
enabled.  
 
Follow-up and device interrogation 
ICD treated patients were periodically seen at the outpatient clinic every 3-6 months, which 
included device interrogation. Printouts were checked for appropriate and inappropriate therapy 
(ATP and shocks). Adjudication of the delivered therapy was performed by a trained 
electrophysiologist. Unscheduled device interrogations were performed in case of symptomatic 
episodes of arrhythmia and during unplanned hospitalization.  
Last follow-up data was acquired in February, 2009. Patients with more than six months 
of missing data were considered lost to follow-up. 
 
End-points  
All-cause mortality was considered the primary end-point. ICD therapies were classified 
appropriate when they occurred in response to ventricular tachycardia or ventricular fibrillation 
(secondary end-point) and inappropriate when triggered by sinus or supraventricular tachycardia, 




 Furthermore the risk for subsequent VA after the first experienced VA was assessed and 
compared between both subgroups. By definition, secondary prevention patients have 
experienced a VA prior to ICD implantation and primary prevention patients have not. Therefore, 
to evaluate differences in the risk for subsequent VA, the risk of a first appropriate shock in 
secondary prevention patients was compared to the risk of a second appropriate shock in primary 
prevention patients.  
 
Statistical analysis  
Continuous data are expressed as mean ± standard deviation; categorical data are presented as 
numbers and percentages. Differences at baseline were evaluated with the independent-sample t-
test for continuous variables, and Chi-square test for categorical variables. Cumulative incidences 
were analyzed by method of Kaplan-Meier and compared using the log rank test. The 95% 
confidence intervals (CI) were calculated as 1.96 times the standard error in each direction. The 
relation between baseline characteristics and end-points was assessed by using Cox regression 
analysis and described with hazard ratios (HR) and 95% CI. In the multivariate Cox regression 
analysis for all-cause mortality, adjustments were made for age, gender, QRS-duration, New 
York Heart Association (NYHA) functional class, renal function, LVEF, history of atrial 




A total of 2471 patients received ICD treatment during the study period. Two-hundred-and-six 
(8%) patients were diagnosed with a congenital monogenetic cardiac disease. One-hundred-




secondary prevention and 79 (60%) patients for primary prevention. The remaining 2134 patients 
were considered the study population and had a mean follow-up duration of 3.4±2.8 years.  
The study population was, as mentioned above, grouped by type of prevention (secondary 
or primary) for sudden cardiac death. Thirteen-hundred-and-two (61%) patients received an ICD 
for primary prevention and 832 (39%) patients for secondary prevention. Primary prevention 
patients had a mean follow-up duration of 2.5±2.0 years and secondary prevention patients a 
mean follow-up duration of 4.9±3.3 years. As can be seen in Table 1, comparison of the two 
groups revealed in the primary prevention group a higher NYHA functional class (mean NYHA: 
2.3 ± 0.8 vs. 1.8 ± 0.8, p<0.001), a wider QRS complex (mean QRS: 130 ± 35 ms vs. 120 ± 32 
ms, p<0.001) and a lower LVEF (mean LVEF: 29 ± 12% vs. 37 ± 15%, p<0.001). 
 
All-cause mortality 
During follow-up, 423 (20%) patients died. Cumulative incidence for all-cause mortality was 6% 
(95%CI 5-7%) at 1 year, 16% (95%CI 14-17%) at 3 years and 25% (95%CI 22-28%) at 5 years. 
Comparison between the two groups demonstrated a higher, but not statistically significant 
cumulative incidence for all-cause mortality for primary prevention patients as compared to 
secondary prevention patients during follow-up (Figure 1); at 5 years of follow-up the incidence 
was respectively 25% (95%CI 21-29%) versus 23% (95%CI 20-26%). As can be seen in Figure 
1, during the first 3 years of follow-up, differences in mortality rates between both groups 
increased, whereas after 3 years the differences in mortality rates remained stable. The risk for 
all-cause mortality was higher for primary prevention patients than for secondary prevention 
patients, but did not reach significance (HR 1.2 95%CI 1.0-1.5) after 5 years of follow-up 
(p=0.05). Moreover, multivariate Cox regression analysis demonstrated that after adjustment for 




fibrillation primary prevention patients exhibited similar risk for death as compared to secondary 
prevention patients. (HR 1.1 95%CI 0.8-1.4, p=0.6). 
 
Table 1. Baseline characteristics of primary vs. secondary prevention ICD patients. 
	   Primary	  (n=1302)	   Secondary	  (n=832)	   p-­‐value	  
Clinical	  parameters	   	   	   	  
Male	  gender	   1035	  (80%)	   680	  (82%)	   0.204	  
Age	  (years)	   63	  ±	  11	   63	  ±	  13	   0.459	  
Ischemic	  heart	  disease	   881	  (68%)	   605	  (73%)	   0.020	  
NYHA	  functional	  class	   	   	   <0.001	  
I	   245	  (19%)	   372	  (45%)	   	  
II	   486	  (37%)	   288	  (34%)	   	  
III	   529	  (41%)	   158	  (19%)	   	  
IV	   42	  (3%)	   14	  (2%)	   	  
QRS	  duration	  (ms)	   130	  ±	  35	  	   120	  ±	  32	   <0.001	  
Renal	  clearance	  (ml/min)*	   78	  ±	  36	   79	  ±	  38	   0.791	  
LVEF	  (%)	   29	  ±	  12	   37	  ±	  15	   <0.001	  
History	  of	  atrial	  fibrillation	   347	  (27%)	   173	  (21%)	   0.002	  
Type	  of	  device	   	   	   <0.001	  
Single	  chamber	   36	  (5%)	   219	  (26%)	   	  
Dual	  chamber	   517	  (40%)	   487	  (59%)	   	  
CRT-­‐D	   722	  (55%)	   126	  (15%)	   	  
Medication	   	   	   	  
Beta	  blockers	   830	  (64%)	   337	  (41%)	   <0.001	  
ACE	  inhibitor	  /	  AT	  antagonist	   1100	  (85%)	   569	  (68%)	   <0.001	  
Diuretics	   975	  (75%)	   429	  (52%)	   <0.001	  
Amiodarone	   117	  (14%)	   226	  (27%)	   <0.001	  
Statins	   864	  (66%)	   436	  (52%)	   <0.001	  
*Renal clearance was determined with the formula of Cockcroft-Gault. ACE = angiotension-
converting enzyme; AT = angiotensin; CRT-D = cardiac resynchronization therapy – 





Figure 1: All-cause mortality. Kaplan-Meier curves of all-cause mortality for primary and 
secondary prevention ICD recipients. In the parenthesis, next to patients at risk, the yearly 




Ventricular arrhythmia triggered appropriate therapy (ATP or shock) in 674 (32%) patients. A 
total of 1529 episodes of VA were terminated by ICD shocks in 423 (20%) patients. Appropriate 
ATP ended VA in 14006 episodes in 466 (22%) patients. Cumulative incidence for appropriate 
therapy was 18% (95%CI 16-19%) at 1 year, 33% (95%CI 31-35%) at 3 years and 43% (95%CI 
40-46%) at 5 years. Comparison between the two study groups demonstrated a cumulative 5-year 
incidence for appropriate therapy of 37% (95%CI 33-42%) for primary prevention patients and 
51% (95%CI 47-55%) for secondary prevention patients (Figure 2). Cox regression analysis 
demonstrated a 74% increased risk of appropriate therapy in the secondary prevention group as 






Figure 2: Appropriate therapy. Kaplan-Meier curves of appropriate therapy for primary and 
secondary prevention ICD recipients. 
 
 
Cumulative incidence for appropriate shock only was 28% (95%CI 25 - 31%) at 5 years. 
For primary prevention patients, the 5-year cumulative incidence for appropriate shocks was 20% 
(95%CI 16 - 23%) as compared to 37% (95%CI 33 - 41%) for secondary prevention patients 
(Figure 3). Secondary prevention patients exhibited more than double the risk for appropriate 
shocks during long-term follow-up (HR 2.3, 95%CI 1.9 – 2.9, p<0.001).  
 
Risk for subsequent appropriate shock   
In the primary prevention group, 141 (11%) patients received appropriate shocks. Of these 141 
patients, 49 (35%) patients experienced a second appropriate device shock 275±455 days after the 
first episode. As can be seen in Figure 4, the 5-year cumulative incidence of a second appropriate 
device shock in primary prevention patients was 50% (95%CI 38-62%) and the cumulative 
incidence of a first appropriate shock in secondary prevention patients was 37% (95%CI 33-




twice the risk for a subsequent appropriate shock as compared to a first appropriate shock in the 
secondary prevention group (HR 2.0, 95%CI 1.5-2.7, p<0.001).  
 
Figure 3: Appropriate shocks. Kaplan-Meier curves of appropriate shocks for primary and 




Figure 4: Subsequent risk for appropriate shock. Kaplan-Meier curves of appropriate shock 
for the second appropriate shock in primary prevention ICD recipients and the first appropriate 





During follow-up, 241 (14%) patients experienced inappropriate device discharges with a mean 
number of 2.9 ± 4.5 shocks. Cumulative incidence for inappropriate shocks was 7% (95%CI 6-
8%) at 1 year, 13% (95%CI 11-14%) at 3 years and 17% (95%CI 15-19%) at 5 years. As can be 
seen in Figure 5, the comparison between the two study groups demonstrated a cumulative 5-year 
incidence for inappropriate shocks of 18% (95%CI 14-21%) for primary prevention patients and 
17% (95%CI 14-20%) for secondary prevention ICD patients. Cox regression analysis showed 
comparable risk of experiencing an inappropriate shock between the two groups (HR 1.0, 95%CI 
0.8-1.3, p=0.9).  
 
Figure 5: Inappropriate shocks. Kaplan-Meier curves of inappropriate shocks in primary and 




The main findings of the current study on the 5 years outcome of primary and secondary 
prevention ICD patients can be summarized as follows: 1) Patients treated for secondary 




mortality was comparable for both groups; 3) Risk for subsequent VA was higher in primary 
prevention patients than in secondary prevention patients; 4) No differences were demonstrated in 
the incidence of inappropriate shocks. 
Previously executed large randomized trials have proven the beneficial effect of ICD 
treatment for primary and secondary prevention of sudden cardiac death. These trials, however, 
required specific patient criteria for inclusion and might therefore not be representative for the 
overall population presently considered for ICD treatment. The current study is of additive value 
to current literature since it assesses long-term follow-up in a large population of primary and 
secondary prevention ICD recipients in general practice, outside the setting of a clinical trial. 
 
Survival in ICD recipients 
Large randomized clinical trials for primary and secondary prevention have demonstrated 
improved survival in patients treated with ICD therapy.8-11, 16 The first trials on the secondary 
prevention of sudden cardiac death reported all-cause mortality rates ranging from 16% to 36% 
over 18 to 57 months, respectively.5-7 Primary prevention trials, on the other hand, demonstrated 
mortality incidences ranging from 14% to 23% over 20 to 39 months follow-up, respectively.8-11, 
17 In the current study comparable mortality rates were observed. During long-term follow-up of 5 
years, 23% of secondary prevention patients died as compared to 25% of primary prevention 
patients. Considering the different clinical characteristics at baseline, one should expect higher 
mortality rates for primary prevention ICD patients. After all, primary prevention ICD patients 
have more advanced heart disease and more coexisting comorbidity which is in line with previous 
clinical trials.5, 7, 9-11, 16, 17 Undisputedly, these characteristics are related to an increased risk for 
nonarrhythmic death. In contrast, secondary prevention ICD recipients exhibited a higher risk of 
experiencing life-threatening arrhythmic events than primary prevention patients, as can be 




only in case of VA and not in case of nonarrhythmic events, one might expect higher all-cause 
mortality rates in primary prevention patients. It is therefore interesting that in the current study 
this thesis was not confirmed. Inaccuracy due to the smaller number of primary prevention 
patients with long-term follow-up could be an explanation, since initially the mortality curves 
were divergent (up to 3 years of follow-up). Another explanation could be the supposed negative 
impact of appropriate shocks on mortality (HR 2.2, p<0.001).19 As demonstrated, secondary 
prevention patients exhibit a 74% increased risk for appropriate therapy and accordingly this 
might affect the mortality curve of the secondary prevention group more than it affects the curve 
of the primary prevention group. 
 
Occurrence of appropriate and inappropriate ICD therapy 
Germano and co-workers evaluated the incidence of appropriate therapy in 7 major primary and 
secondary prevention ICD trials and reported appropriate ICD therapy rates ranging from 54% 
during 45 months of follow-up to 64% during 36 months of follow-up in secondary prevention 
trials.18 In primary prevention trials, lower incidences were reported ranging from 17% over 29 
months of follow-up to 31% over 24 months of follow-up in primary prevention trials.18 These 
results were in line with the observed cumulative incidences in the current study. As expected, the 
prevalence of appropriate ICD therapy was highest in survivors of life-threatening arrhythmias.  
 In the current study, inappropriate shocks were relatively common in both groups of ICD 
recipients, occurring in 18% of primary prevention patients and in 17% of secondary prevention 
patients after 5 years of follow-up. Comparable findings were observed in the review by Germano 
et al.18 It should be noted that both groups had similar risk for experiencing inappropriate shocks. 
Previously reported studies in literature characterize patients who experience inappropriate 
shocks as younger patients with non-ischemic heart disease, and a history of atrial fibrillation and 




inappropriate shocks occur mainly due to erroneous discrimination of supraventricular 
arrhythmias or abnormal sensing by the algorithms within the ICD.24, 25 Therefore, criteria for the 
classification of primary and secondary prevention (i.e. depressed LVEF or prior life-threatening 
VA) do not predispose for the occurrence of inappropriate shocks.  
 
Limitations 
This was a prospective observational study, performed to assess differences between primary and 
secondary prevention ICD patients. Since patients were collected over a long period of time, 
evolving guidelines could have created a heterogeneous population.  
 
Conclusion 
During long-term follow-up, compared to secondary prevention ICD patients, primary prevention 
ICD recipients exhibited a lower risk of VA which triggered appropriate ICD therapy but 
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Background: In primary prevention implantable cardioverter defibrillator (ICD) patients, the 
relatively low incidence of ventricular arrhythmias (VA), combined with the limited battery 
service-life potentially results in a large group of patients who have had no benefit of the ICD 
during first service-life. Data on the occurrence of VA after device replacement remain scarce. 
Objective: The purpose of this study was to give clinicians better insight in the dilemma whether 
or not to replace an ICD after an event-free first battery service-life. 
Methods: All patients treated with an ICD for primary prevention who had a replacement 
because of battery depletion and who did not receive appropriate therapy before device 
replacement were included in the current analysis. 
Results: Out of 154 primary prevention ICD patient needing replacement because of battery 
depletion, 114 (74%) patients (mean age 61 ± 11 years, 80% male) had not received appropriate 
ICD therapy for VA. Follow-up was 71 ± 24 months after the initial implantation and 25 ± 21 
months after device replacement. Following replacement, three year cumulative incidence of 
appropriate therapy in response to ventricular tachycardia or ventricular fibrillation was 14% 
(95% CI 5-22%).  
Conclusion: The majority of primary prevention ICD patients do not experience VA during first 
battery service-life. However, a substantial part of these patients does experience appropriate ICD 






Sudden cardiac death mainly caused by ventricular arrhythmias (VA) is a major cause of 
mortality in the western world.1-4 Initially, patients were treated with implantable cardioverter 
defibrillator (ICD) therapy after survival of a life threatening VA (secondary prevention), but 
because of the low survival rate after experiencing a VA, focus shifted to the identification of 
patients at high risk for developing an arrhythmic event (primary prevention). Large randomized 
trials demonstrated a reduction in all-cause mortality in patients treated with ICD therapy, 
initially in patients treated for secondary prevention,5-7 but later also in patients who are at risk for 
arrhythmic death, the primary prevention.8-11 Findings of these trials led to the inclusion of 
primary prevention ICD treatment in the current guidelines. Not only did the implementation of 
these results change the ICD-treated population from VA survivors to patients, characterized by a 
low LVEF and symptomatic or asymptomatic heart failure, it also increased the number of 
implantations dramatically.12 Hauser demonstrated that current ICD service-life is approximately 
4.7 years for single-chamber devices and 4.0 years for dual-chamber devices and therefore, a 
large number of (mainly primary prevention) ICD replacements can be expected.13 Although 
these primary prevention patients are at high risk for developing an arrhythmia, data from 
randomized studies showed that only 35% receives appropriate therapy for ventricular 
tachycardia (VT) or ventricular fibrillation (VF).14 Data from observational clinical studies even 
showed a lower number of patients receiving appropriate therapy.15 Therefore, a significant 
number of patients treated for primary prevention who are eligible for ICD replacement, have not 
developed a VA during the first ICD service-life, posing a dilemma whether or not the patient 
will receive potentially life saving ICD therapy after this replacement. In other words: do patients 




Since 1996, all primary prevention ICD recipients in the Leiden University Medical 
Center have been assessed and followed-up. This large cohort offers possibilities for the 




Since 1996, all patients who received an ICD in Leiden University Medical Center were 
registered in the departmental Cardiology Information System. Characteristics at baseline and 
data of all follow-up visits were recorded. Eligibility for ICD implantation was based on the 
international guidelines which, due to evolving guidelines, might have changed over time.4, 12 For 
the current study, all ICD treated patients up to august 2008 with a primary indication for 
implantation, who had a replacement because of battery depletion and who did not receive 
appropriate therapy before device replacement were included. Prevention was considered primary 
in case of poor LVEF without prior sustained VA.8, 9, 11, 12 Patients with a congenital structural or 
monogenetic heart disease (associated with increased risk of ventricular arrhythmias) were 
excluded.  
 
Device implantation and programming 
All implantations were carried out in the catheterization laboratory and all devices were 
implanted transvenously and without thoracotomy. During implantation, sensing and pacing 
thresholds were tested and defibrillation threshold testing was performed. Implanted devices 
included single-chamber, dual-chamber and cardiac resynchronization therapy-defibrillator 
(CRT-D) devices and were manufactured by Biotronik (Berlin, Germany), Medtronic 




Guidant [St. Paul, MN, United States]) and St. Jude Medical/Ventritex (St. Paul, MN, United 
States).  
All devices were programmed with three consecutive zones: a monitor zone (150-188 
bpm), an antitachycardia pacing (ATP) shock zone (188-210 bpm) and an initial shock zone 
(≥210 bpm). In the monitor zone, no therapy was programmed unless VA was detected during 
follow-up. In the ATP-shock zone, arrhythmias were initially attempted to be terminated by two 
bursts of ATP and, if arrhythmia continued, defibrillator shocks were used. In case of VA faster 
than 210 bpm, device shocks were the initial therapy. Furthermore, atrial arrhythmia detection 
was set to >170 bpm with supraventricular tachycardia discriminators enabled. In replaced 
devices, therapy settings were adopted from the initially implanted devices.  
 
Follow-up and device interrogation 
ICD treated patients were periodically followed-up every 3-6 months, which included device 
interrogation. Printouts were checked for appropriate and inappropriate therapy (ATP and 
shocks). Unscheduled device interrogations were performed in case of symptomatic episodes of 
arrhythmia and during unplanned hospitalization. Last follow-up data were acquired in August 
2008. 
Since periodical follow-up is performed every 3-6 months, patients with more than six 
months of missing data were considered lost to follow-up. 
 
Statistical analysis  
Continuous data are expressed as mean ± standard deviation; categorical data are presented as 
numbers and percentages. Baseline characteristics for patients who received appropriate therapy 
versus those who did not were compared with the independent-sample t-test for continuous 




considered significant. VT or VF, triggering appropriate ICD therapy was considered the primary 
endpoint. Cumulative incidences were analyzed by method of Kaplan-Meier. Mortality was 




A total of 2437 patients were treated with an ICD during the study period. Of these, 184 (8%) 
were diagnosed with a congenital structural or monogenetic cardiac disease and therefore 
excluded from the study. Of the remaining 2253 patients, 1367 (61%) patients had a primary 
indication for ICD implantation of whom 154 (11%) had a replacement because of battery 
depletion. Of these patients, 114 (74%) did not receive appropriate therapy before device 
replacement and were therefore considered the study population. Mean follow-up was 71 ± 24 
months after the initial implantation and 25 ± 21 months after device replacement. At baseline, 
the majority of patients (mean age 61 ± 11 years, 80% male) had a depressed LVEF (26 ± 9%, 
range 7-39%), wide QRS complex (136 ± 36 ms) and poor renal function (renal clearance 76 ± 31 
ml/min). Sixty-seven (59%) patients had ischemic heart disease, 28 (25%) patients had a history 
of atrial fibrillation and the majority of patients were in New York Heart Association functional 
class 3 (n=60, 53%). Medication included beta blockers in 54%, ACE inhibitors in 80% and 





 Table 1. Baseline characteristics. 
	   All	  patients	  
(n=114)	  
Clinical	  parameters	   	  
	  	  	  Male	  gender	   91	  (80%)	  
	  	  	  Age	  (yrs)	   61	  ±	  11	  
	  Ischemic	  heart	  disease	   67	  (59%)	  
NYHA	  functional	  class	   	  
	  	  	  	  I	   24	  (21%)	  
	  	  	  	  II	   27	  (24%)	  
	  	  	  	  III	   60	  (52%)	  	  
	  	  	  	  IV	   3	  (3%)	  
	  	  QRS-­‐duration	  (ms)	   136	  ±	  36	  
Renal	  clearance	  (ml/min)*	   76	  ±	  31	  
LVEF	  (%)	   26	  ±	  9	  
Range	  (%)	   7-­‐39	  
History	  of	  atrial	  fibrillation	  	   28	  (25%)	  
Medication	   	  
Diuretics	   81	  (71%)	  
ACE	  inhibitors	   91	  (80%)	  
	  	  	  	  	  Beta	  blocker	   62	  (54%)	  
* Renal clearance was determined with the formula  of Cockcroft-Gault. ACE = angiotensin-





By definition, all patients in the study population had a device replacement because of battery 
depletion. Over-all device longevity was 47 ± 12 months and differences were observed between 
different types of ICDs. The longevity was 54 ± 10 months for single-chamber devices, 55 ± 15 
months for dual-chamber devices and 42 ± 8 months for CRT-D devices (Table 2). 
 
Table 2. Device longevity per type of ICD. 








Longevity	  (months)	   47	  ±	  12	   54	  ±	  10	   55	  ±	  15	   42	  ±	  8	  






Occurrence of ventricular arrhythmia 
In the study population, 14 (12%) patients received appropriate therapy in response to VT or VF, 
on average 65 ± 21 months after the first implantation and 20 ± 15 months after device 
replacement. The cumulative event rate for appropriate therapy after replacement was 7% (95% 
CI 2-13%) at one year, 9% (95% CI 5-15%) at 2 years and 14% (95% CI 5-22%) at 3 years 
(Figure 1). In Table 3, baseline clinical characteristics between patients who received appropriate 
therapy versus patients who did not receive appropriate therapy are demonstrated. As can be seen, 
the only significant difference was observed in the number of patients who used beta blockers: 
29% of patients who received appropriate therapy used beta blockers versus 58% of patients who 
did not receive appropriate therapy (p<0.05) (Table 3).  
	  
Table 3. Baseline characteristics for patients who received ICD therapy after replacement versus 
patients who did not receive ICD therapy after replacement. 
	   Patients	  who	  received	  
therapy	  (n=14)	  




Clinical	  parameters	   	   	   	  
	  	  	  Male	  gender	   11	  (79%)	   80	  (80%)	   0.569	  
	  	  	  Age	  (yrs)	   60	  ±	  11	   62	  ±	  11	   0.798	  
Ischemic	  heart	  disease	   11	  (79%)	   56	  (56%)	   0.108	  
NYHA	  functional	  class	   	   	   0.467	  
	  	  	  	  I	   4	  (29%)	   20	  (20%)	   	  
	  	  	  	  II	   4	  (29%)	   23	  (23%)	   	  
	  	  	  	  III	   5	  (36%)	  	   55	  (55%)	   	  
	  	  	  	  IV	   1	  (6%)	   2	  (2%)	   	  
	  	  QRS-­‐duration	  (ms)	   125	  ±	  29	   139	  ±	  35	   0.263	  
Renal	  clearance	  (ml/min)*	   83	  ±	  31	   77	  ±	  30	   0.678	  
LVEF	  (%)	   23	  ±	  10	   27	  ±	  9	   0.211	  
Range	  (%)	   7-­‐39	   10-­‐39	   	  
History	  of	  atrial	  fibrillation	  	   5	  (36%)	   23	  (23%)	   0.301	  
Medication	   	   	   	  
	  	  	  Diuretics	   10	  (71%)	   71	  (71%)	   0.974	  
	  	  	  ACE	  inhibitors	   10	  (71%)	   81	  (81%)	   0.403	  
	  	  	  Beta	  blocker	   4	  (29%)	   58	  (58%)	   0.038	  
* Renal clearance was determined with the formula  of Cockcroft-Gault. ACE = angiotensin-






Figure 1: Appropriate therapy after a long event-free period. Kaplan-Meier curve for 




The main findings of the current study on the occurrence of ventricular arrhythmia after an event-
free first ICD service-life can be summarized as follows: 1) 74% of patients did not receive 
appropriate therapy, prior to the first battery depletion; 2) Following device replacement after a 
therapy-free first ICD service-life, 14% of the patients received appropriate ICD therapy after 3 
years of follow-up. 
The current study is of additive value to current literature since it is the first to assess the 
need for ICD back-up after an event-free first battery service-life. These data could give 
clinicians better insight in the dilemma whether or not to replace an ICD. 
 
The inclusion of primary prevention ICD treatment in the current guidelines increased the number 
of implantations dramatically. Because of reported device longevities of 4 - 4.7 years and an 




depletion can be expected.16 Since primary prevention ICD recipients show a relatively low 
occurrence of appropriate therapy, battery depletion will occur prior to the need for ICD back-up 
in a large number of patients.14, 17 This hypothesis is supported by the findings in the current study 
that in 74% of cases of battery depletion, the ICD has not been required to give its potentially 
life-saving therapy. Since the patients have not needed ICD back-up during this first battery life, 
clinicians involved in the follow-up of ICD patients will be posed with questions about the 
usefulness of device replacement.   
 The present study is the first to assess the occurrence of VA, requiring ICD back-up after 
an event-free first battery-life, making direct comparison to previous studies difficult. However, 
other studies have assessed the occurrence of first appropriate device therapy after long term 
follow-up and demonstrate a substantial rate of first VA, long after implantation. Alsheikh-Ali 
and co-workers have evaluated the occurrence and time-dependence of first appropriate therapy, 
standardized by patient-years in primary prevention ICD patients. The results demonstrated an 
increased rate of first appropriate therapy in the first two years following implantation. Annual 
rates of first appropriate therapy were similar in year three, four, five, six and seven after 
implantation. These results support the current findings that first VA can occur long after the 
initial implantation and thereby after ICD replacement because of battery depletion.18 In the 
Leiden out-of-hospital cardiac arrest study, 456 secondary prevention ICD patients with ischemic 
heart disease were followed for a mean of 54 months. During this follow-up, Borleffs et al. 
described a 9% increase in first appropriate ICD therapy from the fifth to the eighth year 
following implantation. Additionally, the authors state that during this long period of follow-up, 
12% of patients experiencing a life threatening VA had their first occurrence more than five years 
after implantation.19 Finally, in a study by Tandri and co-workers, incidences of appropriate 




recipients. In the total study population, probability of appropriate therapy was 8% over the 
following year, 20% over the next five years, and 24% over the next 10 years.20  
Although the higher incidence of appropriate therapy in secondary prevention ICD 
patients might make comparison to findings in the currently studied (primary prevention) 
population difficult,17 results from previous studies are consistent in the finding of a steady rate of 
first VA, even after a long event-free period. These findings, combined with the results of the 
present study indicate that, although the majority of patients do not receive appropriate therapy 
during first battery service-life, a substantial number of these patients will still receive potentially 
life-saving appropriate therapy after replacement, warranting device replacement.  
 
Study limitations 
Since patients were collected over a period of time, expanding guidelines for the implantation of 
defibrillators, treatment of acute myocardial infarction, and pharmacological antiarrhythmic 
therapy could have created a heterogeneous population. Furthermore, a significant group of 
patients who received an ICD for primary prevention at the Leiden University Medical Center 
could not be included in the current study, since their ICDs had not reach end of service life at the 
time of the study.  
 
Conclusion 
The current study demonstrates that the majority of primary prevention ICD patients do not 
experience VA during first battery service-life. However, a substantial number of these patients 
do experience appropriate ICD therapy after replacement justifying device replacement even if no 
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Aims: To assess survival and to construct a baseline mortality risk score in primary prevention 
implantable cardioverter defibrillator (ICD) patients with non-ischemic or ischemic heart disease. 
Methods and results: Since 1996, data of all consecutive patients who received an ICD system 
in the Leiden University Medical Center were collected and assessed at implantation. For the 
current study, all 1036 patients (age 63 (SD 11) years, 81% male) with a primary indication for 
defibrillator implantation were evaluated and followed for 873 (SD 677) days. During follow-up, 
138 patients (13%) died. Non-ischemic and ischemic patients demonstrated similar survival but 
exhibited different factors that influence risk for mortality. A risk score, consisting of simple 
baseline variables could stratify patients in low, intermediate and high risk for mortality. In non-
ischemic patients, annual mortality was 0.4% (95% CI 0.0-2.2%) in low risk and 9.4% (95% CI 
6.6-13.1%) in high risk patients. In ischemic patients, mortality was 1.0% (95% CI 0.2-3.0%) in 
low risk and 17.8% (95% CI 13.6-22.9%) in high risk patients. 
Conclusion: Utilisation of an easily applicable baseline risk score can create an individual 






Sudden cardiac death, mainly caused by ventricular arrhythmias degenerating into ventricular 
fibrillation, is responsible for 50% of all cardiac mortality worldwide.1-3 Large randomised trials 
have shown a beneficial effect of an implantable cardioverter defibrillator (ICD), initially in 
survivors of life-threatening arrhythmias,4-6 but more recently also as primary prevention of 
sudden arrhythmic death in selected non-ischemic and ischemic patients at high risk.7-10 Since the 
implementation of primary prevention in the international guidelines, implantation rates have 
increased drastically to 160 000 yearly in the United States.11-13 So far, data on the survival of 
primary prevention ICD patients are limited to post-hoc analyses of large randomised trials 
requiring specific patient characteristics for inclusion. This could cause the results to be less 
applicable to the more diverse, presently indicated population outside the setting of a clinical trial. 
Since 1996, all ICD recipients in the Leiden University Medical Center have been assessed and 
followed up. This cohort offers a unique opportunity to study mortality and to identify baseline 
parameters that influence risk. Furthermore, an easy-to-use and clinically applicable algorithm is 
created to aid clinicians in patient tailored survival estimations for patients with non-ischemic or 
ischemic heart disease. 
 
Methods 
Patients and study protocol  
From 1996 to 2007, all consecutive patients who received an ICD system in the Leiden 
University Medical Center were prospectively collected in the departmental Cardiology 
Information System (EPD-Vision®, Leiden University Medical Center). Characteristics at 
baseline, data of the implant procedure, and data of all follow-up visits were recorded. For the 




 Eligibility for ICD implantation in this population was based on international guidelines 
for primary prevention which, due to evolving guidelines, might have changed over time. In the 
majority of patients, indication for an ICD was made in the presence of a depressed left 
ventricular ejection fraction [LVEF] with or without non sustained ventricular tachycardia 
(nsVT).14, 15 Ischemic heart disease was defined as the presence of significant coronary artery 
disease (a diameter stenosis of at least 50% in at least one coronary artery).16 Patients with 
congenital structural or monogenetic heart disease (associated with an increased risk of sudden 
arrhythmic death) were excluded from the analysis. 
 
Definitions of variables 
All tested variables were acquired at defibrillator implantation and were defined and categorised 
according to literature or common practice. Age was categorised in ≥ 70 years or < 70 years;17 a 
history of nsVT was defined as a run of 3 to 30 ventricular ectopic beats at a rate > 120 beats per 
minute;18 renal clearance was estimated with the formula of Cockroft-Gault and categorised in 
normal or stage 1 renal failure (> 90 ml/min), stage 2 renal failure (60-90 ml/min), or stage 3-5 
renal failure (≤ 60 ml/min);19 QRS duration was categorised as ≥ 130 ms or < 130 ms; LVEF was 
categorised as ≤ 25% or > 25%;20 atrial fibrillation (AF) was defined as a history of AF, as 
documented on ECG; a history of smoking was defined if a patient had a positive answer when 




All defibrillator systems used were implanted transvenously and without thoracotomy. During the 
implant procedure testing of sensing and pacing thresholds and defibrillation threshold testing 




(Minneapolis, MN, United States), Boston Scientific (Natick, MA, United States, formerly CPI, 
Guidant [St. Paul, MN, United States]) and St. Jude Medical/Ventritex (St. Paul, MN, United 
States). 
Defibrillators were programmed as follows: a ventricular arrhythmia monitor zone was 
programmed in all patients (150-188 bpm) No therapy was programmed in this zone until during 
follow-up arrhythmias were detected. Ventricular arrhythmias faster than 188 bpm were initially 
attempted to be terminated with two bursts of ATP and, after continuation of the arrhythmia, with 
defibrillator shocks. In the case of a ventricular arrhythmia faster than 210 bpm, device shocks 
were the initial therapy. Furthermore, atrial arrhythmia detection was set to >170 bpm with SVT 
discriminators enabled. Settings were adapted, only when clinically indicated (i.e. hemodynamic 
well tolerated ventricular tachycardia at high rate; ventricular tachycardia in the monitor zone). 
 
Long-term follow-up  
Patient check-up was scheduled every three-six months. Device interrogation printouts were 
checked for appropriate and inappropriate ICD therapy (ATP or shocks). Therapies were 
classified as appropriate when they occurred in response to ventricular tachycardia or ventricular 
fibrillation and as inappropriate when triggered by sinus or supraventricular tachycardia, T-wave 
oversensing, or electrode dysfunction. Furthermore, follow-up included all-cause mortality.  
In the Dutch health care system, all patients are followed by the implanting centre. Since 
periodical follow-up was performed every three to six months, patients without data on the past 
six months were considered as lost to follow-up. 
 
Statistical analysis  
Continuous data are expressed as mean with standard deviation (SD) or median with 25th and 




Event rates for all-cause mortality were analyzed by method of Kaplan-Meier. Differences in 
event rates (non-ischemic vs. ischemic heart disease) were assessed using logistic regression. 
Missing values were imputed using the single imputation procedure.23 Last follow-up data were 
acquired in November 2008.  
To obtain a risk score, composed of robust, reproducible and non clinician driven 
variables, the use of medication at baseline was not used in its construction. All other baseline 
variables were entered as categorical variables. Firstly, the variables were studied in univariate 
logistic regression models, with all-cause mortality as outcome. Variables with a p-value <0.10 
were further evaluated in a multivariate logistic model, using backward stepwise selection. At 
each step, the least significant variable was discarded from the model, until all variables in the 
model reached a p-value <0.25. With the variables’ regression coefficient in this multivariate 
model, a simple risk stratification score was designed by giving a base regression coefficient the 
value of one point on the risk score and giving all variables the associating score, according to 
their multiplication of this base regression coefficient and rounding it of to the nearest whole or 
half number. Subsequently, the patient specific values for the predictors in the score were 
summed to obtain a score for each patient. The ability of the score to discriminate between 
patients who did and patients who did not reach the end-point was estimated by the area under the 
curve of the receiver operator curve. After the determination of the individual risk score per 
patients, cut offs were determined for a population at low, intermediate and high risk of mortality. 
These cut-offs were chosen to optimize the discriminative effect of the model without making 
groups too small. Bootstrap with 1000 resamples was used for internal validation and to assess 
the stability of variable selection.24 In the calculation of the 95% confidence interval (95% CI) for 
event rates, a Poisson distribution of the observed number of events was presumed. All analyses 
(except bootstrapping analysis) were performed with SPSS for Windows, version 14.0 (SPSS, 





Baseline characteristics  
Since 1996, data of 1086 consecutive patients receiving an ICD for primary prevention and 
without diagnosed congenital heart disease or monogenetic heart disease (associated with an 
increased risk of sudden arrhythmic death) were prospectively collected. Fifty patients (4.6%) 
were lost to follow-up. The remaining 1036 ICD recipients were included in the analysis. Median 
follow-up time was 721 days (interquartile range, 308 to 1271 days). The majority of patients 
(81% men, mean age 63 (SD 11) years) had a depressed LVEF (29 (SD 12) %), wide QRS (131 
(SD 35) ms) and poor renal function (renal clearance 78 (SD 35) ml/min). Medication included 
beta blockers in 73%, ACE inhibitors or AT antagonists in 85% and diuretics for congestive heart 
failure in 75%. Baseline characteristics are summarised in Table 1. Seven-hundred-and-four 
(68%) out of all 1036 patients had ischemic heart disease. The remaining 332 (32%) patients were 
considered non-ischemic. Ischemic ICD recipients were more often male (87% vs. 66%, 
p<0.001), had a higher age (64 (SD 11) vs. 61 (SD 12) years, p<0.001) and shorter QRS duration 
(126 (SD 34) vs. 140 (SD 36) ms, p<0.001), as is shown in Table 1. 
 
Follow-up 
During a median follow-up time was 721 days (interquartile range, 308 to 1271 days), 138 
patients (13%) died. Total follow-up was 2475 patient-years. Survival analysis showed a 
cumulative mortality of 6% (95% CI 4-7%) at one year, 17% (95% CI 13-20%) at three years and  
27% (95% CI 22-32%) at six years follow-up. Stratification by type of underlying disease did not 
demonstrate differences in survival (Figure 1) (odds ratio, adjusted for age: 1.0, 95% CI 0.7-1.5). 
 A total of 6575 episodes of ventricular arrhythmia, causing appropriate device therapy, 








Table 1. Baseline characteristics  











Clinical	  parameters	   	   	   	   	   	  
	  	  	  	  Male	  gender	  (%)	   835	  (81)	   220	  (66)	   615	  (87)	   <0.001	   0	  
	  	  	  	  Age,	  mean	  (SD),	  years	  
	  	  	  	  	  	  median	  (interquartile	  range),	  	  










<0.001	   0	  
	  	  	  	  History	  of	  nsVT	  (%)	   287	  (28)	   96	  (29)	   191	  (27)	   0.5	   0	  
	  	  	  	  Renal	  clearance,	  mean	  (SD),	  	  	  
	  	  	  	  	  	  ml/min*	  	  	  
78	  (35)	   80	  (37)	   77	  (34)	   0.3	   41	  (4)	  
	  	  	  	  QRS-­‐duration,	  mean	  (SD),	  ms	   131	  (35)	   140	  (36)	   126	  (34)	   <0.001	   8	  (1)	  
	  	  	  	  LVEF,	  mean	  (SD),	  %	   29	  (12)	   29	  (14)	   29	  (11)	   0.7	   59	  (6)	  
	  	  	  	  History	  of	  atrial	  fibrillation	  (%)	   283	  (27)	   107	  (32)	   176	  (25)	   0.015	   2	  (0)	  
	  	  	  	  Diabetes	  (%)	   226	  (22)	   54	  (16)	   172	  (24)	   0.003	   35	  (3)	  
	  	  	  	  History	  of	  smoking	  (%)	   491	  (47)	   146	  (44)	   345	  (49)	   0.130	   63	  (6)	  
	  	  	  	  Body	  mass	  index,	  mean	  (SD),	  	  	  	  	  	  
	  	  	  	  	  	  	  kg/m2	  
26	  (4)	   26	  (4)	   26	  (4)	   0.3	   51	  (5)	  
Implantable	  cardioverter	  defibrillator	   	   	   	   	   	  
	  	  	  	  Single	  chamber	   50	  (5%)	   17	  (5%)	   33	  (5%)	   0.8	   0	  
	  	  	  	  Dual	  chamber	   409	  
(40%)	  
83	  (25%)	   326	  
(46%)	  
<0.001	   0	  






<0.001	   0	  
Medication	   	   	   	   	   	  
	  	  	  	  Beta-­‐blocker	  (%)	   647	  (63)	   212	  (64)	   435	  (62)	   0.5	   0	  
	  	  	  	  Sotalol	  (%)	   112	  (11)	   27	  (8)	   85	  (12)	   0.057	   0	  
	  	  	  	  ACE	  inhibitors	  /	  AT	  antagonist	  (%)	   879	  (85)	   284	  (86)	   595	  (85)	   0.7	   0	  
	  	  	  	  Statins	  (%)	   681	  (66)	   106	  (32)	   575	  (82)	   <0.001	   0	  
	  	  	  	  Diuretics	  for	  CHF	  (%)	   781	  (75)	   271	  (82)	   510	  (72)	   <0.001	   0	  
	  	  	  	  Amiodarone	  (%)	   149	  (14)	   44	  (13)	   105	  (15)	   0.5	   0	  
* Renal clearance was determined with the formula of Cockroft-Gault. 
ACE = angiotensin-converting enzyme; AT = angiotensin; CHF = congestive heart failure; 








Figure 1: All-cause mortality. Kaplan-Meier curve for cumulative all-cause mortality in patients 
with non-ischemic heart disease vs. ischemic heart disease. 
 
Mortality risk score in non-ischemic heart disease 
Univariate and subsequent multivariate logistic regression identified the following variables as 
suitable for the construction of a predictive model: (1) poor renal function, (2) poor LVEF, (3) 
history of AF and (4) high age. The strongest predictor of mortality was a renal clearance ≤60 
ml/min (odds ratio 5.4, 95% CI 1.7-17.5), when compared to renal clearance > 90 ml/min (Table 
2). Bootstrap analysis showed that renal clearance, LVEF, a history of AF and high age were 
selected in 97%, 95%, 60%, and 49% respectively. As base regression coefficient, 0.4 was used. 
For each variable, the appropriate risk score was determined by calculating the multiplications of 
this base regression coefficient (Table 3). The area under the receiver operator curve of the 
acquired risk score was reasonably good: 0.76 (95% CI 0.69 – 0.82). Application of this risk 
score on the study population with non-ischemic heart disease facilitates the stratification in three 






Table 2. Multivariate logistic regression model and corresponding risk score for patients with 
non-ischemic heart disease. 




P-­‐value	   Score	  
Renal	  clearance*	   	   	   .007	   	  
	  	  	  	  ≤60	  ml/min	   1.694	   5.444	  (1.696	  –	  17.472)	   	   4	  
	  	  	  	  61-­‐90	  ml/min	   0.837	   2.309	  (0.722	  –	  7.381)	   	   2	  
LVEF	  ≤	  25%	   0.991	   2.694	  (1.321	  –	  5.493)	   .006	   2.5	  
History	  of	  atrial	  fibrillation	   0.481	   1.693	  (0.853	  –	  3.360)	  	   .132	   1	  
Age	  ≥	  70	  yrs	   0.401	   1.493	  (0.715	  –	  3.117)	   .286	   1	  
* Renal clearance was determined with the formula of Cockroft-Gault. 
CI = Confidence interval; LVEF = left ventricular ejection fraction 
  
Table 3. Risk stratification and corresponding event rates for mortality in patients with non-
ischemic heart disease. 
	   Risk	  score	   Patients	   Patient-­‐years	   Events	   Event	  rate	  per	  100	  
patient-­‐years	  
(95%	  CI)	  
Low	  risk	   0-­‐2	   91	   256	   1	   0.4	  (0.0-­‐2.2)	  
Intermediate	  risk	   2.5-­‐4	   91	   226	   8	   3.5	  (1.5-­‐7.0)	  
High	  risk	   4.5-­‐8	   150	   372	   35	   9.4	  (6.6-­‐13.1)	  
Total	   	   332	   854	   44	   5.2	  (3.7-­‐6.9)	  
 
 
In patients with low risk for all-cause mortality (91/332, 27%), one patient (1%) died 
during 256 patient-years, corresponding to an event-rate of 0.4 (95% CI 0.0-2.2) per 100 patient-
years (Table 4). Survival analysis showed a cumulative mortality of 1% (95% CI 0-3%) at one 
year, three years and at six years follow-up (Figure 2). In the population with intermediate risk 
(91/332, 27%), eight patients (9%) died during 226 patient-years. Therefore, the calculated event 
rate is 3.5 (95% CI 1.5-7.0) per 100 patient-years. Survival analysis showed a survival of 1% 




years follow-up. Finally, in the population with a risk score ≥ 4.5 points (150/332, 45%), 35 
patients died during 372 patients-years, which corresponds to an event rate of 9.4 (95% CI 6.6-
13.1) per 100 patients-years. For this group, survival was 8% (95% CI 3-12%) at one year, 26% 
(95% CI 17-35%) at three years and 46% (95% CI 30-62%) at six years follow-up. 
 
 
Figure 2: Risk stratification for all-cause mortality in non-ischemic cardiomyopathy. 
Kaplan-Meier curve for cumulative all-cause mortality in patients with non-ischemic heart 





Mortality risk score in ischemic heart disease 
In ICD patients with ischemic heart disease, the multivariate logistic model contained the 
following variables: (1) poor renal function, (2) history of smoking, (3) diabetes, (4) poor LVEF,  
 (5) high age and (6) long QRS duration. Similar to the non-ischemic population, the strongest 
predictor of mortality was a renal clearance ≤60 ml/min (odds ratio 4.5, 95% CI 2.1-9.7), when 
compared to renal clearance > 90 ml/min (Table 4). Bootstrapping analysis showed that renal 
clearance, history of smoking, diabetes, LVEF, high age, and long QRS duration were selected in 
100%, 100%, 98%, 99%, 97%, and 84% respectively. The area under the receiver operator curve 
of the acquired risk score was reasonably good: 0.81 (95% CI 0.76 – 0.87). Using 0.4 as the base 
regression coefficient, the risk score for each variable was determined. Stratification resulted in 
three risk categories: (1) low risk (0-2 points); (2) intermediate risk (3-7 points); and (3) high risk 
(8-13 points).  
 
 
Table 4. Multivariate logistic regression model and corresponding risk score for patients with 
ischemic heart disease. 




P-­‐value	   Score	  
Renal	  clearance*	   	   	   .000	   	  
	  	  	  	  ≤60	  ml/min	   1.509	   4.523	  (2.119	  –	  9.657)	   	   4	  
	  	  	  	  61-­‐90	  ml/min	   0.388	   1.474	  (0.667	  –	  3.256)	   	   1	  
History	  of	  smoking	   1.146	   3.145	  (1.884	  –	  5.252)	   .000	   3	  
Diabetes	   0.889	   2.434	  (1.466	  –	  4.041)	   .001	   2	  
LVEF	  ≤	  25%	   0.870	   2.388	  (1.465	  –	  3.892)	   .000	   2	  
Age	  ≥	  70	  yrs	   0.788	   2.200	  (1.283	  –	  3.773)	   .004	   2	  
QRS	  duration	  ≥	  130	  ms	   0.498	   1.694	  (1.035	  –	  2.772)	   .036	   1	  
* Renal clearance was determined with the formula of Cockroft-Gault. 






As can be seen in Table 5, event rates varied from 1.0 (95% CI 0.2-3.0) per 100 patient-
years in the low-risk group, to 17.8 (95% CI 13.6-22.9) per 100 patient-years in the high risk 
group. Six-year mortality was 4% (95% CI 0-10%) in ischemic low risk patients, and 66% (95% 
CI 49-82%) in the high risk population. 
 
Table 5. Risk stratification and corresponding event rates for mortality in patients with ischemic 
heart disease. 
	   Risk	  score	   Patients	   Patient-­‐years	   Events	   Event	  rate	  per	  100	  
patient-­‐years	  
(95%	  CI)	  
Low	  risk	   0-­‐2	   127	   291	   3	   1.0	  (0.2-­‐3.0)	  
Intermediate	  risk	   3-­‐7	   416	   993	   31	   3.1	  (2.1-­‐4.4)	  
High	  risk	   8-­‐13	   161	   337	   60	   17.8	  (13.6-­‐22.9)	  




Figure 3: Risk stratification for all-cause mortality in ischemic cardiomyopathy. Kaplan-
Meier curve for cumulative all-cause mortality in patients with ischemic heart disease with low, 





In the current study on the long-term follow-up and the construction of an easy-to-use mortality 
risk score in non-ischemic and ischemic primary prevention ICD patients, the findings can be 
summarised as follows: 1) Cumulative mortality was approximately 5% per year; 2) Non-
ischemic and ischemic patients demonstrated an equal survival; 3) Non-ischemic and ischemic 
ICD recipients exhibited a different risk profile in the prediction of mortality; 4) A baseline risk 
score can easily estimate an individual patient’s risk for mortality.  
Using the presented risk score, a patient, considered for primary prevention ICD 
treatment, could be stratified as follows: 1) determine if the patient has ischemic or non-ischemic 
heart disease to determine the risk factors, influencing mortality risk (Table 2 or Table 4); 2) add 
the risk score points, associated with patient’s risk factors; 3) allocate patient as low, intermediate 
or high risk for mortality en estimate event-rate (Table 3 or Table 5).  
 
Mortality 
In the current analysis, 138 patients (13%) died during a mean follow-up of median follow-up 
time was 721 days (interquartile range, 308 to 1271 days). Cumulative mortality after one, three 
and six year was 6%, 17% and 27% respectively and was not different in non-ischemic or 
ischemic ICD recipients. Previously, few trials have been conducted on a population containing 
non-ischemic, as well as ischemic patients. Bardy and co-workers show a beneficial effect of 
defibrillator implantation in ICD recipients with non-ischemic or ischemic heart disease and 
congestive heart failure.25 In their population, crude annual death rates reach up to 5.7% which 
are comparable to our annual crude death rate of 5.6%. Other large trials assessing the effect of an 
ICD in patients with ischemic heart disease only, demonstrate an annual death rate of 7.0% to 




eligible for inclusion. The study population might therefore not prove to be completely 
representative for the “real life” population considered for defibrillator implantation.  
 
Risk factors 
The current study reveals different factors influencing risk for mortality for either type of heart 
disease. For all-cause mortality in non-ischemic patients, a history of AF, depressed LVEF, poor 
renal function and high age are predictors of mortality during follow-up. A depressed LV 
function has proven to be one of the most powerful markers of cardiac death in patients without 
an ICD, causing it to be the current main criterion for primary prevention defibrillator 
eligibility.28, 29 Furthermore, AF, renal failure and high age have been described in the prediction 
of death in a population with, as well as without an ICD.30-34 Furthermore, renal failure has 
previously been noted as one of the strongest predictors of mortality in a population with cardiac 
disease.35, 36 Characteristics increasing risk for mortality in ischemic patients were more diverse: 
renal failure, a history of smoking, diabetes, poor LV function, high age and prolonged QRS 
duration.  Risk stratification in the ischemic ICD recipients of MADIT II revealed similar risk 
factors, as described by Goldenberg et al.37 Additionally, a sub-analysis of the MUSTT exposed 
these factors as predictors of mortality in the non-ICD treated arm.38  
 
Risk score 
Previous studies constructing a risk score were mainly limited to patients in the setting of large 
clinical trials, requiring specific characteristics to be eligible for inclusion, and followed patients 
for a relatively short time. This might cause the findings to be less applicable to the more diverse 
population, currently receiving an ICD for primary prevention in a “real life” population. In a 
sub-study of the MUSTT, Buxton and co-workers constructed a model containing eight factors in 




electrophyiologically (EP) guided therapy to reduce risk of arrhythmic events, all included 
patients underwent EP testing. Inducibility of VT at EP testing was one of the factors, found to 
increase risk for all-cause mortality. In the current study, as in the present population receiving 
ICD treatment, not all patients underwent EP testing, therefore making it hard to assess its 
prognostic value. The power of the presented model to correctly identify patients in the MUSTT 
was 0.78, which is comparable to the 0.81 in the current study. Goldenberg and co-workers 
constructed a model with five factors in the post-myocardial infarction population of the MADIT 
II.40 This model, containing New York Heart Association functional class, AF, a wide QRS, high 




The results of this study imply that the large population, currently indicated for ICD treatment, 
can be easily stratified for mortality risk. The proposed risk score can prove an easily applicable 
mean to aid clinicians in making individual patient-tailored statements on risk for mortality, prior 
to defibrillator implantation in daily practice. Its utilisation could greatly increase survival 
estimation for the clinician, as well as the patient. Of note that the proposed risk score does 
require validation. Furthermore, clinicians have shown concern that the population, eligible for 
primary prevention ICD treatment, is of such magnitude that provision of ICD therapy will strain 
financial resources and the pool of trained personnel.41, 42 In current daily practice, the choice on 
the most efficient allocation of ICD treatment is mostly based on the life expectancy of the 
patient. With the current study, a group of patients, currently indicated for ICD treatment, can be 
identified who have a very short life expectancy, regardless of ICD implantation. These findings 






This was a non-randomised prospective observational study, performed to assess the long-term 
follow-up in non-ischemic or ischemic primary prevention ICD patients outside the setting of a 
clinical trial. Since patients were collected over a period of eleven years, expanding guidelines for 
the implantation of defibrillators, treatment of acute myocardial infarction, and pharmacological 
antiarrhythmic therapy could have created a heterogeneous population.43, 44 The currently 
constructed risk score does not take pharmacological treatment in consideration since inclusion of 
these clinician driven variables would lead to a less robust and reproducible score. Furthermore, 
since no control group was assessed, no statements can be made on the effect of ICD treatment. 
Finally, the constructed risk score requires external validation. 
 
Conclusion 
Non-ischemic and ischemic primary prevention ICD recipients demonstrate similar survival 
during long-term follow-up but exhibit different factors that influence risk for mortality. 
Utilisation of an easily applicable baseline risk score can create an individual patient-tailored 
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Objective: To assess the prevalence of different types of atrial fibrillation (AF) and their 
prognostic importance in implantable cardioverter defibrillator (ICD) patients. 
Background: The prevalence of AF has taken epidemic proportions in the population with 
cardiovascular disease. The prognostic importance of different types of AF in ICD patients 
remains unclear. 
Methods: Data on 913 (79% men, mean age 62±13 years) consecutive patients receiving an ICD 
at the Leiden University Medical Center were prospectively collected. Among other 
characteristics, the existence and type of AF (paroxysmal, persistent or permanent) was assessed 
at implantation. During follow-up, the occurrence of appropriate or inappropriate device therapy, 
as well as mortality was noted. 
Results: At implantation, 73% of patients had no history of AF, 9% had a history of paroxysmal 
AF, 7% had a history of persistent AF and 11% had permanent AF. During 833±394 days follow-
up, 117 patients (13%) died, 228 patients (25%) experienced appropriate device discharge and 
139 patients (15%) received inappropriate shocks. Patients with permanent AF exhibited more 
than double the risk for mortality, ventricular arrhythmias triggering device discharge, and 
inappropriate device therapy. Patients with paroxysmal or persistent AF did not show a 
significant increased risk for mortality or appropriate device therapy but demonstrated almost 
three times risk for inappropriate device therapy. 
Conclusions: In the population currently receiving ICD treatment outside the setting of clinical 
trials a large portion has either a history of AF or permanent AF. Both types of AF have 








Large randomized trials have shown a beneficial effect of implantable cardioverter defibrillator 
(ICD) therapy, initially in survivors of life-threatening arrhythmias,(1-3) but more recently also in 
the primary prevention of sudden arrhythmic death in selected ischemic and non ischemic 
patients at high risk, based solely on a poor left ventricular ejection fraction (LVEF).(4-7) The 
implementations of these results in the international guidelines have, besides a considerable 
increase in the number of implants, caused a significant change in the population considered for 
ICD therapy as the majority of implantations now occurs in patients with a low LVEF and 
symptoms of heart failure (primary prevention patients) (8) 
Atrial fibrillation (AF) is common in patients with low LVEF and symptoms of heart 
failure with a reported prevalence of AF in congestive heart failure patients of up to 50% in 
patients with New York Heart Failure (NYHA) functional class IV.(9-12). Furthermore, AF is 
associated with significant morbidity and mortality both in the general population and more 
specific in patients with heart failure.(13, 14)  
As the number of ICD implants in patients with low LVEF and heart failure is increasing, 
it can be expected that more patients with paroxysmal, persistent or permanent AF will receive an 
ICD. So far, most studies focused on a single type of AF (e.g. paroxysmal/persistent or permanent 
AF) and were often conducted in the setting of a clinical trial.(15-19) The prevalence and 
prognostic implications of a history of AF at ICD implant remain unclear. The present study aims 
at providing insight in the effects of AF on mortality, occurrence of ventricular arrhythmias and 





Patients and study protocol  
Since 1996, all patients receiving an ICD at the Leiden University Medical Center were 
prospectively collected in the departmental Cardiology Information System (EPD-Vision®, 
Leiden University Medical Center). Characteristics at baseline, data of the implant procedure, and 
data of all follow-up visits were recorded.  
 Eligibility for ICD implantation in this population was based on international guidelines 
which, due to evolving guidelines, might have changed over time. Patients were implanted after 
surviving life-threatening ventricular arrhythmias or in the presence of a depressed LVEF with or 
without non sustained ventricular tachycardia.(8, 20)  
 
Atrial fibrillation 
At baseline, patients were grouped according to the type of AF. This resulted in the following 
four groups: (1) patients without a history of (documented) AF, the “no AF” group; (2) patients 
with a history of paroxysmal AF as documented on ECG; (3) patients with a history of persistent 
AF as documented on ECG; and (4) patients with permanent, accepted AF.  If the arrhythmia 
terminates spontaneously and within 7 days, AF is designated paroxysmal; when sustained 
beyond 7 days or being terminated by pharmacological or electrical cardioversion, AF is termed 
persistent. The category of persistent AF also includes cases of long-standing AF, usually leading 
to permanent AF, in which cardioversion has failed or has been foregone.(10, 21) 
  
Device implantation 
All defibrillator systems used were implanted transvenously and without thoracotomy. During the 




was performed. Used systems were manufactured by Biotronik (Berlin, Germany), Medtronic 
(Minneapolis, MN, United States), Boston Scientific (Natick, MA, United States, formerly CPI, 
Guidant [St. Paul, MN, United States]) and St. Jude Medical/Ventritex (St. Paul, MN, United 
States). 
 
Long-term follow-up  
Patient check-up was scheduled every three to six months. Device interrogation printouts were 
checked for appropriate and inappropriate ICD therapy (anti tachycardia pacing [ATP] or 
shocks). Therapies were classified as appropriate when they occurred in response to ventricular 
tachycardia or ventricular fibrillation and as inappropriate when triggered by sinus or 
supraventricular tachycardia, T-wave oversensing, or electrode dysfunction. Furthermore, follow-
up included all-cause mortality.  
In the Dutch health care system, all patients are followed by the implanting center. Since 
periodical follow-up was performed every three to six months, patients without data on the past 
six months were considered as lost to follow-up. 
 
Statistical analysis 
Continuous data are expressed as mean ± standard deviation; dichotomous data are presented as 
numbers and percentages. Comparison of continuous or dichotomous data was performed with 
the Student’s t test for paired and unpaired data and Chi-square tests with Yates correction when 
appropriate. Non-parametric data (NYHA functional class) was compared using the Mann-
Whitney U-test. Cumulative event rates (all-cause mortality, appropriate device therapy, 
appropriate device shocks and inappropriate device shocks) were analyzed by the method of 
Kaplan-Meier. The relation between different types of AF at baseline and the occurrence of end-




95%-confidence interval (95% CI) and adjusting for age, sex, renal clearance, LVEF, QRS-




Baseline characteristics  
Data of 955 consecutive patients receiving an ICD in the Leiden University Medical Center were 
prospectively collected. Forty-two patients (4.4%) were lost to follow-up. The remaining 913 
ICD recipients were included in the analysis. Mean follow-up time was 833±394 days. The 
majority of patients (79% men, mean age 62±13 years) had a depressed LVEF (32±14%), wide 
QRS complex (127±35 ms) and poor renal function (renal clearance 83±38 ml/min). Medication 
included beta blockers in 76%, ACE inhibitors or AT antagonists in 82% and diuretics for heart 
failure in 70%. Baseline characteristics are summarized in Table 1. 
Six-hundred-and-sixty-three (73%) out of all 913 patients had no history of AF (no AF), 
84 (9%) patients had a history of paroxysmal AF, 64 (7%) patients had a history of persistent AF, 
and the remaining 102 (11%) patients had permanent AF. All patients with a history of 
paroxysmal or persistent AF were in sinus rhythm at discharge after device implantation. As is 
shown in Table 1, when compared to patients without a history of AF, patients with AF were 
older, had higher NYHA functional class and were more often treated with diuretics, amiodarone 





Table 1. Baseline characteristics. 













Clinical	  parameters	   	   	   	   	   	  
	  	  	  	  Male	  gender	   722	  (79%)	   515	  (78%)	   64	  (76%)	   53	  (83%)	   90	  (88%)†	  
	  	  	  	  Age	  (yrs)	   62±13	   61±13	   64±11*	   66±10†	   67±10‡	  
	  	  	  	  Secondary	  prevention	   140	  (15%)	   94	  (14%)	   22	  (26%)†	   9	  (14%)	   15	  (15%)	  
	  	  	  	  	  	  	  	  History	  of	  VT	   93	  (66%)	   62	  (66%)	   15	  (68%)	   7	  (78%)	   9	  (60%)	  
	  	  	  	  	  	  	  	  History	  of	  VF	   47	  (34%)	   32	  (34%)	   7	  (32%)	   2	  (22%)§	   6	  (40%)	  
	  	  	  	  Primary	  prevention	   773	  (85%)	   569	  (86%)	   62	  (74%)†	   55	  (86%)	   87	  (85%)	  
	  	  	  	  	  	  	  	  History	  of	  nsVT	   201	  (26%)	   150	  (26%)	   17	  (27%)	   15	  (27%)	   19	  (22%)	  
	  	  	  	  Ischemic	  heart	  disease	   561	  (61%)	   423	  (64%)	   49	  (58%)	   39	  (61%)	   50	  (49%)†	  
	  	  	  	  NYHA	  functional	  class	   	   	   	   	   	  
	  	  	  	  	  	  	  	  I	   228	  (25%)	   188	  (28%)	   17	  (20%)	   10	  (16%)*	   13	  (13%)‡	  
	  	  	  	  	  	  	  	  II	   346	  (38%)	   253	  (38%)	   37	  (44%)	   24	  (38%)	   32	  (31%)	  
	  	  	  	  	  	  	  	  III	   320	  (35%)	   208	  (31%)	   28	  (33%)	   30	  (47%)*	   54	  (53%)‡	  
	  	  	  	  	  	  	  	  IV	   19	  (2%)	   14	  (2%)	   2	  (2%)§	   0	  (0%)§	   3	  (3%)§	  
	  	  	  	  Renal	  clearance	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  (ml/min)	  
83±38	   86±38	   75±39†	   77±43	   72±29‡	  
	  	  	  	  QRS-­‐duration	  (ms)	   127±35	   125±34	   123±33	   129±35	   140±34‡	  
	  	  	  	  LVEF	  (%)	   32±14	   33±14	   32±15	   32±14	   30±12	  
	  	  	  	  Diabetes	   177	  (19%)	   127	  (19%)	   16	  (19%)	   14	  (22%)	   20	  (20%)	  
	  	  	  	  History	  of	  smoking	   380	  (42%)	   287	  (43%)	   36	  (43%)	   24	  (38%)	   33	  (32%)*	  
	  	  	  	  Body	  mass	  index	  	  	  
	  	  	  	  (kg/m2)	  	  	  	  
26±4	   26±4	   26±4	   6±4	   26±4	  
Device	  type	   	   	   	   	   	  
	  	  	  	  Single	  chamber	   43	  (5%)	   20	  (3%)	   4	  (5%)§	   2	  (3%)§	   17	  (17%)‡§	  
	  	  	  	  Dual	  chamber	   409	  (45%)	   234	  (49%)	   39	  (46%)	   26	  (41%)	   20	  (20%)‡	  
	  	  	  	  CRT-­‐D	   461	  (51%)	   319	  (48%)	   41	  (49%)	   36	  (56%)	   65	  (64%)†	  
Medication	   	   	   	   	   	  
	  	  	  	  Beta-­‐blockers	   691	  (76%)	   510	  (77%)	   63	  (75%)	   46	  (72%)	   72	  (71%)	  
	  	  	  	  ACE	  inhibitors	  /	  	  
	  	  	  	  	  	  	  	  AT	  antagonist	  
750	  (82%)	   548	  (83%)	   66	  (79%)	   49	  (77%)	   87	  (85%)	  
	  	  	  	  Ca-­‐antagonists	   64	  (7%)	   52	  (8%)	   3	  (4%)	   3	  (5%)§	   6	  (6%)	  
	  	  	  	  Diuretics	  	   641	  (70%)	   440	  (66%)	   65	  (77%)*	   47	  (73%)	   89	  (87%)‡	  
	  	  	  	  Statins	   594	  (65%)	   445	  (67%)	   53	  (63%)	   44	  (69%)	   52	  (51%)‡	  
	  	  	  	  Amiodarone	   125	  (14%)	   68	  (10%)	   19	  (23%)‡	   15	  (23%)†	   23	  (23%)‡	  
	  	  	  	  Aspirin	   364	  (40%)	   300	  (45%)	   32	  (38%)	   22	  (34%)	   10	  (10%)‡	  
	  	  	  	  Oral	  anticoagulants	   504	  (55%)	   316	  (48%)	   51	  (61%)*	   42	  (66%)†	   95	  (93%)‡	  
*p < 0.05; †p < 0.01; ‡p < 0.001. All  compared with no AF group.  
§Comparison was performed with Yates correction. 
ACE = angiotensin-converting enzyme; AT = angiotensin; CRT-D = cardiac resynchronization 
therapy-defibrillator; LVEF = left ventricular ejection fraction; nsVT = non sustained ventricular 





During a mean follow-up of 833±394 days, 117 patients (13%) died. Study population mortality 
was 5% (95% CI 4-7%) at one year, 11% (95% CI 8-13) at two years and 15% (95% CI 12-17) at 
three years of follow-up. In the comparison of the four groups, survival analysis showed a three 
year cumulative event rate for mortality of 12% (95% CI 9-15%) for no AF, 15% (95% CI 8-
24%) for paroxysmal AF, 17% (95% CI 7-27%) for persistent AF, and 32% (95% CI 20-43%) for 
permanent AF (Figure 1). 
 Of interest, patients with paroxysmal AF or persistent AF did not demonstrate a 
significant higher risk for mortality. However, patients with permanent AF exhibited a 70% 




           
Figure 1: All-cause mortality. Kaplan-Meier curve for all-cause mortality in patients without a 






Appropriate device therapy 
During follow-up, ventricular arrhythmias, causing appropriate device therapy (ATP or shocks), 
were observed in 228 (25%) patients. A total of 5116 episodes was noted, consisting of 4793 
(range 1-2194) episodes terminated with ATP in 166 patients and 304 (range 1-33) episodes 
terminated by ICD shock in 112 patients.   
Cumulative event rate for appropriate device therapy (ATP or shock) was 15% (95% CI 
13-18%) at one year, 24% (95% CI 21-27) at two years and 30% (95% CI 24-34) at three years of 
follow-up. As is shown in Figure 2, three years cumulative event rate for appropriate device 
therapy was 29% (95% CI 24-33%) for no AF, 26% (95% CI 14-39%) for paroxysmal AF, 26% 
(95% CI 13-38%) for persistent AF, and 49% (95% CI 36-61%) for permanent AF. Patients with 
permanent AF exhibited twice the risk for appropriate therapy, when compared to patients 
without a history of AF (adjusted hazard ratio 2.2, 95% CI 1.6-3.2, p<0.001). The group with no 
history of AF demonstrated similar event rates as patients with a history of paroxysmal or 
persistent AF. 
              
Figure 2: Appropriate device therapy. Kaplan-Meier curve for the occurrence of first 
appropriate device therapy in patients without a history of AF (no AF), paroxysmal AF, persistent 





Figure 3: Appropriate device shock. Kaplan-Meier curve for the occurrence of first appropriate 
shock in patients without a history of AF (no AF), paroxysmal AF, persistent AF, or permanent 
AF. 
  
As is shown in Figure 3 and Table 2, the occurrence of appropriate shocks alone showed 
a similar distribution as the occurrence of all appropriate therapy among the four groups. No 
differences were observed between patients without a history of AF and those with a history of 
paroxysmal or persistent AF. Moreover, a doubled risk of appropriate shocks was observed in the 
permanent AF group when compared to patients with no history of AF (adjusted hazard ratio 2.4, 
95% CI 1.5-4.0, p<0.001). 
 
Inappropriate device shocks 
One-hundred-thirty-nine (15%) patients experienced at least one inappropriate device discharge. 
When comparing the four groups, major differences in event rates were observed. Three years 
event rate for inappropriate shocks was 13% (95% CI 10-17%) for no AF, 28% (95% CI 15-40%) 







permanent AF (Figure 4). When compared to the group without a history of AF, the permanent 
AF group showed a more than doubled risk for the inappropriate shocks (adjusted hazard ratio 
2.7, 95% CI 1.7-4.4, p<0.001). Patients with a history of paroxysmal AF had the highest risk for 
inappropriate device shocks (adjusted hazard ratio 2.9, 95% CI 1.7-4.8, p<0.001) during follow-
up. It is of note that in the group without a history of AF, (new-onset) AF during follow-up was 
the cause of inappropriate device shocks in 27 patients (4%)  
 
 
Figure 4: Inappropriate device shock. Kaplan-Meier curve for the occurrence of first 
inappropriate device shock in patients without a history of AF (no AF), paroxysmal AF, persistent 
AF, or permanent AF. 
 
Discussion 
The main findings of the current study on the prognostic importance of AF in ICD patients can be 
summarized as follows: (1) in the population, currently receiving ICD treatment, 9% have a 
history of paroxysmal AF, 7% have a history of persistent AF and 11% have permanent AF; (2) 




arrhythmias triggering device discharge, and inappropriate device shocks than patients without 
AF; (3) patients with a history of paroxysmal or persistent AF did not show a significantly 
increased risk for mortality or appropriate device therapy but demonstrated a almost tripled risk 
for inappropriate device shocks. 
 The present analysis adds to prior literature in that it discriminates between different 
types of AF and that it assesses the population, presently considered for ICD treatment outside the 
setting of clinical trial. 
 
Mortality 
Previous trials have demonstrated the importance of AF in the general population, as well as in a 
population with symptomatic or asymptomatic heart failure.(13, 14) Benjamin and co-workers 
showed that the occurrence of AF was associated with a 1.5- to 1.9-fold risk for all-cause 
mortality, even after adjustment for further cardiovascular conditions related to AF.(13) These 
findings seem comparable to the 1.7 times increased risk for mortality in patients with permanent 
AF, as observed in the current analysis. However, when specifically assessing a population with 
symptoms of heart failure, findings in current literature are inconsistent in the potential relation 
between AF and the risk for mortality.(14, 22-25) In a post-hoc analyses of the second 
Multicenter Automatic Defibrillator Implantation Trial, Zareba and co-workers made a 
comparison between patients with sinus rhythm and AF. Since AF was defined by its presence on 
the ECG at enrollment, one might assume that all the patients identified with AF have permanent 
AF and those with paroxysmal or persistent AF, if not coincidentally present at enrollment, will 
have been classified as having sinus rhythm.(7, 19) Furthermore, the trial only included primary 
prevention ICD recipients with a prior myocardial infarction. In contrast to the current study, 





Appropriate ICD therapy 
One might hypothesize that the occurrence of any type of AF is a marker of worse general cardiac 
status and therefore that AF will be positively correlated with the occurrence of ventricular 
arrhythmias. On the other hand, AF could initiate episodes of ventricular arrhythmias and might 
therefore directly influence the occurrence of ventricular arrhythmias and consequent appropriate 
device therapy. The facilitation of AF in the initiation of ventricular tachyarrhythmias has been 
observed by Roy and co-workers during an electrophysiological study.(26) Afterwards, Stein et 
al. observed 8.9% of the episodes of ventricular arrhythmia to be accompanied by AF.(27) Earlier 
studies suggested that ventricular arrhythmias are evoked by rapid and uncontrolled AV 
conduction.(28-30) More recently, Grönefeld et al. suggested that the AV nodal conduction 
pattern preceding ventricular tachyarrhythmia were short-long-short sequences, rather than solely 
a rapid conduction.(16) The irregular ventricular excitation leads to heterogeneous depolarization, 
which subsequently renders the myocardium more susceptible to ventricular arrhythmias.(31, 32) 
In line with the current findings, prior studies confirm AF to have a positive correlation with the 
occurrence of ventricular arrhythmias.(16-18) Interestingly, a post-hoc analysis of the Multicenter 
Automatic Defibrillator Implantation Trial II did not demonstrate a difference in the occurrence 
of appropriate therapy when comparing (mostly permanent) AF with patients in sinus rhythm.(19) 
A possible explanation for this difference could be that the permanent AF group in the current 
study is sicker in a manner not completely accounted for by post hoc statistical adjustment. The 
present study did not show an increase in appropriate device therapy in the groups with a history 
of paroxysmal or persistent AF, which could imply that these patients do not have a deterioration 
of general cardiac status of such magnitude to consequently cause higher occurrence of 
ventricular arrhythmia. Thus far, no analysis had been reported on the prognostic implications of 





Inappropriate ICD shocks 
Previous studies have demonstrated the relationship between the existence of AF and 
inappropriate device discharge and the consequent negative effect of inappropriate device 
discharge on patient quality of life.(33-35) Furthermore, recent research has demonstrated the 
impact of inappropriate shock delivery on mortality.(33, 36) These findings stress the importance 
of clear identification of patients at high risk for inappropriate shocks in order to better inform 
patients and to optimize individual patient treatment. The current study maps the importance of 
different types of AF on the occurrence of inappropriate shocks and highlights the high event rate 
in patients with persistent, permanent and, most outspoken, paroxysmal AF. A potential 
explanation of the higher event rate in the paroxysmal AF group, even when compared to the 
group with permanent AF, can be explained by the fact that clinicians will more often adjust their 
treatment (such as AV-node ablation) if AF is ongoing. Additionally, the higher occurrence of 
ventricular arrhythmias in the group with permanent AF might cause a more aggressive 
pharmacological antiarrhythmic treatment.  
 
Limitations 
This was a non-randomized prospective observational cohort study, performed to assess the long-
term follow-up in ICD patients outside the setting of a clinical trial. Since patients were collected 
over a period of four years, expanding guidelines for the implantation of defibrillators, treatment 
of acute myocardial infarction, and pharmacological antiarrhythmic therapy could have created an 
heterogeneous population. Furthermore, standard ICD settings at discharge could have been 







In the population, currently receiving ICD treatment outside the setting of a clinical trial, 11% has 
permanent AF and 16% has a history of paroxysmal or persistent AF. The existence of permanent 
AF doubles the risk for mortality and appropriate, as well as inappropriate device therapy. 
Paroxysmal and persistent AF did not prove to have an effect on mortality or the occurrence of 
appropriate device discharge. However, the rate of inappropriate shocks is importantly increased 
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Objectives: The aim of the study was to assess the risk for non-benefit from implantable 
cardioverter defibrillator (ICD) treatment in primary prevention ICD patients with ischemic heart 
disease. 
Background: Although the beneficial effect of ICD therapy has been well established as primary 
prevention in a selected population at high risk for sudden arrhythmic death, a substantial part 
does not benefit from ICD treatment during long-term follow-up.  
Methods:  Since 1996, all ICD recipients in the Leiden University Medical Center have been 
clinically assessed at implantation. For the current study, patients with ischemic heart disease and 
a primary indication for implantation have been included. During follow-up, all-cause mortality 
and device therapy (anti-tachycardia pacing or shock) were noted. Non-benefit was defined as 
death, prior to first appropriate ICD therapy. Out of baseline variables, a baseline risk score was 
constructed to estimate risk for non-benefit.  
Results: Nine-hundred patients (87% men, mean age 64 ± 10 years) were included in the 
analysis. During a median follow-up of 669 days (interquartile range, 363 to 1322 days), 150 
patients (17%) died and 191 (21%) patients received appropriate device therapy. A total of 114 
(13%) patients were considered the non-benefit group. Stratification for non-benefit resulted in 
risk categorization of patients as low, intermediate or high-risk. Advanced age was the strongest 
predictor of non-benefit. Five-year cumulative incidence for non-benefit ranged from 12% (95% 
confidence interval (CI) 5–18%) in low-risk patients to 49% (95%CI 38–60%) in high-risk 
patients.  
Conclusions: The risk of non-benefit can be predicted in primary prevention ICD patients with 






Large randomized trials have demonstrated that implantable cardioverter defibrillator (ICD) 
treatment is the treatment of choice for patients with prior life-threatening arrhythmias (secondary 
prevention) (1-3) and for selected patients at high risk for sudden cardiac death, regardless of 
prior arrhythmia (primary prevention) (4-7). Since implementation of primary prevention in the 
international guidelines, implantation rates have increased dramatically to an estimated 275000 
devices in 2008 (8, 9). However, with the inclusion of primary prevention in the currently ICD 
indicated population, rates of appropriate therapy for ventricular arrhythmias have decreased to 
35% during long-term follow-up in the second Multicenter Automatic Defibrillator Implantation 
Trial (MADIT-II) compared to 64% in secondary prevention patients (1, 10). Furthermore, 
clinicians have expressed concern that the number of patients needed to treat with a primary 
prevention ICD might be too high and that the population, eligible for primary prevention ICD 
treatment, is of such magnitude that provision of ICD therapy will strain financial resources and 
the pool of trained personnel (11). In addition, ICD therapy is associated with adverse events such 
as pocket related infections and inappropriate shocks (12). The relatively low actual need for 
defibrillator therapy during follow-up, combined with the associated adverse events and the 
incapability to implant all indicated patients, urges for refinement of the current selection criteria 
for ICD treatment. Therefore, it would be of interest to identify a population, currently receiving 
ICD treatment, not benefiting from ICD therapy (i.e. death prior to appropriate ICD therapy).   
Since 1996, all patients receiving an ICD at the Leiden University Medical Center have 
been assessed and followed up. This thoroughly screened cohort provided an opportunity to 
identify ICD recipients who do not benefit from ICD treatment and to assess whether baseline 
parameters influence the risk of non-benefit. Finally, a clinically applicable risk model is 
constructed to aid clinicians in individual risk estimations for primary prevention ICD patients 





Since 1996, all patients who received an ICD at the Leiden University Medical Center were 
prospectively collected in the departmental Cardiology Information System (EPD-Vision®, 
Leiden University Medical Center, Leiden, the Netherlands). Characteristics at baseline, data of 
the implant procedure and of all follow-up visits were recorded. For the current analysis, patients 
with a primary indication for defibrillator implantation and ischemic heart disease were selected. 
 It should be noted that, due to evolving guidelines, eligibility for ICD implantation in this 
population might have changed over time (13, 14). Nonetheless, in the majority of patients, 
indication for an ICD was made in the presence of a depressed left ventricular ejection fraction 
(LVEF) with or without non sustained ventricular tachycardia (8, 13). Ischemic heart disease was 
defined as the presence of significant coronary artery disease (a diameter stenosis of at least 50% 
in at least one coronary artery) (15, 16). Exclusion criteria for the current analysis consisted of 




All tested variables were collected at device implantation and defined and categorized according 
to literature or common practice. Age was categorized as <65 years, 65–74 years and ≥75 years; a 
history of non sustained ventricular tachycardia was defined as a run of 3 to 30 ventricular ectopic 
beats at a rate >120 beats per minute (6); renal clearance was estimated with the formula of 
Cockroft-Gault and categorized in normal or stage 1 renal failure (>90 ml/min), stage 2 renal 
failure (60-90 ml/min), or stage 3-5 renal failure (<60 ml/min) (17); QRS duration was 
categorized as <100 ms, 100-130 ms, or >130 ms; LVEF was categorized as ≤25% or >25%;(18) 
Heart failure symptoms were categorized as mild (New York Heart Association (NYHA) 




defined as a history of atrial fibrillation as documented on ECG; a history of smoking was defined 
if a patient had a positive answer when asked for past or present smoking (20); and body mass 
index was categorized as <30 kg/m2 or ≥30 kg/m (21). 
 
Device implantation 
All ICD systems used were implanted in the pectoral region. Used systems were manufactured by 
Biotronik (Berlin, Germany), Medtronic (Minneapolis, MN, United States), Boston Scientific 
(Natick, MA, United States, formerly CPI, Guidant [St. Paul, MN, United States]) and St. Jude 
Medical/Ventritex (St. Paul, MN, United States). 
Defibrillators were programmed as follows: a ventricular arrhythmia monitor zone was 
programmed in all patients (150-188 bpm). Ventricular arrhythmias faster than 188 bpm were 
initially attempted to be terminated with two bursts of anti-tachycardia pacing (ATP) and, after 
continuation of the arrhythmia, with defibrillator shocks. In the case of a ventricular arrhythmia 




All patients were seen at the implanting center. Follow-up started at the time of implantation and 
lasted until death or last date of data acquisition (February 2009). Devices were interrogated 
every three to six months or more frequently when clinically indicated. Printouts of device 
interrogations were checked for delivered therapy, which was classified as appropriate when 
occurring in response to ventricular tachycardia or ventricular fibrillation. Furthermore, all-cause 
mortality was noted. Patients without data on the past six months were considered lost to follow-
up. As previously reported, non-benefit from ICD treatment was defined as death from any cause, 




Statistical analysis  
Continuous data are expressed as mean with standard deviation (SD) or median with 25th and 
75th percentile where appropriate. Dichotomous data are presented as numbers and percentages. 
Baseline characteristics in the non-benefit group and the remaining study population were 
compared with the chi-square test and unpaired Student’s t-test as appropriate. All-cause 
mortality, appropriate therapy, non-benefit and mortality after delivered appropriate therapy were 
analyzed by method of Kaplan-Meier, evaluated using the log rank test and presented with a 95% 
confidence interval (CI) (24). In the calculation of the cumulative incidence of non-benefit, 
appropriate therapy was considered a censoring event.   
 Baseline medication was excluded from risk score construction, since this clinician 
driven variable could bias the results and impede reproducibility. All other baseline variables 
were entered as categorical variables. Initially, the variables were entered in univariate logistic 
regression models, with non-benefit from ICD treatment as only outcome. Variables with a p-
value <0.10 were further analyzed in a multivariate logistic regression model, using backward 
stepwise selection until all variables in the model reached a p-value <0.25. Based on the 
variables’ regression coefficient in this multivariate model, a risk stratification score was 
constructed by giving a base regression coefficient the value of one point on the risk score and 
giving all variables the associating score, according to their multiplication of this base regression 
coefficient and rounding it off to the nearest whole or half number. Subsequently, the patient 
specific values for the predictors in the score were summed to obtain a score for each patient. The 
ability of the score to discriminate between patients who did and patients who did not reach the 
endpoint was estimated by the area under the curve of the receiver operating curve. After the 
determination of the individual patient risk score, cut-offs were determined for a population at 
low, intermediate and high risk of non-benefit from ICD treatment. These cut-offs were chosen to 




internal validation and to assess the stability of variable selection, bootstrap with 1000 resamples 




Patient characteristics  
From 1996 to 2008, 935 patients with ischemic heart disease underwent ICD implantation for 
primary prevention. Thirty-five (3.7%) patients were lost to follow-up. Median follow-up of the 
remaining 900 patients was 669 days (interquartile range, 363-1322 days). 
Baseline characteristics are provided in Table 1. The majority of patients (mean age 
64±10 years) were male (87%), had a depressed LVEF (29±11%) and wide QRS (125±33 ms). 
Beta blockers were used by 63% of the patients, sotalol by 12% and ACE inhibitors or AT 
antagonists by 85%.  
 
Incidence of all-cause mortality and first appropriate ICD therapy 
During follow-up, 150 patients (17%) died. Cumulative incidence of all-cause mortality in the 
study population was 27% (95%CI 22-31%) after five years. A total of 3638 episodes of 
ventricular arrhythmia, causing appropriate device therapy, were noted in 191 (21%) patients. 
These consisted of 3333 arrhythmia episodes being terminated by ATP in 128 (14%) patients and 
298 episodes being terminated by ICD shocks in 100 (11%) patients. Cumulative incidence of 
first appropriate therapy in the study population was 39% (95%CI 34-44%) after five years 






Table 1. Baseline characteristics  




Clinical	  parameters	   	   	  
	  	  	  	  Male	  gender	  (%)	   779	  (87)	   0	  
	  	  	  	  Age,	  mean	  (SD),	  years	   64	  (10)	   0	  
	  	  	  	  	  	  	  	  median	  (interquartile	  range),	  years	   66	  (57-­‐72)	   	  
	  	  	  	  NYHA	  functional	  class	   	   17	  (2)	  
	  	  	  	  	  	  	  	  I	   193	  (21)	   	  
	  	  	  	  	  	  	  	  II	   352	  (39)	   	  
	  	  	  	  	  	  	  	  III	   325	  (36)	   	  
	  	  	  	  	  	  	  	  IV	   30	  (3)	   	  
	  	  	  	  History	  of	  nsVT	  (%)	   221	  (25)	   0	  
	  	  	  	  Renal	  clearance,	  mean	  (SD),	  ml/min	   78	  (37)	   53	  (6)	  
	  	  	  	  QRS-­‐duration,	  mean	  (SD),	  ms	   125	  (33)	   10	  (1)	  
	  	  	  	  LVEF,	  mean	  (SD),	  %	   29	  (11)	   52	  (6)	  
	  	  	  	  History	  of	  atrial	  fibrillation	  (%)	   228	  (25)	   3	  (0)	  
	  	  	  	  Diabetes	  (%)	   227	  (25)	   36	  (4)	  
	  	  	  	  History	  of	  smoking	  (%)	   429	  (48)	   50	  (6)	  
	  	  	  	  Body	  mass	  index,	  mean	  (SD),	  kg/m2	   27	  (4)	   54	  (6)	  
Implantable	  cardioverter	  defibrillator	   	   0	  
	  	  	  	  Single	  chamber	  (%)	   40	  (4)	   	  
	  	  	  	  Dual	  chamber	  (%)	   423	  (47)	   	  
	  	  	  	  Cardiac	  resynchronization	  therapy	  (%)	   437	  (49)	   	  
Medication	   	   0	  
	  	  	  	  Beta-­‐blocker	  (%)	   570	  (63)	   	  
	  	  	  	  Sotalol	  (%)	   106	  (12)	   	  
	  	  	  	  ACE	  inhibitors	  /	  AT	  antagonist	  (%)	   767	  (85)	   	  
	  	  	  	  Statins	  (%)	   742	  (82)	   	  
	  	  	  	  Diuretics	  for	  CHF	  (%)	   651	  (72)	   	  
	  	  	  	  Amiodarone	  (%)	   126	  (14)	   	  
Abbreviations: ACE, angiotensin-converting enzyme; AT, angiotensin; LVEF, left ventricular 




Non-benefit from ICD treatment  
During follow-up, 114 (13%) patients died without prior appropriate ICD treatment and were 
considered the non-benefit group. Cumulative incidence of death without prior ICD treatment was 
7% (95%CI 6-8%) after one year, 18% (95%CI 15-22%) after three years and 24% (95%CI 21-




 Comparison of the non-benefit group with the remaining study population demonstrated 
that the non-benefit group was older, had higher NYHA functional class, worse renal function, 
longer QRS duration, lower LVEF, and more often a history of diabetes and smoking (Table 2). 
Subsequently, multivariate logistic modeling for the prediction of non-benefit from ICD treatment 
contained the following variables: (1) age (65-74 and ≥75 years), (2) diabetes, (3) LVEF ≤25%, 
(4) NYHA functional class III-IV and (5) a history of smoking. The strongest predictor of non-
benefit from ICD treatment was age ≥75 years (odds ratio 2.95, 95%CI 1.7-5.1%) (Table 3). 
Bootstrap analysis demonstrated that age, diabetes, LVEF, NYHA and smoking were selected in 
99, 99, 98 96, 97%, respectively. The area under the receiver operator curve of the acquired risk 
score was reasonably good: 0.73 (95%CI 0.68 – 0.78). 
For construction of the non-benefit prediction model, the following risk point cut-offs 
were used: (1) low risk (0-1.5 points); (2) intermediate risk (2-2.5 points); and (3) high risk (3-5.5 
points). When extrapolated to the total study population, 371(41%) patients exhibited low risk of 
non-benefit, 323 (36%) patients intermediate risk and 206 (23%) patients high risk. Cumulative 
incidence of non-benefit after 5 years was 12% (95%CI 5-18%) in low risk patients, 22% (95%CI 




Table 2. Baseline characteristics of patients who do not benefit from ICD treatment versus the 
remaining study population.  
	   Non-­‐benefit	  group	  
(n=114)	  
Remaining	  group	  
(n=786)	   p-­‐value	  
Clinical	  parameters	   	   	   	  
Male	  gender	  (%)	   102	  (90)	   677	  (86)	   0.33	  
Age	   	   	   <	  0.001	  
<	  65	  years	  (%)	   41	  (36)	   386	  (49)	   	  
65	  -­‐	  74	  years	  (%)	   40	  (35)	   286	  (36)	   	  
≥	  75	  years	  (%)	   33	  (29)	   114	  (15)	   	  
NYHA	  functional	  class	   	   	   <	  0.001	  
I	  or	  II	  (%)	   45	  (39)	   500	  (64)	   	  
III	  or	  IV	  (%)	   69	  (61)	   286	  (36)	   	  
History	  of	  nsVT	  (%)	   25	  (22)	   196	  (25)	   0.49	  
Renal	  failure	   	   	   <	  0.001	  
Stage	  1	  (	  >	  90ml/min)	  (%)	   15	  (13)	   262	  (33)	   	  
Stage	  2	  (60	  –	  90	  ml/min)	  (%)	   23	  (20)	   311	  (40)	   	  
Stage	  3	  (<	  60	  ml/min)	  (%)	   76	  (67)	   213	  (27)	   	  
QRS-­‐duration	   	   	   0.01	  
<	  100	  ms	  (%)	   15	  (13)	   163	  (21)	   	  
100-­‐130	  ms	  (%)	   42	  (37)	   344	  (44)	   	  
>130	  ms	  (%)	   57	  (50)	   279	  (35)	   	  
LVEF	  ≤	  25%	  (%)	   66	  (58)	   280	  (36)	   <	  0.001	  
History	  of	  atrial	  fibrillation	  (%)	   35	  (31)	   193	  (25)	   0.10	  
Diabetes	  (%)	   46	  (40)	   181	  (23)	   <	  0.001	  
History	  of	  smoking	  (%)	   65	  (57)	   364	  (46)	   0.03	  
Body	  mass	  index	  ≥	  30	  kg/m2	  (%)	  	   18	  (16)	   144	  (18)	   0.31	  
Implantable	  cardioverter	  defibrillator	   	   	   0.003	  
Single	  chamber	  (%)	   2	  (5)	   38	  (2)	   	  
Dual	  chamber	  (%)	   40	  (49)	   383	  (35)	   	  
Cardiac	  resynchronization	  therapy	  (%)	   72	  (46)	   365	  (63)	   	  
Abbreviations: LVEF, left ventricular ejection fraction; nsVT, non sustained ventricular 
tachycardia; NYHA, New York Heart Association.  
  
Table 3. Multivariate logistic regression model and corresponding risk score for non-benefit from 
ICD treatment  




p-­‐value	   Score	  
Age	   	   	   <	  0.001	   	  
65	  –	  74	  years	   0.26	   1.30	  (0.81	  –	  2.10)	   0.28	   .5	  
≥	  75	  years	   1.08	   2.95	  (1.69	  –	  5.14)	   <	  0.001	   2	  
LVEF	  ≤	  25%	   0.76	   2.13	  (1.40	  –	  3.24)	   <	  0.001	   1.5	  
Diabetes	  	   0.72	   2.05	  (1.33	  –	  3.15)	   0.001	   1	  
NYHA	  functional	  class	  III-­‐IV	   0.64	   1.89	  (1.23	  –	  2.90)	   0.003	   1	  
History	  of	  smoking	   0.65	   1.91	  (1.25	  –	  2.94)	   0.004	   1	  
Abbreviations: CI, confidence interval; LVEF, left ventricular ejection fraction; NYHA, New 





Figure 1. Risk stratification for non-benefit. Kaplan-Meier curve for non-benefit in patients 
with low, intermediate or high risk. 
 
 
Follow-up after appropriate therapy 
Cumulative incidences of appropriate therapy did not differ between the different non-benefit risk 
groups: 32% (95%CI 24-40%) in low risk patients, 46% (95%CI 35-37%) in intermediate risk 
patients and 44% (95%CI 31-58%) in high risk patients (p=NS). However, mortality after 
delivery of appropriate therapy did differ significantly between the non-benefit risk groups. After 
5 years of follow-up, cumulative incidences of mortality after appropriate therapy were 11% 
(95%CI 1-21%) in low risk patients, 28% (95%CI 12-43%) in intermediate risk patients and 61% 




              
Figure 2. Mortality after appropriate therapy. Kaplan-Meier curve for mortality after 





In the current study on the identification of primary prevention ICD patients with ischemic heart 
disease who do not benefit from ICD treatment, the findings can be summarized as follows: 1) 
Five-year cumulative incidence was 27% for all-cause mortality and 39% for first appropriate 
ICD therapy; 2) Five-year cumulative incidence of non-benefit was 24%; 3) Strongest predictor 
of non-benefit was advanced age; 4) Almost 50% of high risk patients did not benefit from ICD 
treatment after five years follow-up. 
The current study adds to current literature in that it is the first to propose a risk model for 





In recent literature, several subgroup analyses of the MADIT-II focused on the identification of 
patients who were most likely to receive appropriate device therapy. These analyses mentioned 
interim hospitalization for heart failure or a coronary artery event, no beta-blocker usage, current 
smoking, NYHA class >II, renal dysfunction, high body mass index and digitalis use as factors 
increasing the risk of ventricular arrhythmia during follow-up (20, 26, 27). Interestingly, these 
baseline predictors for ICD therapy were similar to baseline variables associated with an 
increased risk for mortality (26, 28). Consequently, the patients with the highest risk of receiving 
potentially life-saving appropriate device therapy have the worst prognosis, regardless of the 
implanted device. This paradox makes the findings in literature difficult to interpret. Therefore, a 
different approach to assess ICD efficacy was necessary. Koller and co-workers combined 
appropriate ICD therapy with all-cause mortality and defined non-benefit from ICD treatment as 
death prior to appropriate therapy, instead of focusing on patients with the lowest occurrence of 
ICD therapy. They demonstrated that usage of diuretics for heart failure – which was considered a 
surrogate of advanced heart failure – compared with nonuse was found to be the only significant 
predictor of non-benefit from ICD treatment. The current analysis demonstrated that besides 
advanced heart failure, a history of smoking, diabetes and higher age were also associated with 
non-benefit from ICD treatment. Differences between the study by Koller et al and the current 
analysis might be explained by the limited set of variables, smaller population size and 
heterogeneity (e.g. primary and secondary prevention ICD patients) of the study population 
assessed in the analysis of Koller and co-workers (23).  
 Goldenberg et al demonstrated in a risk analysis of MADIT-II that benefit from ICD 
treatment is following a U-shaped pattern with evident benefit for patients with intermediate risk 
of all-cause mortality and little benefit in low and high-risk patients (29). This principle implies 
two non-benefiting groups at both ends of this efficacy curve. One group comprises patients with 




(sudden) death. The other group consists of relatively healthy ICD patients who exhibit very low 
risk for life-threatening ventricular arrhythmia. It should be noted that, according to the observed 
risk factors, the current risk stratification identified the first mentioned group of non-benefit ICD 
patients with high risk of non-arrhythmic mortality. To identify the other group (i.e. with low-risk 
for ventricular arrhythmia) a different approach is desirable. Hallstrom and co-authors focused on 
predictors of recurrent arrhythmia in a subgroup analysis of the Antiarrhythmics versus 
Implantable Cardioverter Defibrillator Trial as secondary prevention of sudden cardiac death and 
identified, based on sextiles of the hazard distribution, a subgroup for which ICDs did not render 
survival advantage over amiodarone (22). Indeed, they reported on a ‘healthy’ subgroup, 
presenting with an isolated episode of ventricular fibrillation, few comorbidities and moderate 
preserved LVEF, which was not likely to benefit from ICD treatment over amiodarone.  
 Refinement of the current selection criteria for primary prevention patients with ischemic 
heart disease is essential. The current study provides a model to predict the individual risk for 
non-benefit, which may assist physicians in the decision-making process whether or not to 
prophylactically implant an ICD. It is however important to realize that patients at high-risk for 
non-benefit do not per se receive no appropriate ICD therapy at all. Some of the parameters that 
are associated with high risk of non-benefit are also identified as predictors of all-cause mortality, 
sudden cardiac death or appropriate therapy, like advanced age, depressed ejection fraction and 
smoking (26, 29, 30). This paradox could be explained with the short life-expectancy of this very 
sick group of patients. Consequently, even after potentially life-saving appropriate ICD therapy, 
life expectancy is still very short in high-risk patients (Figure 2). Thus, despite the fact that ICD 
therapy is not uncommon is this subset of patients, the survival advantage of prophylactic ICD 
implantation is limited.  
Limitations of the findings are due to the non-randomized prospective study design. Since 




heterogeneous population. Additionally, the proposed risk score does not take clinician driven 
variables (medication) or follow-up acquired variables (hospitalizations, adverse events) in 
account since this could lead to a decrease in baseline applicability and reproducibility. Finally, 
the constructed risk score requires validation. 
 A significant number of primary prevention ICD patients with ischemic heart disease 
does not benefit from ICD treatment during long-term follow-up. The use of a baseline risk score 
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Abstract               
Background: In primary prevention implantable cardioverter defibrillator (ICD) patients, the 
incidence of life-threatening ventricular arrhythmias resulting in ICD therapy is relatively low, 
prompting for better risk stratification. The aim of this study was to assess the value of the QRS-T 
angle for prediction of ICD therapy and mortality in primary prevention patients with ischemic 
heart disease (IHD).                                
Methods and results: ICD patients (n=412, 361 male, age 63±11 years) with IHD and a left 
ventricular ejection fraction ≤ 40% were included. After device implantation, the occurrence of 
appropriate ICD therapy and mortality was noted. A survival analysis was performed comparing 
patients with a planar QRS-T angle ≤ 90º (n=124, 30%) to patients with a planar QRS-T angle > 
90º before device implantation. Furthermore, patients with a spatial QRS-T angle ≤ 100º (n=56, 
14%) were compared to patients with a spatial QRS-T angle > 100º, prior to implant.  
 For patients with a planar QRS-T angle >90º as compared to ≤ 90º, the adjusted hazard 
ratio for the occurrence of appropriate device therapy was 2.4 (95% CI 1.1-5.2);  a spatial QRS-T 
angle > 100º was associated with an adjusted hazard ratio of 7.3 (95% CI 1.0-53.8). Furthermore, 
a spatial QRS-T angle ≤ 100º exhibited a positive predictive value of 98% (95% CI 95-100%) for 
the prediction of an appropriate therapy-free follow-up.           
Conclusions: A wide QRS-T angle is a strong predictor of appropriate device therapy in primary 
prevention ICD recipients with IHD. Furthermore, a spatial QRS-T angle ≤ 100º might be of 
value in the identification of patients in whom, although currently indicated, ICD treatment 






Introduction                                         
Sudden cardiac death (SCD), mainly caused by ventricular arrhythmias, accounts for 
approximately 50% of all cardiac mortality worldwide.1-3 It is recognised that patients with 
ischemic heart disease and depressed left ventricular ejection fraction (LVEF) are at high risk of 
SCD,4, 5 and large randomised trials have demonstrated that  implantable cardioverter 
defibrillator (ICD) therapy reduces all-cause mortality, as well as SCD. 6-10 
Implementation of these results in the international guidelines resulted in a significant 
increase of the number of ICD implantations.11, 12 However, long-term follow-up studies 
in currently indicated patients show a relatively low incidence of ventricular arrhythmias 
that trigger ICD therapy.13 Additionally, approximately 6% of ICD patients experience 
severe device-related adverse events (i.e. pocket infections, sepsis), causing the need for 
surgical re-intervention, additional hospitalization, or even death.14, 15 This led to critical 
appraisal of the wide-spread application of ICD therapy and stressed the need for more 
precise risk stratification criteria.16 In an attempt to identify those criteria, post-hoc 
analyses of the second Multicenter Automatic Defibrillator Implantation Trial (MADIT II) 
revealed several clinical criteria associated with an increased risk for ventricular 
arrhythmias resulting in appropriate device therapy.17-19 So far, however, in low LVEF 
patients no criteria have been recognised which may identify patients at low risk of 
ventricular arrhythmias during follow-up. If possible to identify a low risk population, 
ICD therapy in this group may be reconsidered.      
 Recently, a wide angle between the QRS and T axes, the QRS-T angle, on the 
standard 12-lead ECG was recognised as a novel and easy applicable marker of increased 




associated with the increased incidence of appropriate device therapy and mortality in 
primary prevention ICD recipients with non-ischemic cardiomyopathy.22 However, no 
data are available on the value of the QRS-T angle in ICD patients with IHD.  
 The aim of the current study was, to assess the value of the QRS-T angle in 
predicting life threatening ventricular arrhythmias in primary prevention ICD patients 
with IHD. Furthermore the value of the QRS-T angle was evaluated as a parameter to 
identify patients at low risk for ventricular arrhythmias. 
 
Methods                   
Patients                    
Patients with IHD who underwent implantation of an ICD, based on the international treatment 
guidelines, in the Leiden University Medical Center were selected for the current study.11 
Criterion for inclusion were a depressed LVEF (<40%) with or without a history of non sustained 
ventricular tachycardia. Since 1996, these patients were prospectively registered in the 
departmental Cardiology Information System (EPD-Vision®).23 Prior to implantation, a 
comprehensive assessment of patient characteristics was performed as described previously.24  
 During follow-up, the occurrence of appropriate ICD therapy and patient mortality was 
noted. In addition, for the purpose of this study, the ECG made before implantation was analyzed. 
                  
Implantable cardioverter defibrillator implantation and follow-up                                  
All defibrillator systems were implanted transvenously without thoracotomy. Device follow-up 
was scheduled every three to six months. All printouts were carefully checked for appropriate and 
inappropriate ICD therapy. In case of any ICD therapy, an electrophysiologist, blinded to QRS-T 






anti-tachycardia pacing (ATP) or shock, were classified as appropriate when they occurred in 
response to life threatening arrhythmias; ventricular tachycardia (VT) or ventricular fibrillation 
(VF) and as inappropriate when triggered by sinus or supraventricular tachycardia (SVT), T-wave 
oversensing, or electrode dysfunction.        
 Defibrillators were programmed as follows:  ventricular arrhythmia faster than 150 bpm 
was monitored by the device without consequent defibrillator therapy. Ventricular arrhythmias 
faster than 188 bpm were initially attempted to be terminated with two bursts of ATP and, after 
continuation of the arrhythmia, with defibrillator shocks. In the case of a ventricular arrhythmia 
faster than 210 bpm, device shocks were the initial therapy. Furthermore, atrial arrhythmia 
detection was set to >170 bpm with SVT discriminators enabled. Settings were adapted, only 
when clinically indicated (i.e. hemodynamic well tolerated ventricular tachycardia at high rate; 
ventricular tachycardia in the monitor zone).       
                        
Electrocardiographical analysis             
First, the quality of ECGs was evaluated. If electrode displacement, missing leads or signal noise 
was present, the ECGs were excluded from the analysis. Since right ventricular pacing alters 
normal cardiac conduction and results, by definition, in an abnormal QRS-T angle, patients with a 
pacemaker were excluded from the analysis.25 Subsequently, the ECGs were analyzed with a 
dedicated computer program (LEADS, Leiden ECG Analysis and Decomposition Software).26 
Full details on the computation method and LEADS based values of vector characteristics in 
healthy subjects, have been extensively described earlier.27 In short, the software converts the 
standard ECG into a vectorcardiogram and computes the three dimensional orientation of the 
QRS- and T-axes. Thereafter, the QRS-T angle is calculated in the plane formed by the QRS- and 
T-axes, the spatial QRS-T angle. In addition, the more commonly used but less precise projection 




studies demonstrated that a spatial QRS-T angle wider than 100º is associated with the presence 
of cardiac disease and increased cardiovascular mortality.20, 21 Pavri et al. recently demonstrated 
that a planar QRS-T angle wider than 90º is associated with an increased incidence of appropriate 
device shocks and mortality22. In the present study, these cut-offs (100º for the spatial and 90º for 
the planar QRS-T angle) were applied.   
        
Statistical analysis 
A survival analysis, comprising of the following end-points, was performed: (1) first appropriate 
ICD therapy (ATP and/or shock); (2) all-cause mortality; and (3) a composite end-point of all-
cause mortality and first appropriate device therapy, whichever occurs first. ICD recipients with a 
narrow QRS-T angle were compared to those with a wide QRS-T angle. The points of cut-off 
were pre-defined as described above, 100º for the spatial and 90º for the planar QRS-T angle. 
Cumulative event rates of end-points were analyzed by the method of Kaplan-Meier. 
Relationships between baseline parameters and end-points were assessed with Cox’s proportional 
hazard regression analysis. For the composite end-point, survival time was defined as time to all-
cause death or appropriate device therapy, whichever occurred first. For each variable a hazard 
ratio with a 95%-confidence interval (95% CI) was calculated. Therapy-free follow-up was 
defined as a study follow-up without the occurrence of appropriate ICD therapy.   
 Continuous data are expressed as mean ± standard deviation or median and quartiles 
where appropriate; dichotomous data are presented as numbers and percentages. Comparison of 
data at baseline was performed with the Student’s t test for unpaired data and Chi-square tests 
with Yates correction when appropriate.        
 The authors had full access to the data and take responsibility for its integrity. All authors 






Results                                                
Patients and follow-up                  
A total of 460 patients with ischemic heart disease and a LVEF ≤ 40% underwent ICD 
implantation for primary prevention of sudden cardiac death in the Leiden University Medical 
Center. Thirty-two (7%) patients were excluded due to the presence of a pacemaker and 16 (3%) 
patients were excluded since their ECG prior to device implantation could not be analyzed 
because of technical reasons such as electrode displacement, missing leads, or signal noise. The 
remaining 412 (90%) ICD recipients (63±11 yrs, 88% male) were included in the analysis and 
were followed for 22±17 months (range 0 to 77 months). Baseline characteristics are summarised 
in Table 1.  
During follow-up, 46 (11%) patients died, and a total of 482 episodes of appropriate 
device therapy for ventricular arrhythmias occurred in 56 (14%) patients; 386 episodes of 
ventricular arrhythmia, terminated by ATP in 35 (8%) patients, and 96 episodes triggering device 
shocks in 28 (7%) patients. During follow-up, the first end-point (first appropriate device therapy) 
was reached in 56 patients (24 shock, 32 ATP), the second end-point (all-cause death) was 
reached in 46 patients and the composite end-point (death or first appropriate device therapy) was 





Table 1. Patient characteristics 
	   All	  
patients	  
Planar	  QRS-­‐T	  angle	  	  
≤	  90º	  
Spatial	  QRS-­‐T	  angle	  
≤	  100º	  
	   	   Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  No	   Yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  No	  
Patients	   412	   124	  (30%)	  	  	  	  	  288	  
(70%)	  
56	  (14%)	  	  	  	  	  356	  (86%)	  
Clinical	  parameters	   	   	   	  
	  	  	  Age	  (yrs)	   63±11	   61±11	  	  	  	  	  	  	  	  	  	  	  	  64±10*	   62±11	  	  	  	  	  	  	  	  	  	  63±10	  
	  	  	  Male	  (%)	   361	  
(88%)	  
110	  (89%)	  	  	  	  	  251	  
(87%)	  
51	  (91%)	  	  	  	  	  310	  (87%)	  
	  	  	  Biventricular	  ICD	  (%)	   194	  
(47%)	  
43	  (35%)	  	  	  	  	  	  	  151	  
(52%)†	  
22	  (39%)	  	  	  	  	  172	  (48%)	  
	  	  	  LVEF	  (%)	   26±7	   28±7	  	  	  	  	  	  	  	  	  	  	  	  	  	  25±7†	   30±6	  	  	  	  	  	  	  	  	  	  	  	  26±7†	  
	  	  	  NYHA	  functional	  class	   	   	   	  
	  	  	  	  	  	  	  I-­‐II	   261	  
(63%)	  
92	  (74%)	  	  	  	  	  	  	  169	  
(59%)*	  
41	  (73%)	  	  	  	  	  220	  (62%)	  
	  	  	  	  	  	  	  III-­‐IV	   151	  
(37%)	  
32	  (26%)	  	  	  	  	  	  	  119	  
(41%)*	  
15	  (27%)	  	  	  	  	  136	  (38%)	  




24	  (19%)	  	  	  	  	  	  	  86	  (30%)*	   6	  (11%)	  	  	  	  	  	  	  104	  
(29%)†	  
	  	  	  History	  of	  nicotine	  abuse	  (%)	   190	  
(46%)	  
55	  (44%)	  	  	  	  	  	  	  135	  
(47%)	  
29	  (52%)	  	  	  	  	  161	  (45%)	  
	  	  	  Current	  nicotine	  abuse	  (%)	   86	  (21%)	   25	  (20%)	  	  	  	  	  	  	  60	  (21%)	   12	  (21%)	  	  	  	  	  74	  (21%)	  
	  	  	  History	  of	  atrial	  fibrillation	  /	  	  
	  	  	  lutter	  (%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
98	  (24%)	   24	  (19%)	  	  	  	  	  	  	  74	  (26%)	   10	  (18%)	  	  	  	  	  88	  (25%)	  
	  	  	  Atrial	  fibrillation	  /	  flutter	  at	  	  
	  	  	  implantation	  (%)	  	  	  	  	  	  	  
39	  (9%)	   8	  (6%)	  	  	  	  	  	  	  	  	  	  	  31	  (11%)	   2	  (4%)	  	  	  	  	  	  	  	  	  37	  (10%)	  
	  	  	  History	  of	  nonsustained	  VT	  
(%)	  
81	  (20%)	   24	  (19%)	  	  	  	  	  	  	  57	  (20%)	   10	  (18%)	  	  	  	  	  71	  (20%)	  
	  	  	  Body	  mass	  index	  (kg/m2)	   27±4	   26±4	  	  	  	  	  	  	  	  	  	  	  	  	  	  27±5	   27±3	  	  	  	  	  	  	  	  	  	  	  	  27±4	  
Medication	   	   	   	  
	  	  	  Beta	  blocker	  (%)	   317	  
(77%)	  
99	  (80%)	  	  	  	  	  	  	  218	  
(76%)	  
42	  (75%)	  	  	  	  	  	  275	  
(77%)	  
	  	  	  ACE	  inhibitor	  /	  	  
	  	  	  AT	  antagonist	  (%)	  
358	  
(87%)	  
110	  (89%)	  	  	  	  	  248	  
(86%)	  
49	  (88%)	  	  	  	  	  	  309	  
(87%)	  
	  	  	  Diuretics	  for	  CHF	  (%)	   317	  
(77%)	  
90	  (73%)	  	  	  	  	  	  	  227	  
(79%)	  
38	  (68%)	  	  	  	  	  	  279	  
(78%)	  
	  	  	  Statins	  (%)	   349	  
(85%)	  
111	  (90%)	  	  	  	  	  238	  
(83%)	  
53	  (95%)	  	  	  	  	  	  296	  
(83%)*	  
	  	  	  Amiodarone	  (%)	   57	  (14%)	   15	  (12%)	  	  	  	  	  	  	  42	  (15%)	   1	  (2%)	  	  	  	  	  	  	  	  	  	  56	  (16%)†	  
ECG	  parameters	   	   	   	  
	  	  	  Heart	  rate	  (bpm)	   66±16	   66±15	  	  	  	  	  	  	  	  	  	  	  	  66±16	   67±16	  	  	  	  	  	  	  	  	  	  	  66±15	  
	  	  	  QRS	  duration	  (ms)	   130±33	   120±29	  	  	  	  	  	  	  	  	  	  134±34†	   115±28	  	  	  	  	  	  	  	  	  132±33†	  
	  	  	  QTc	  Bazett	  (ms)	   431±51	   431±52	  	  	  	  	  	  	  	  	  	  431±51	   434±50	  	  	  	  	  	  	  	  	  431±52	  
	  	  	  Frontal	  QRS-­‐T	  angle	  (º)	   116±52	   	  	  47±24	  	  	  	  	  	  	  	  	  	  146±26†	   62±33	  	  	  	  	  	  	  	  	  	  	  125±50†	  
	  	  	  Spatial	  QRS-­‐T	  angle	  (º)	   139±32	   112±35	  	  	  	  	  	  	  	  	  	  151±22†	   75±18	  	  	  	  	  	  	  	  	  149±20†	  
* p<0.05; † p<0.01 as compared to patients with a narrow planar/spatial QRS-T angle.      
ACE = angiotensin converting enzyme; AT = angiotensin; CHF = congestive heart failure; ICD = 
implantable cardioverter defibrillator; LVEF = left ventricular ejection fraction; NYHA = New 






QRS-T angle and all-cause mortality                 
In 124 (30%) patients, a planar QRS-T angle smaller or equal to 90º was measured on the 
baseline ECG. As summarised in Table 1, patients with a narrow planar QRS-T angle were more 
likely to be younger (61±11 yr vs. 64±10 yr, p<0.05), to have a better LVEF (28±7% vs. 25±7%, 
p<0.001), and shorter QRS duration (120±29 ms vs. 134±34 ms, p<0.001). The hazard ratio of a 
planar QRS-T angle > 90º for mortality was 3.1 (95% CI 1.3-7.3) as compared to patients with a 
narrow planar QRS-T angle. The cumulative event-free follow-up for all cause mortality in 
patients with a narrow planar QRS-T angle was 99% (95% CI 98-100%) at one year, 92% (95% 
CI 87-98%) at two years, and 92% (95% CI 87-98%) at four years of follow-up (Figure 1).                             
 
Figure 1. Kaplan-Meier curve for cumulative event rate for all cause mortality in patients 
with a planar QRS-T angle ≤ 90º vs. a planar QRS-T angle > 90º (panel A) and with a 




Fifty-six (14%) patients had a baseline spatial QRS-T angle smaller than or equal to 100º. 
These patients were younger, had a more preserved LVEF (30±6% vs. 26±7%, p<0.01), a shorter 
QRS duration (115±28 ms vs. 132±33 ms, p<0.01), used statins more often (95% vs. 83%, 
p<0.05) and were using amiodarone less frequently (2% vs. 16%, p<0.01) (Table 1). As is shown 
in Table 2, patients with a wide spatial QRS-T angle exhibited a hazard ratio for all-cause 
mortality of 1.7 (95% CI 0.6-4.9).  



















	   Yes	  	  	  	  	  	  	  	  	  	  	  No	   	   	   Yes	  	  	  	  	  	  	  	  	  	  	  No	   	   	  
Appropriate	  
therapy	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*Hazard ratio was adjusted for age, sex, LVEF, and QRS duration.                       
CI = confidence interval; HR = hazard ratio 
 
QRS-T angle and ventricular arrhythmia  
The hazard ratio of a planar QRS-T angle wider than 90º for the occurrence of ventricular 
arrhythmia triggering appropriate device therapy was 2.9 (95% CI 1.4-6.1). When adjusted for 
age, sex, LVEF and QRS duration, the hazard ratio was 2.4 (95% CI 1.1-5.2). Furthermore, this 
group demonstrated an almost threefold risk increase (hazard ratio 2.9, 95% CI 1.6-5.0) for the 
composite end-point of appropriate therapy and mortality (Table 2). The cumulative event-free 
follow-up for appropriate therapy in patients with a narrow planar QRS-T angle was 95% (95% 






years of follow-up (Figure 2).         
 As is shown in Table 2, patients with a wide spatial QRS-T angle exhibited a near tenfold 
risk for the occurrence of ATP or shocks (hazard ratio 9.9, 95% CI 1.4-71.7) during follow-up. 
When adjusted for age, sex, LVEF, and QRS duration the hazard ratio was 7.3 (95% CI 1.0-53.8). 
Strikingly, the cumulative event-free follow-up for ventricular arrhythmia which triggered device 
therapy was 100% at two years and 96% (95% CI 87-100%) at four years of follow-up, as can be 
readily seen in Figure 2.  
          
      
Figure 2. Kaplan-Meier curve for cumulative event rate for appropriate therapy in 
patients with a planar QRS-T angle ≤ 90º vs. a planar QRS-T angle > 90º (panel A) and 





Identification of patients free of life-threatening arrhythmias             
Evaluation of the usefulness of a planar QRS-T angle smaller than or equal to 90º at baseline in 
the prediction of an appropriate therapy-free follow-up revealed a positive predictive value of 
94% (95% CI 89-98%) and a negative predictive value of 17% (95% CI 12-21%).  
 The spatial QRS-T angle had a positive predictive value of 98% (95% CI 95-100%) and a 
negative predictive value of 15% (95% CI 12-19%) for the prediction of an appropriate therapy-
free follow-up. Most importantly, only 2% of the patients with a spatial QRS-T angle ≤ 100º had 
appropriate device discharges during follow-up, the only event occurring after 745 days (Figure 
2).            
                    
Discussion                  
In the current study on the clinical application of the planar and spatial QRS-T angle in the 
prediction of ventricular arrhythmias in ischemic primary prevention ICD patients, the main 
findings can be summarised as follows: after adjustment for age, sex, LVEF, and QRS-duration, 
1) patients with a wide planar QRS-T angle exhibited a nearly 2.5-fold risk for mortality, as well 
as for appropriate device therapy; 2) patients with a wide spatial QRS-T angle had a sevenfold 
risk for ventricular arrhythmias triggering appropriate device therapy; and 3) patients with a 
spatial QRS-T ≤ 100º prior to implantation, exhibited an absolute risk of 2% for appropriate 
therapy during follow-up.         
                  
With primary prevention ICD therapy as a class I indication in international guidelines in patients 
with a low LVEF, the indicated population, and therefore the worldwide defibrillator 
implantation rates, have increased significantly.11, 12 This expansion is of such magnitude that 






ICD implantations.16, 28 Furthermore, MADIT II demonstrated a cumulative incidence of the need 
for defibrillator back-up of only 35% of patients after three years.13 Moreover, 6% of ICD treated 
patients, experience severe device-related adverse events.14 These issues underscore the need for 
better risk stratification within the indicated population.       
 Ideally, a parameter for the identification of a population at high or at low risk for the 
need for defibrillator back-up should be non-invasive and easily acquired. An ECG derived 
parameter such as the QRS-T angle, validated in the current analysis, would fit these demands. 
 
Risk stratification with the QRS-T angle 
The QRS-T angle is the angle between the electrical axes of depolarisation and repolarisation. In 
the present study, clinical application of both the planar as well as the spatial QRS-T angle has 
been investigated in primary prevention ICD recipients with ischemic heart disease. The planar 
QRS-T angle is the projection of the spatial QRS-T angle in the frontal plane. As with any 
projection, it is sensitive to variations of the anatomical position of the heart in thorax. Therefore, 
the spatial QRS-T angle, which is calculated in the plane that the QRS- and T-axes form, is a 
more robust clinical tool. This is an important issue as the results from this study demonstrate that 
a narrow spatial angle is associated with a lower risk of ventricular arrhythmias. And although the 
spatial QRS-T angle cannot be derived directly from the surface ECG, recent studies have 
provided easy methods to acquire the spatial QRS-T angle from the standard 12-lead ECG.29  
 In our population of ischemic primary prevention ICD recipients, patients with a wide 
planar QRS-T angle demonstrated a hazard ratio of 2.5 for the need of defibrillator back-up and 
3.1 for all-cause mortality. In the recently published post hoc analysis of the DEFINITE trial, by 
Pavri and co-workers22, the planar QRS-T angle was analyzed as a predictor of the composite 




with non-ischemic cardiomyopathy. In this study, the hazard ratio of a planar QRS-T angle wider 
than 90º for the occurrence of appropriate device therapy was 1.95 (95% CI 1.24-3.08). The 
hazard ratio for all-cause mortality was 1.81 (95% CI 1.04-3.13).     
 After adjustment for other commonly used risk factors, the presence of a spatial QRS-T 
angle wider than 100º was associated with a hazard ratio of 7.3 for the occurrence of device 
therapy for ventricular arrhythmias as compared to patients with a spatial QRS-T angle ≤ 100º, in 
our population. More importantly, all patients with a spatial QRS-T angle ≤ 100º were free of 
device generated therapy during two years following implantation. This indicates that the spatial 
QRS-T angle may have an important potential for risk stratification in patients with ischemic 
heart disease.           
 Previous studies on the spatial QRS-T angle have already indicated its high value in the 
risk stratification for cardiac death in a population without ICDs.20, 21 In a large cohort of patients, 
Yamazaki et al. observed a hazard ratio of 1.9 (95% CI 1.7-2.1) on cardiovascular death for a 
spatial QRS-T angle > 100º after correction for other ECG parameters.21    
 As a consequence of the balanced regulation of electrical activation and recovery of the 
ventricles, a narrow QRS-T angle is generally observed in healthy individuals.27 Ventricular scar 
or residual ischemia, which is the arrhythmic substrate in ischemic cardiomyopathy, causes a 
disbalance of this process, sometimes referred to as electrical heterogeneity or discordance of de- 
and repolarisation.30 Vectorcardiographically, these alterations in cardiac electrophysiology 
become, amongst others, apparent through directional changes of the QRS and T vectors and 
consequent widening of the QRS-T angle. When patients with ischemic cardiomyopathy have a 
narrow QRS-T angle, which is then associated with electrical homogeneity, it could be postulated 
that the amount of arrhythmic substrate is limited and may even be absent. The high incidence of 
ventricular arrhythmias in patients with a wide QRS-T angle and the low incidence in patients 






Clinical implications            
Several non-invasive parameters that could improve patient selection for ICD therapy have been 
proposed. These include LVEF, QRS duration, QT interval, heart rate variability, ventricular 
ectopy on ambulatory monitoring, exercise capacity, and T-wave alternans.31 In addition, total 
cosine R to T, which is also a measure of QRS-T concordance like the QRS-T angle, has been 
proven a promising parameter in the mortality risk stratification in patients following myocardial 
infarction.32, 33 However, this variable has not been assessed in an ICD treated population, to our 
knowledge. Although the majority of these parameters appear promising, only LVEF has proven 
its usefulness in patient selection for ICD implantation and is currently the most important factor 
in the clinician’s choice whether or not an ICD is indicated.11 Still, in the implanted ischemic 
population, identified as being at high risk for ventricular arrhythmia based on depressed LVEF, 
35% of patients actually experiences appropriate device therapy during follow-up, prompting for 
the identification of a sub-population at low risk.13 In our population of ischemic primary 
prevention ICD recipients, patients with a spatial QRS-T angle ≤100º demonstrated no ventricular 
arrhythmias during the first two years following implantation and only 2% during further follow-
up. These results imply that this parameter could be used in the discrimination of patients in 
whom the beneficial effects of an ICD might not exceed the costs and potential morbidity 
accompanying ICD therapy.         
                  
Limitations                 
This was a non-randomised prospective observational study, performed to assess the long-term 
follow-up in ischemic primary prevention ICD recipients and to assess the value of the planar and 
spatial QRS-T angle in baseline risk stratification. Adjustment for additional variables in the 




patients without therapy during study follow-up might have reached an end-point, had follow-up 
been longer. Additionally, since not all patients had post-mortem ICD interrogation, some cases 
of death might have been arrhythmic. Finally, since patients were included over a period of 11 
years, expanding guidelines for the implantation of defibrillators, treatment of acute myocardial 
infarction, and pharmacological anti-arrhythmic therapy could have created an inhomogeneous 
population.             
                  
Conclusion                     
In patients with ischemic heart disease, currently indicated for primary prevention ICD therapy, a 
baseline spatial QRS-T angle > 100º is associated with a sevenfold risk for the occurrence of 
appropriate device therapy, even after adjustment for commonly used risk factors. More 
importantly, a spatial QRS-T angle ≤ 100º on the ECG prior to implantation can identify patients 
with very low risk of life-threatening ventricular arrhythmias in whom the beneficial effect of 
ICD treatment might not exceed the costs and potential complications.    
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Background: The performance of small diameter implantable cardioverter defibrillator (ICD) 
leads has been questioned. The current study provides an update on the lead failure and cardiac 
perforation rate of Medtronic’s Sprint Fidelis ICD lead and St. Jude Medical’s Riata ICD lead in 
comparison to a large benchmark cohort.  
Methods and Results: Since 1996, all ICD system implantations at the Leiden University 
Medical Center, the Netherlands, are registered. For the current study, data on 396 Sprint Fidelis 
leads (follow-up 3.4±1.5 years), 165 8-French (F) Riata leads (follow-up 4.6±2.6 years) and 30 7-
F Riata leads (follow-up 2.9±1.3 years) were compared with a benchmark cohort of 1602 
transvenously implanted ICD leads (follow-up 3.4±2.7 years) and assessed for the occurrence of 
lead failure and cardiac perforation. During follow-up, the yearly lead failure rate of the Sprint 
Fidelis lead, 7-F Riata lead, 8-F Riata lead and the benchmark cohort was 3.54%, 2.28% 0.78% 
and 1.14%, respectively. In comparison to the benchmark cohort, the adjusted hazard ratio of lead 
failure was 3.7 (95%CI 2.4-5.7, p<0.001) for the Sprint Fidelis lead and 4.2 (95%CI 1.0-18.0, 
p<0.05) for the 7-F Riata lead. Only one cardiac perforation was observed (0.05%) in the Riata 
group versus none in the Sprint Fidelis lead population.  
Conclusion: The risk of lead failure was significantly increased for both the Sprint Fidelis and 








Manufacturers of implantable cardioverter defibrillator (ICD) leads constantly aim to improve 
design to allow easier implantation of additional leads, maintain venous blood flow and reduce 
subclavian crush syndrome.1 However, recently became clear that these developments go together 
with some serious drawbacks. In particular, studies have reported on higher-than-expected lead 
failure rates for Medtronic’s Sprint Fidelis lead (Medtronic Inc, MN, USA) as well as for St. 
Jude’s 7-F Riata lead (St. Jude Medical Inc, MN, USA).2-6 Moreover, studies have observed 
relatively high cardiac perforation rates associated with the Riata 1580/1581 lead (8-F) and the 
Riata 7000 series (7-F).5, 7 As a consequence, Medtronic ceased production of the Sprint Fidelis 
lead and announced several safety advisories to improve early detection and reduce the number of 
inappropriate shocks due to lead failure. 4, 8, 9  
Given the high number of leads implanted worldwide (268 000 Sprint Fidelis leads and 
227 000 Riata leads) it is important to monitor these patients carefully and provide up-to-date data 
on lead performance. Our center reported earlier on preliminary results of the performance of the 
Sprint Fidelis and 7-F Riata lead.7, 10 This study provides an update on the performance of both 
leads with an extended follow-up duration and compares lead failure and cardiac perforation rates 
of the Sprint Fidelis lead, the Riata 7-F and the Riata 8-F lead with complication rates of a large 




Since 1996, all patients who received an ICD system at the Leiden University Medical Center, 
Leiden, the Netherlands, are registered in the departmental Cardiology Information System (EPD-




visits were recorded. For the current analysis, only patients with a Sprint Fidelis lead (Medtronic 
Inc, MN, USA; model type 6949, 6948, 6931, 6930) and patients with a Riata lead (St. Jude 
Medical Inc, MN, USA; model type 1570, 1580, 1582, 7000, 7001, 7002, 7020) were included. 
For comparison of follow-up data, a large benchmark cohort of patients with transvenously 
implanted defibrillation leads, other than Sprint Fidelis leads or Riata leads was used. These leads 
were manufactured by Boston Scientific (MA, USA [formerly CPI Guidant, MN, USA]), 
Biotronik (Germany), Medtronic (MN, USA) and St. Jude Medical/Ventritex (MN, USA). 
Eligibility for ICD implantation was based on international guidelines and included both 
secondary prevention and primary prevention of sudden cardiac death.11, 12 Testing of sensing and 




The follow-up was from lead implantation to February 1, 2011. Periodic device interrogation was 
performed every 3–6 months or earlier if patient had symptomatic events. During these 
examinations, all leads were systematically evaluated for adequate function and integrity. As 
reported previously, all patients with a Sprint Fidelis lead and a Medtronic device were invited for 
implementation of Medtronic’s safety advisories.10 In brief, advisories consisted of adjustment of 
device settings, uploading of the Lead Integrity Algorithm and remote monitoring with 
CareLink®.10 The benchmark cohort was followed and assessed for the occurrence of lead failure 
up to February 2008.7 
 
Definition of lead failure and cardiac perforation 
Defibrillation lead removal or capping was classified as lead failure if one of the following 






incapability of sensing, pacing, or defibrillation; (3) inappropriate shocks secondary to electrical 
noise artifacts; (4) abnormal lead impedance; (5) Lead Integrity Algorithm triggering an ICD 
alert.3, 4 Cardiac perforation was diagnosed when a pericardial effusion was detected by 
transthoracic echocardiography in combination with abnormal lead impedance and/or pacing 
thresholds during follow-up.5 
 
Statistical analysis 
Continuous variables were analyzed as mean±SD. Categorical variables were analyzed as 
percentages as numbers and percentages. The cumulative incidence of lead failure was calculated 
using the Kaplan-Meier methodology. Chi-square tests were used to compare categorical 
variables and student t-tests were used for continuous variables. The occurrence of lead failure 
was compared with the benchmark cohort using three groups based on manufacturer and lead 
diameter: 1) Sprint Fidelis leads, 2) 7-F Riata leads (comprising lead model types 7000, 7001, 
7002, 7020) and 3) 8-F Riata leads (comprising lead model types 1570, 1580, 1582). Cumulative 
incidences were analyzed by method of Kaplan-Meier and compared using the log-rank test. The 
95% confidence intervals (CI) were calculated as 1.96 times the standard error in each direction. 
Multivariate Cox regression analysis, adjusted for known confounders (left ventricular ejection 
fraction, age, gender, and cardiomyopathy), was used to assess the risk of lead failure, described 
as hazard ratios (HR) with 95% CI.13, 14 The statistical tests were performed using SPSS 18.0 for 
Windows. For all tests, a p-value <0.05 was considered significant. 
 
Results 
Since 1996, a total of 396 Sprint Fidelis defibrillation leads were implanted in 390 patients and 




1602 leads, implanted in 1553 patients. As can be seen in Table 1, the majority of patients was 
male and had ischemic cardiomyopathy. During an average follow-up of 3.5±2.5 years, 372 
patients died. To our knowledge, no patient died as a direct or indirect result of lead failure or 
cardiac perforation.  
 
Table 1. Baseline clinical characteristics. 





F	  Riata	  lead	  
(n=28)	  







Baseline	  characteristics	   	   	   	   	  
Age,	  year	   63±12	   63±13	   63±12	   61±14	  
Male	  sex,	  %	   81	   89	   82	   80	  
Ejection	  fraction,	  %	   32±14	   39±11	   38±15	   34±14	  
Ischemic	  etiology,	  %	   67	   74	   72	   64	  
Primary	  indication,	  %	   73	   67	   58	   58	  
ICD = Implantable cardioverter defibrillator; F = French 
 
 
Sprint Fidelis lead performance 
The average follow-up of all 396 Sprint Fidelis lead was 3.4±1.5 years. As demonstrated in Table 
2, the majority of patients received a Sprint Fidelis lead of Model Type 6931 (62%). During 
follow-up, 47 leads (12%) failed. These were implanted in 47 patients, of whom, 17 (36%) 
received 117 inappropriate shocks in total. Average time from implant to lead failure was 2.6±1.0 
years. As can be seen in Figure 1, cumulative incidence of lead failure increased exponentially 
after 1 year of follow-up. After 2 years of follow-up, cumulative incidence was 4.1% (95%CI 1.9-
6.3%), after 4 years 15.0% (95%CI 10.7-19.3%) and after 6 years 17.8% (95%CI 12.9-22.7%). In 
addition, yearly lead failure rates in first, second, third and fourth year of follow-up were 0.4%, 












 Of the 47 failed leads, 8 failures (17%) were observed during routine evaluation, 21 
patients (45%) were warned by a device alert without experiencing inappropriate shocks, 18 
patients (38%) received inappropriate shocks of whom 2 patients were alerted by the device 
minutes before the shocks. Prior to implementation of the Lead Integrity Algorithm (only 
available for Medtronic ICDs), 10 out of 15 (67%) patients with a Medtronic ICD received an 
inappropriate shock related to lead failure. After implementation, 6 out of 24 (25%) patients 
received an inappropriate shocks related to lead failure (p<0.05). In addition, average number of 
repetitive inappropriate shocks decreased from 5.6±7.7 to 1.0±2.9 inappropriate shocks per case 
of lead failure (p<0.05) after implementation of the advisories. No cardiac perforations were 







Table 2. Model type of all implanted ICD leads. 
	   	  
Benchmark	  cohort	  (n=1602)	   	  
Biotronik	  8-­‐F,	  n	  (%)	   98	  (6)	  
Boston	  Scientific	  11-­‐F,	  n	  (%)	   163	  (10)	  
Boston	  Scientific	  9-­‐F,	  n	  (%)	   911	  (57)	  
Medtronic	  10.5-­‐F,	  n	  (%)	   76	  (5)	  
Medtronic	  9-­‐F,	  n	  (%)	   322	  (20)	  
St	  Jude	  Medical	  11-­‐F,	  n	  (%)	   32	  (2)	  
Medtronic’s	  7-­F	  Sprint	  Fidelis	  leads	  (n=396)	   	  
6930,	  n	  (%)	   1	  (<1)	  
6931,	  n	  (%)	   247	  (62)	  
6948,	  n	  (%)	   48	  (12)	  
6949,	  n	  (%)	   100	  (25)	  
St	  Jude	  Medical’s	  7-­F	  and	  8-­F	  Riata	  leads	  (n=195)	   	  
1570,	  n	  (%)	  	   114	  (59)	  
1580,	  n	  (%)	   44	  (22)	  
1582,	  n	  (%)	   7	  (4)	  
7000,	  n	  (%)	   5	  (3)	  
7001,	  n	  (%)	   1	  (<1)	  
7002,	  n	  (%)	   23	  (12)	  
7020,	  n	  (%)	   1	  (<1)	  
ICD = Implantable cardioverter defibrillator; F = French 
 
 
Removal of the leads was performed in 25 (53%) of the cases, sealing of the lead 
occurred in 22 patients (47%; Table 3). Two minor complications (4.2%) associated with Sprint 
Fidelis lead revision were observed: 1) right atrial lead dislodgement and 2) detachment of the 
distal part of the Sprint Fidelis lead (model type 6949) during manual traction, which required an 







Table 3. Performance of the implanted ICD leads 









Active,	  n	  (%)	   198	  (50.0)	   90	  (54.5)	   19	  (63.3)	   1063	  (66.4)	  
Failed,	  n	  (%)	   47	  (11.9)	   6	  (3.6)	   2	  (6.7)	   62	  (3.9)	  
Non-­‐active,	  n	  (%)	   110	  (27.8)	   51	  (30.9)	   5	  (16.7)	   314	  (19.6)	  
Died,	  n	  (%)	   81	  (20.4)	   32	  (19.4)	   3	  (10.0)	   256	  (16.0)	  
Prophylactically	  replaced	  or	  
sealed,	  n	  (%)	  
12	  (3.0)	   0	  (0.0)	   0	  (0.0)	   0	  (0.0	  
Replaced/sealed	  for	  other	  
reasons,	  n	  (%)	  
7	  (1.8)	   2	  (1.2)	   1	  (3.3)	   15	  (0.9)	  
Infection,	  n	  (%)	   10	  (2.5)	   17	  (10.3)	   0	  (0.0)	   43	  (2.7)	  
Followed	  up	  elsewhere,	  n	  (%)	   41	  (10.4)	   18	  (10.9)	   4	  (13.3)	   163	  (10.1)	  
Average	  follow-­‐up,	  y	   3.4±1.5	   4.6±2.6	   2.9±1.3	   3.4±2.7	  
Total	  follow-­‐up,	  y	   1327.1	   767.0	   87.6	   5449.3	  
Failure	  rate	  %/y	   3.54	   0.78	   2.28	   1.14	  
ICD = Implantable cardioverter defibrillator; F = French 
 
 
Riata lead performance 
Of the 195 implanted Riata leads, 165 leads had a diameter of 8-F and 30 leads a diameter of 7-F.  
During an average follow-up of 4.4±2.5 years, 8 (4.1%) leads implanted in 7 different patients 
failed. Due to the failure, 2 patients experienced a total of 11 inappropriate shocks. For 7-F leads, 
cumulative incidence of lead failure was 3.8% (95%CI 0-11.2) after 2 years and 8.0% (95%CI 0-
18.8) after 4 years. For 8-F leads, cumulative incidence was 1.5% (95%CI 0-3.5%) after 2 years 
and 3.2% (95%CI 0.1-6.3%) after 4 years of follow-up (Figure 2). Average time from implant to 
lead failure was 1.9±0.5 years for 7-F leads and 3.8±2.3 years for 8-F leads.  
Revision of the 8 failed leads resulted in removal of 3 leads and sealing of 5 leads. One 
complication occurred during these revisions, which consisted of right atrial lead dislodgement.  
One cardiac perforation (0.5%), caused by a 7-F Riata lead, model type 7002, was observed 





Lead performance in benchmark cohort  
In 1602 leads in the benchmark cohort, 62 cases (3.9%) of lead failure occurred during 3.4±2.7 
years follow-up. Cumulative incidence of lead failure was 0.7% (95%CI 0.3-1.1%) after 2 years 
of follow-up, 3.4% (95%CI 2.2-4.6%) after 4 years, 8.3 % (95%CI 5.9-10.7%) after 6 years and 
11.5% (95%CI 8.2-14.8%) after 8 years (Figure 1&2). Average time from implant to lead failure 
was 4.2±2.3 years. 
 
Figure 2. Failure of Riata leads. Kaplan Meier curve for cumulative incidences of lead failure, 
grouped by lead diameter (French). 
 
 
Differences in failure rate 
As can be seen in Table 2, major differences in failure rates were observed between the groups. 
Whereas the benchmark cohort and the 8-F Riata leads demonstrated yearly lead failure rates of 
1.14% and 0.78%, respectively, the Sprint Fidelis showed a yearly lead of 3.54% and the 7-F 
Riata lead of 2.28%. The adjusted risk of failure was 3.7 times higher for Sprint Fidelis leads in 
comparison to the benchmark cohort (HR 3.7 95%CI 2.4-5.7, p<0.001) and 4.2 times higher for 








The principal findings of this update study can be summarized as follows: 1) the risk for lead 
failure was significantly increased for both the Sprint Fidelis and the 7-F Riata lead as compared 
to a benchmark cohort, 2) implementation of Medtronic’s safety advisories significantly reduced 
the number of inappropriate shocks, 3) cardiac perforations occurred rarely. 
 
Sprint Fidelis lead performance 
Three years after its introduction in 2004, Hauser et al. were first to report the higher-than-
expected failure rate of Sprint Fidelis leads.2 Within three months following this preliminary 
report, Medtronic suspended distribution and announced recommendations for impedance alert 
programming, followed one year later, by recommending the usage of remote monitoring and 
Lead Integrity Algorithm. Since then several studies have reported high yearly failure rates 
varying from 2.8% to 3.6%.2, 14-16 The current study observed an overall yearly lead failure rate of 
3.5% as compared to 1.1% in the benchmark cohort. Additionally, this failure rate accelerated 
over time: if a lead survived its first 3 years of follow-up, the failure rate for the following year 
increased up to 7.3%. This accelerating phenomenon was first described by Farwell et al. during a 
mean follow-up of 1.7 year and in the current study with an extended follow-up of 3.5 years, this 
was confirmed.3 This sheds important light on the still ongoing discussion whether or not to 
replace the leads prophylactically, especially since an estimated 166000 Sprint Fidelis leads are 
still active worldwide.17  
To come to a well-considered decision, one should realize that the risk of complications 
with lead revision is substantial. In literature, complication rates associated with 




two minor complications in 348 patients who underwent Sprint Fidelis lead revision, Parkash et al 
reported on major complications in 7.0% and minor complications in 7.5% of 468 Sprint Fidelis 
lead revisions.18, 19 Noteworthy, all revisions reported in the study by Maytin et al were performed 
by highly skilled operators with a large volume of experience.18 In the current study, no major 
complications occurred and the minor complication rate was 4.2%. Overall, the complication rate 
is still too high to justify prophylactic lead replacement, although, taken in mind the accelerating 
risk of lead failure, over time the benefits of prophylactic lead replacement might outweigh the 
lead failure-related risks. 
 
Riata lead and cardiac perforation   
Around 2007, several studies and case reports observed higher-than-expected cardiac perforation 
rates in patients with a Riata lead. When taken these reports as a whole, the cardiac perforation 
rate was 2.5% which far exceeds registry data (<0.5%).20 Hereafter, Danik et al demonstrated a 
comparable rate (2.8%) in a larger population with longer follow-up duration. However, they 
observed perforations only in patients with a specific Riata lead model type including 1580/1581 
(8-F) and 7000 (7-F) and stated that similarities in design of the lead, rather than the size of the 
lead alone, might contributed to this relatively high complication rate.5 In addition, Ellis and 
Rottman found comparable high risks of cardiac perforation for these specific lead types.6  
In sharp contrast to the previous reports is an industry-sponsored study of the Riata lead, 
comprising more than 15 000 patients. They observed a perforation rate of 0.38% and owed the 
differences with the previous results to a statistical phenomenon.21, 22 In the current study, only 
one perforation was observed in a patient with a Riata lead (0.5%) versus none in patients with a 
Sprint Fidelis lead, which is in accordance with the large registry studies.21, 22  
 






Interestingly, this study also demonstrated that the adjusted risk of failure for the 7-F Riata leads 
was more than four times higher than the benchmark cohort. This was earlier observed in a study 
by Ellis et al. who demonstrated in 62 patients with a 7-F Riata lead an even higher failure rate of 
8.1% during a follow-up of less than 1 year.6 And although this is preliminary data of a small 
cohort of 30 (this study) and 62 leads, the high lead failure rate is worrying. Again data of the 
multiple registry studies did not support this and reported a lead failure rate of <1%.21, 22 
However, it should be noted that data of industry driven studies are sometimes better than clinical 
practice studies – as was the case with data of Medtronic on the performance of the Sprint Fidelis 
lead.14 For proper analysis, it is therefore essential to have a non-industry driven European or 
worldwide data registry.23 
 
Limitations 
The presented results are subjected to the usual limitations of a retrospective analysis. 
Furthermore, cases of lead failure and cardiac perforation might occur without symptoms or 
changes in electric parameters, causing them to go unnoticed. 
  
Conclusion 
From this study becomes clear that the risk of Sprint Fidelis lead failure continues to accelerate 
over time. Adverse events related to Sprint Fidelis lead failure were significantly reduced as a 
result of the safety advisories. A comparable failure rate was observed for the smallest 7-F Riata 
lead. In contrast, no higher-than-expected cardiac perforation rates were observed for the Sprint 






 1.  Roelke M, O'Nunain SS, Osswald S, Garan H, Harthorne JW, Ruskin JN. Subclavian crush 
syndrome complicating transvenous cardioverter defibrillator systems. Pacing Clin 
Electrophysiol 1995;18:973-9. 
 2.  Hauser RG, Kallinen LM, Almquist AK, Gornick CC, Katsiyiannis WT. Early failure of a 
small-diameter high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm 
2007;4:892-6. 
 3.  Farwell D, Green MS, Lemery R, Gollob MH, Birnie DH. Accelerating risk of Fidelis lead 
fracture. Heart Rhythm 2008;5:1375-9. 
 4.  Hauser RG, Hayes DL. Increasing hazard of Sprint Fidelis implantable cardioverter-
defibrillator lead failure. Heart Rhythm 2009;6:605-10. 
 5.  Danik SB, Mansour M, Heist EK, Ellinor P, Milan D, Singh J et al. Timing of delayed 
perforation with the St. Jude Riata lead: a single-center experience and a review of the 
literature. Heart Rhythm 2008;5:1667-72. 
 6.  Ellis CR, Rottman JN. Increased rate of subacute lead complications with small-caliber 
implantable cardioverter-defibrillator leads. Heart Rhythm 2009;6:619-24. 
 7.  Borleffs CJ, van EL, van Bommel RJ, van der Velde ET, van der Wall EE, Bax JJ et al. 
Risk of failure of transvenous implantable cardioverter-defibrillator leads. Circ Arrhythm 
Electrophysiol 2009;2:411-6. 
 8.  Groves R; Sprint Fidelis Lead Performance Update (Models 6949, 6948, 6931, 6930). 
Minneapolis: Medtronic, May 7, 2008. (Accessed November 25, 2008, at 
http://www.medtronic.com/product-advisories/physician/sprint-fidelis/index.htm.). 2008 
May. 
 9.  Groves R; Urgent medical device information: Sprint Fidelis lead patient management 
recommendations. Minneapolis: Medtronic,October 15, 2007. (Accessed November 25, 
2008, at http://www.medtronic.com/product-advisories/physician/sprint-fidelis/PROD-
ADVISORY-OCT.htm). 2007 Oct. 
 10.  van Rees JB, Borleffs CJ, Bax JJ, Nagtegaal EM, van der Velde ET, van EL et al. 
Implementation of lead safety recommendations. Pacing Clin Electrophysiol 2010;33:431-
6. 
 11.  Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al. 
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular 
Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American 
College of Cardiology/American Heart Association Task Force and the European Society 
of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines 
for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden 
Cardiac Death): developed in collaboration with the European Heart Rhythm Association 
and the Heart Rhythm Society. Circulation 2006;114:e385-e484. 
 12.  Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, III, Freedman RA, Gettes LS et al. 
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm 
Abnormalities: a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines (Writing Committee to Revise the 
ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and 
Antiarrhythmia Devices): developed in collaboration with the American Association for 
Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008;117:e350-e408. 
 13.  Ha AC, Vezi BZ, Keren A, Alanazi H, Gollob MH, Green MS et al. Predictors of fracture 







 14.  Hauser RG, Maisel WH, Friedman PA, Kallinen LM, Mugglin AS, Kumar K et al. 
Longevity of Sprint Fidelis implantable cardioverter-defibrillator leads and risk factors for 
failure: implications for patient management. Circulation 2011;123:358-63. 
 15.  Kallinen LM, Hauser RG, Tang C, Melby DP, Almquist AK, Katsiyiannis WT et al. Lead 
integrity alert algorithm decreases inappropriate shocks in patients who have Sprint Fidelis 
pace-sense conductor fractures. Heart Rhythm 2010;7:1048-55. 
 16.  Faulknier BA, Traub DM, Aktas MK, Aguila A, Rosero S, Daubert JP et al. Time-
dependent risk of Fidelis lead failure. Am J Cardiol 2010;105:95-9. 
 17.  Fischer A. How much scrutiny and stress can the Fidelis lead withstand? Circulation 
2011;123:353-4. 
 18.  Maytin M, Love CJ, Fischer A, Carrillo RG, Garisto JD, Bongiorni MG et al. Multicenter 
experience with extraction of the Sprint Fidelis implantable cardioverter-defibrillator lead. J 
Am Coll Cardiol 2010;56:646-50. 
 19.  Parkash R, Crystal E, Bashir J, Simpson C, Birnie D, Sterns L et al. Complications 
associated with revision of Sprint Fidelis leads: report from the Canadian Heart Rhythm 
Society Device Advisory Committee. Circulation 2010;121:2384-7. 
 20.  Lloyd MS, Shaik MN, Riley M, Langberg JJ. More late perforations with the Riata 
defibrillator lead from a high-volume center: an update on the numbers. Pacing Clin 
Electrophysiol 2008;31:784-5. 
 21.  Epstein AE, Baker JH, Beau SL, Deering TF, Greenberg SM, Goldman DS. Performance of 
the St. Jude Medical Riata leads. Heart Rhythm 2009;6:204-9. 
 22.  Porterfield JG, Porterfield LM, Kuck KH, Corbisiero R, Greenberg SM, Hindricks G et al. 
Clinical performance of the St. Jude Medical Riata defibrillation lead in a large patient 
population. J Cardiovasc Electrophysiol 2010;21:551-6. 
 23.  Goette A, Cantu F, van EL, Geelen P, Halimi F, Merino JL et al. Performance and survival 



























The general introduction (Chapter 1) of this thesis describes how implantable cardioverter 
defibrillator (ICD) therapy became the treatment of choice for patients at risk for life-threatening 
arrhythmias either as secondary or primary prevention. Chapter 1 further specifies on specific 
technical developments, large randomized controlled trials leading to the construction of currently 
adopted international guidelines, future developments, cost-effectiveness and currently used 
methods for risk stratification.  
 The aim of this thesis was to give better insight in the treatment of patients at risk for life-
threatening arrhythmias by studying a large population of patients treated with ICD therapy 
outside the setting of a clinical trial. Firstly, to assess long-term follow-up in patients with 
different indications for implantation and to give better insight in the need for device replacement 
(Part I). Secondly, to improve risk stratification by evaluating the currently used parameters and 
to evaluate the added value of new parameters (Part II).  
 
Part I: The actual need for defibrillator backup during long-term follow-up 
In Chapter 2 we assessed differences in mortality and ICD therapy between patients who had a 
primary or secondary indication for ICD implantation. All patients treated with ICD therapy were 
included with the only exception of patients with congenital monogenetic cardiac disease. A total 
of 2134 patients were included of whom 1302 (61%) patients received an ICD for primary 
prevention and 832 (39%) patients for secondary prevention. During a mean follow-up of 3.4 ± 
2.8 years, 423 (20%) patients died. The 5-year cumulative incidence of mortality was 25% (95% 
CI 21-29%) for primary prevention patients and 23% (95% CI 20-26%) for secondary prevention 
patients. During the first 3 years of follow-up, differences in mortality between both groups 




secondary prevention patients exhibited a 74% increased risk for appropriate therapy as compared 
to primary prevention patients (HR 1.7, 95% CI 1.5-2.0, p<0.001). 
 This study demonstrates the difference in long-term follow-up between primary and 
secondary prevention ICD patients. 
 
The purpose of Chapter 3 was to give clinicians better insight in the dilemma whether or not to 
replace an ICD after an event-free first battery service-life. In patients treated for primary 
prevention, the relatively low incidence of ventricular arrhythmias (VA), combined with the 
limited battery service-life potentially results in a large group of patients who have had no benefit 
of the ICD during the first service-life. One-hundred-and-seventy-eight primary prevention ICD 
patients who had a replacement because of battery depletion and who did not received appropriate 
therapy before device replacement were included in the current analysis. During a mean follow-
up of 22 ± 21 months after device replacement, 136 (76%) patients had not received appropriate 
ICD therapy. The 3-year cumulative incidence of appropriate therapy (following replacement) 
was 19% (95% CI 10-29%). 
 This study demonstrates that despite the majority of patients treated for primary 
prevention do not experience VA during first battery service-life, a substantial number of these 
patients do experience appropriate ICD therapy after replacement and therefore justifying device 
replacement. 
 
Part II: Improvements in risk stratification 
The aim of Chapter 4 was to assess survival in primary prevention ICD recipients with non-
ischemic or ischemic heart disease and to construct a baseline mortality risk score. In the study 
1036 patients were included and were followed-up for 29 ± 22 months. During follow-up 138 






exhibit different factors that influence the risk for mortality. A risk score, consisting of simple 
baseline variables could stratify patients in low, intermediate and high-risk for mortality. In non-
ischemic patients, annual mortality was 0.4% (95% CI 0.0-2.2%) in low-risk and 9.4% (95% CI 
6.6-13.1%) in high-risk patients. In ischemic patients, annual mortality was 1.0% (95% CI 0.2-
3.0%) in low-risk and 17.8% (95% CI 13.6-22.9%) in high-risk patients. 
 This chapter shows that utilization of an easy applicable baseline risk score can create an 
individual patient-tailored estimation on mortality risk to aid clinicians in daily practice. 
 
In Chapter 5 we assessed the prevalence of different types of atrial fibrillation (AF) and their 
prognostic importance in ICD patients. The presence of a history of AF (paroxysmal, persistent or 
permanent), the effect of AF on the occurrence of appropriate or inappropriate device therapy, as 
well as mortality was noted in 913 ICD patients. At implantation, 73% of patients had no history 
of AF, 9% had a history of paroxysmal AF, 7% had a history of persistent AF and 11% had 
permanent AF. During 27 ± 13 months follow-up, 117 (13%) patients died, 228 (25%) patients 
experienced appropriate device discharge and 139 (15%) patients received inappropriate shocks. 
Patients with permanent AF exhibit more than double the risk of mortality, ventricular 
arrhythmias triggering device discharge and inappropriate device therapy. Patients with 
paroxysmal or persistent AF did not show a significant increased risk of mortality or appropriate 
device therapy, but demonstrated an almost threefold increased risk of inappropriate therapy.  
 This study clearly demonstrates that different types of AF have prognostic implications 
for mortality, appropriate therapy as well as inappropriate device discharge.  
 
In an attempt to identify patients who do not benefit from ICD treatment, Chapter 6 defined non-
benefit from ICD treatment as death, prior to appropriate ICD therapy. Out of a number of 




a baseline risk score was constructed to estimate the risk for non-benefit in 900 ischemic primary 
prevention ICD recipients. Stratification for non-benefit resulted in risk categorization of patients 
as low, intermediate or high-risk. Advanced age was the strongest predictor of non-benefit. Five-
year cumulative incidence for non-benefit ranged from 12% (95% CI 5-18%) in low-risk patients 
to 49% (95% CI 38-60%) in high-risk patients.  
 This study shows that the risk of non-benefit can be predicted which might have 
important clinical consequences.  
 
The aim of Chapter 7 was to assess the value of the ECG derived QRS-T angle for prediction of 
ICD therapy and mortality in primary prevention patients with ischemic heart disease. For this, 
412 ICD patients with ischemic heart disease and a left ventricular ejection fraction (LVEF) ≤ 
40% were included. After device implantation, the occurrence of appropriate ICD therapy and 
mortality was noted. A survival analysis was performed comparing patients with a planar QRS-T 
angle ≤ 90° (n=124, 30%) to patients with a planar QRS-T angle > 90° before device 
implantation. Furthermore, patients with a spatial QRS-T angle ≤ 100° (n=56, 14%) were 
compared to patients with a spatial QRS-T angle > 100°, prior to implant. For patient with a 
planar QRS-T angle > 90° as compared to ≤ 90°, the adjusted hazard ratio for the occurrence of 
appropriate device therapy was 2.4 (95% CI 1.1-5.2); a spatial QRS-T angle > 100° was 
associated with an adjusted hazard ratio of 7.3 (95% CI 1.0-53.8). Furthermore, a spatial QRS-T 
angle ≤ 100° exhibit a positive predictive value of 98% (95% CI 95-100) for the prediction of an 
appropriate therapy-free follow-up. 
This study shows that an easy acquirable ECG derived parameter can be a powerful 
predictor of appropriate device therapy in primary prevention ICD recipients with ischemic heart 
disease. Furthermore, a spatial QRS-T angle ≤ 100° might be of value in the identification of 







In Chapter 8 we provided an update on the lead failure and cardiac perforation rate of 
Medtronic’s Sprint Fidelis ICD lead and St. Jude Medical’s Riata ICD lead in comparison to a 
large benchmark cohort. For this, data on 396 Sprint Fidelis leads (follow-up 3.4±1.5 years), 165 
8-French (F) Riata leads (follow-up 4.6±2.6 years) and 30 7-F Riata leads (follow-up 2.9±1.3 
years) were compared with a benchmark cohort of 1602 transvenously implanted ICD leads 
(follow-up 3.4±2.7 years) and assessed for the occurrence of lead failure and cardiac perforation. 
During follow-up, the yearly lead failure rate of the Sprint Fidelis lead, 7-F Riata lead, 8-F Riata 
lead and the benchmark cohort was 3.54%, 2.28% 0.78% and 1.14%, respectively. In comparison 
to the benchmark cohort, the adjusted hazard ratio of lead failure was 3.7 (95%CI 2.4-5.7, 
p<0.001) for the Sprint Fidelis lead and 4.2 (95%CI 1.0-18.0, p<0.05) for the 7-F Riata lead. Only 
one cardiac perforation was observed (0.05%) in the Riata group versus none in the Sprint Fidelis 
lead population.  
 This study demonstrates that the risk of lead failure was significantly increased for both 
the Sprint Fidelis and the 7-F Riata lead in comparison the benchmark cohort. The occurrence of 
cardiac perforations was rare.  
 
Conclusions and future perspectives 
Since the introduction of the ICD by Dr Michel Mirowski in 1980, large randomized trials 
undisputedly demonstrated the beneficial effect of ICD therapy in patients at risk for life-
threatening arrhythmias. Despite the results of many large randomized trials, much remains 
unclear about ICD recipients in the daily practice, outside the setting of a clinical trial. The 
current thesis clarifies a few aspects in the rapidly increasing ICD treated population. Firstly, 
during long-term follow-up, differences in the incidence of all-cause mortality and the occurrence 




ICD implantation indications (primary vs. secondary). As expected, patients treated for secondary 
prevention are at increased risk for appropriate therapy. However, similar event-rates of all-cause 
mortality were observed between both groups. Furthermore, insight was given in the actual need 
for device replacement in patients with a long event-free period. Secondly, this thesis evaluated 
the currently used parameters for risk stratification and also evaluated the added value of new 
parameters. A baseline mortality risk score derived from simple baseline clinical variables was 
constructed and the prognostic importance of atrial fibrillation on the occurrence of device 
therapy and mortality was assessed. To improve baseline risk stratification, the value of new 
parameters derived from a simple ECG was assessed for the prediction of ventricular arrhythmia.
 Future research should primarily focus on risk assessment strategies for the primary 
prevention of SCD. Improvement of the current risk assessment strategies can maximize overall 
ICD benefit. To achieve this, two different patient populations should be identified: 1) patients 
who are currently eligible for ICD implantation, but who have demonstrated no benefit from the 
device during follow-up; and 2) patients at high risk for SCD without an indication for ICD 
treatment. 
 
Sudden cardiac death 
Despite advances in preventing and treating cardiovascular disease, sudden cardiac death (SCD) 
remains a major public health issue in the Western world. In the United States alone, the annual 
incidence of SCD varies from 180.000 to 460.000 each year of which most fatal events occur 
outside the hospital.1 Since the introduction of ICD therapy, many studies have proven the 
beneficial effect of ICD treatment for the primary prevention of SCD. The survival benefit is 
demonstrated in a patient population who are at high risk for SCD according to currently used 
risk parameters. Currently used parameters to estimate the risk for SCD are: age, sex, smoking, 






therefore reasonable that patients with many positive risk factors for arrhythmia, show significant 
survival benefit. Recent international guidelines, with LVEF as the single most important risk 
stratification tool, have recommended ICD treatment for a wide range of patients with cardiac 
disease. Therefore, a major part of the population who are at high risk for SCD are indicated for 
an ICD. However, the majority of cases of SCD still occurs in patients without known cardiac 
disease or risk factors, causing ICD treatment to have relatively low impact on the incidence of 
SCD in the general population. Therefore, without novel parameters for the timely identification 
of patients at high-risk for SCD, the majority of cases of SCD cannot be prevented. To 
significantly reduce the incidence of SCD, future efforts should focus on the identification of 
more specific parameters in combination with LVEF to identify this “unknown” subgroup in the 
general population.  
 
Death, prior to first appropriate ICD therapy 
The beneficial effect of ICD therapy is well established and since the implementation of primary 
prevention in the international guidelines, implantation rates increased to an estimated 275.000 
devices in 2008.3 However, potentially life-saving ICD treatment is accompanied by adverse 
events such as inappropriate shocks and pocket related infections.4 As previously described, there 
is an “unknown” subgroup in the general population which could benefit for treatment and, 
therefore, should be identified. On the other hand, within the current indicated ICD population, 
the incidence of appropriate therapy is relatively low and a substantial part even dies, prior to a 
first appropriate therapy. Koller and co-workers analyzed the incidences of appropriate ICD 
therapy and all-cause mortality and defined non-benefit as death prior to appropriate therapy. The 
study demonstrated during a follow-up of 7 years, an incidence of all-cause mortality of 11% 
without prior ICD therapy.5 The current thesis assessed the risk for “non-benefit” from ICD 




population can be identified that has a 5-year cumulative incidence of non-benefit (death, prior to 
appropriate therapy) of 50%. One could conclude that these patients, although currently indicated, 
have no benefit from ICD treatment. However, its negative effects are still present in these 
patients, stressing the importance of timely identification of this population. The exclusion of 
these patients from ICD treatment should improve optimal allocation of these costly devices and 
should increase over-all benefit in the population that will benefit from treatment. Future research 
will primarily have to focus on further evaluation of the individual patient who currently has an 
indication for ICD treatment but does not benefit from ICD treatment. Patients should possibly be 
reconsidered for ICD implantation if they can be identified prior to implantation. The developed 
risk-scores in the current thesis may contribute to identifying these patients.   
 
When dr Mirowski introduced his idea to prevent sudden cardiac death, his vision immediately 
met criticism. Thirty years later criticism shifted to feasibility and effectiveness of ICD therapy. 
The patient population that is eligible for ICD treatment is growing each day, therefore future 
research should focus on the individual person to decrease the “non benefit” population. 
Secondly, new baseline parameters must be identified to improve risk stratification. And thirdly, 
technological improvements need to be developed to decrease the drawbacks of ICD therapy. The 
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De algemene introductie van dit proefschrift (Hoofdstuk 1) beschrijft hoe de behandeling met 
een Implanteerbare Cardioverter Defibrillator (ICD) de behandeling van eerste keus werd voor 
patiënten die een risico hebben op het ontwikkelen van levensbedreigende ventriculaire 
ritmestoornissen. In dit eerste hoofdstuk wordt dieper ingegaan op de technologische 
ontwikkelingen die de afgelopen jaren hebben plaatsgevonden. Daarnaast wordt er gekeken naar 
grote gerandomiseerde studies die een verschuiving teweeg hebben gebracht van secondaire naar 
primaire preventie en die hebben geleid tot de huidige internationale richtlijnen voor de 
implantatie van ICD’s. worden eventuele toekomstperspectieven, de kosteneffectiviteit van ICD’s 
en de op dit moment gebruikte methodes voor risico stratificatie behandeld.   
 Het doel van dit proefschrift is om meer inzicht te krijgen in patiënten die een risico 
hebben op het ontwikkelen van levensbedreigende ventriculaire ritmestoornissen en hiervoor met 
een ICD worden behandeld. Om deze doelstelling te bereiken is een grote patiëntenpopulatie, 
buiten de setting van gerandomiseerde studies, langdurig gevolgd. De resultaten van dit 
onderzoek zijn in twee onderdelen beschreven. Allereerst worden in deel I verschillen beschreven 
tussen patiënten die voor primaire of voor secondaire preventie een ICD hebben gekregen. 
Tevens wordt in dit deel van het proefschrift onderzocht of een ICD gewisseld moet worden als 
zich nog geen ritmestoornissen hebben voorgedaan. Deel II beschrijft de onderzoeksresultaten 






Deel I: De werkelijke noodzaak om tijdens lange-termijn follow-up een ICD als 
reserve therapie te hebben 
In Hoofdstuk 2 onderzochten we of er verschil is in de incidentie van sterfte tussen patiënten die 
een primaire of een secondaire indicatie hadden voor ICD implantatie. Tevens is er gekeken of er 
verschillen in incidentie van ICD therapie zijn tussen beide groepen. Met uitzondering van 
patiënten met een congenitale monogenetische hartziekte, werden alle patiënten met een ICD in 
het onderzoek geïncludeerd. In totaal werden 2134 patiënten met een ICD geïncludeerd. Hiervan 
hadden 1302 (61%) patiënten een primaire indicatie voor implantatie en 832 (39%) patiënten een 
secondaire indicatie. Tijdens een gemiddelde follow-up van 3.4 ± 2.8 jaar zijn 423 (20%) 
patiënten overleden. Voor de primaire preventie ICD patiënten was de  5-jarige cumulatieve 
incidentie van sterfte 25% (95% CI 21-29%), voor de secondaire preventie ICD patiënten was dit 
23% (95% CI 20-26%). Gedurende de eerste 3 jaar van de follow-up werden er groter wordende 
verschillen gezien in sterfte tussen beide groepen, echter na deze 3 jaar bleven de verschillen 
gelijk. In vergelijking met primaire preventie ICD patiënten, hebben secondaire preventie ICD 
patiënten een verhoogd risico van 74% op het krijgen van terechte therapie (HR 1.7, 95% CI 1.5-
2.0, p<0.001).  
 Deze studie laat tijdens langdurige follow-up de verschillen zien tussen primaire 
preventie en secundaire preventie ICD patiënten.  
 
Het doel van Hoofdstuk 3 is om clinici beter inzicht te geven indien zij voor het dilemma komen 
te staan om een ICD te vervangen, nadat patiënten tijdens de levensduur van de eerste ICD geen 
therapie hebben gekregen. In primaire preventie ICD patiënten kan een relatief lage incidentie 
van ventriculaire ritmestoornissen, in combinatie met een beperkte levensduur van de batterij van 
de ICD, resulteren in een grote groep patiënten die geen baat heeft gehad van de eerste ICD 






vervanging van hun ICD hebben gehad, omdat de batterij van de ICD leeg was geraakt en zij 
gedurende deze periode geen terechte ICD therapie hebben gekregen. Tijdens een gemiddelde 
follow-up van 22 ± 21 maanden na het vervangen van de ICD, hebben 136 (76%) patiënten geen 
terechte ICD therapie gekregen. Na vervanging was de 3-jarige cumulatieve incidentie van 
terechte ICD therapie 19% (95% CI 10-29%). 
 Deze studie laat zien dat het grootste deel van primaire preventie ICD patiënten 
gedurende de levensduur van de eerste ICD geen ventriculaire ritmestoornis ontwikkelt. Echter, 
een substantiële hoeveelheid van deze patiënten ontwikkelt toch nog een ventriculaire 
ritmestoornis nadat de ICD vervangen is. Vervanging van de ICD in patiënten die tijdens de 
levensduur van de eerste ICD geen terechte therapie hebben gekregen, wordt hierdoor 
gerechtvaardigd. 
 
Deel II: Verbeteringen in risicostratificatie  
In Hoofdstuk 4 hebben we gekeken naar sterftecijfers in patiënten met een primaire indicatie 
voor een ICD met ischemische of niet-ischemische hartziekten. Tevens hebben we een risicoscore 
gemaakt om de sterfte in deze groep in te kunnen schatten. In het onderzoek werden 1036 
patiënten geïncludeerd die een gemiddelde follow-up hadden van 29 ± 22 maanden. Tijdens de 
follow-up zijn 138 (13%) patiënten overleden. Ondanks het feit dat er geen verschillen in het 
risico op sterfte werden gevonden tussen patiënten met ischemische of niet-ischemische 
hartziekten, bleken de twee groepen van elkaar onderscheiden te kunnen worden door 
verschillende factoren die van invloed zijn op het risico op sterfte. Met behulp van een 
risicoscore, bestaande uit eenvoudige baseline variabelen, konden patiënten gestratificeerd 
worden in laag, middelhoog en hoog risico op overlijden. Bij de niet-ischemische patiënten was 




risico patiënten. Bij ischemische ziekten was de jaarlijkse sterfte 1.0% (95% CI 0.2-3.0%) bij een 
laag risico en 17.8% (95% CI 13.6-22.9%) bij een hoog risico. 
 Deze studie laat zien dat met behulp van een gemakkelijk toepasbare pre-implantatie 
risicoscore een sterfte risicoschatting gemaakt kan worden, toegespitst op een individuele patiënt. 
Gebruik van deze risicoscore kan clinici in de dagelijkse praktijk ondersteunen in hun beleid bij 
deze patiënten.  
 
In Hoofdstuk 5 onderzoeken we in 913 patiënten met een ICD de prevalentie van verschillende 
soorten atrium fibrilleren (AF) en de prognostische waarde hiervan op sterfte en het voorkomen 
van terechte of onterechte ICD therapie. Ten tijde van ICD implantatie had 73% van de patiënten 
geen voorgeschiedenis van AF, 9% had een voorgeschiedenis van paroxysmaal AF, 7% van 
persistent AF en 11% van permanent AF. Tijdens een gemiddelde follow-up van 27 ± 13 
maanden zijn 117 (13%) patiënten overleden, kregen 228 (25%) patiënten terechte ICD therapie 
en 139 (15%) patiënten onterechte ICD therapie. Patiënten met permanent AF hadden een meer 
dan dubbel risico op overlijden, ventriculaire aritmieën en onterechte therapie. Patiënten met 
paroxysmaal of persistent AF toonden geen significant verhoogd risico op sterfte of terechte 
therapie, echter wel een bijna drievoudig verhoogd risico op onterechte ICD schokken. 
Deze studie toont het prognostisch belang aan van deze veelvoorkomende 
ritmestoornissen bij patiënten die worden behandeld met een ICD.  
 
Hoofdstuk 6 gaat over de identificatie van patiënten die geen baat hebben bij behandeling met 
een ICD, de zogenaamde “non-benefit” groep. Dit zijn patiënten die overlijden, nog voordat zij 
een terechte ICD therapie hadden gekregen. In 900 primaire preventie ICD patiënten met een 
ischemische hartziekte, werd een risicoscore geconstrueerd op grond van een aantal verschillende 






mellitus). De risicoscore werd gebruikt om vóór ICD implantatie de kans op non-benefit in te 
schatten. Met behulp van deze risicoscore konden patiënten worden verdeeld in categorieën met 
een laag, gemiddeld of hoog risico, waarbij een hoge leeftijd de sterkste voorspeller was van non-
benefit. De 5 jarige cumulatieve incidentie voor non-benefit varieerde van 12% (95% CI 5-18%) 
in patiënten met een laag risico tot 49% (95% CI 38-60%) in hoog risico patiënten.  
Deze studie toont aan dat het risico op non-benefit voor ICD implantatie kan worden 
voorspeld, hetgeen belangrijke klinische consequenties kan hebben voor de overweging om een 
ICD te implanteren.   
 
Het doel van Hoofdstuk 7 is het evalueren van de voorspellende waarde van de QRS-T hoek op 
een ECG voor ICD therapie en mortaliteit. Hiervoor werden 412 primaire preventie patiënten met 
ischemische hartziekte en een linker ventrikel ejectie fractie (LVEF) van ≤ 40% geïncludeerd. 
Tijdens follow-up werden terechte ICD therapie en mortaliteit geregistreerd. Een survival analyse 
werd uitgevoerd waarbij 124 (30%) patiënten met een kleine (≤ 90°) QRS-T hoek voor ICD 
implantatie, werden vergeleken met patiënten met een grote (> 90°) QRS-T hoek. Tevens werden 
56 (14%) patiënten met een ruimtelijke QRS-T hoek ≤ 100°  vergeleken met patiënten met een 
ruimtelijke QRS-T hoek van > 100°. Patiënten met een QRS-T hoek > 90° hadden een meer dan 
tweevoudig vergroot risico op het optreden van terechte therapie dan patiënten met een hoek ≤ 
90° (relatieve risico 2.4, 95% CI 1.1-5.2). Een ruimtelijke QRS-T hoek van > 100° was 
geassocieerd met een gecorrigeerd relatief risico van 7.3 (95% CI 1.0-53.8%). Een ruimtelijke 
QRS-T hoek ≤ 100° had een positief voorspellende waarde van 98% (95% CI 95-100%) voor een 
klinisch beloop zonder terechte therapie. 
 Deze studie toont aan dat een eenvoudige, van ECG afgeleide parameter, een krachtige 
voorspeller kan zijn van terechte therapie bij primaire preventie ICD patiënten met een 




identificatie van patiënten bij wie, hoewel volgens de richtlijn geïndiceerd, een ICD behandeling 
heroverwogen dient te worden.  
 
In Hoofdstuk 8 hebben we een update geleverd over de incidentie van lead falen en het 
voorkomen van perforaties bij de Medtronic’s Sprint Fidelis ICD lead en de St. Jude Medical’s 
Riata ICD leads in vergelijking met een groot benchmark cohort. Hiervoor hebben we data van 
396 Sprint Fidelis leads (follow-up 3.4±1.5 jaar), 165 8-French (F) Riata leads (follow-up 4.6±2.6 
jaar) en 30 7-F Riata leads (follow-up 2.9±1.3 jaar) vergeleken met een benchmark cohort van 
1602 transveneus geïmplanteerde ICD leads (follow-up 3.4±2.7 jaar). We hebben gekeken of er 
verschil zat in de incidentie van perforaties en lead falen tussen de verschillende leads. Tijdens 
follow-up was de jaarlijkse incidentie van lead falen voor de Sprint Fidelis lead, 7-F Riata lead, 8-
F Riata lead en de benchmark cohort respectievelijk 3.54%, 2.28%, 0.78% en 1.14%. In 
vergelijking met het benchmark cohort, was de aangepaste hazard ratio voor lead falen 3.7 
(95%CI 2.4-5.7, p<0.001) voor de Sprint Fidelis lead en 4.2 (95%CI 1.0-18.0, p<0.05) voor de 7-
F Riata lead. Er was maar 1 perforatie geobserveerd (0.05%) in de Riata groep en niet een in de 
Sprint Fidelis leads. 
 Deze studie laat zien dat in vergelijking met het benchmark cohort het risico op lead falen 
significant verhoogd was voor de Sprint Fidelis en de 7-F Riata leads. Perforaties kwamen zelden 
voor. 
  
Conclusies en toekomstperspectieven 
Sinds de introductie van de ICD door dr Mirowski in 1980, hebben verschillende 
gerandomiseerde studies onbetwist aangetoond dat ICD therapie een gunstig effect heeft op 
patiënten die risico lopen op het krijgen van een levensbedreigende ventriculaire aritmie. 






over de behandeling van patiënten in de dagelijkse praktijk, buiten de setting van een klinische 
studie. In dit proefschrift is een aantal aspecten van ICD behandeling in een steeds groter 
wordende groep patiënten nader onderzocht. Ten eerste zijn tijdens een lange follow-up van 
verschillende subpopulaties van ICD patiënten (primair vs. secondair), verschillen geëvalueerd in 
de incidentie van sterfte en het optreden van terechte en onterechte therapie. Zoals verwacht 
hebben patiënten die ICD hebben ontvangen voor secondaire preventie, in vergelijking tot 
primaire preventie, een verhoogd risico op het krijgen van terechte therapie. Echter, er werden 
geen verschillen gevonden in de incidentie van sterfte tussen beide groepen. Verder werd 
aanvullende informatie gegeven over de noodzaak om een ICD te vervangen bij patiënten die een 
lange periode vanaf implantatie geen ICD therapie hebben gekregen. Ten tweede zijn in dit 
proefschrift de huidige parameters geëvalueerd die gebruikt worden voor risicostratificatie en 
daarbij werd ook gekeken naar de toegevoegde waarde van nieuwe parameters. Een baseline 
risicoscore voor sterfte werd gemaakt op basis van simpele klinische variabelen. Verder is er 
gekeken naar de invloed van atrium fibrilleren op het krijgen van ICD therapie en het optreden 
van sterfte. Om op baseline de risicostratificatie te verbeteren, is van een simpel ECG een nieuwe 
parameter afgeleid en de toegevoegde waarde hiervan op het voorspellen van ventriculaire 
aritmieën, geëvalueerd.  
 Toekomstig wetenschappelijk onderzoek zou zich primair moeten richten op manieren 
om het risico in te schatten op plotselinge hartdood in de primaire preventie groep. Door het 
verbeteren van de huidige risico stratificatie technieken kan de effectiviteit van ICD therapie 
gemaximaliseerd worden. Dit kan gedaan worden door de identificatie van 2 verschillende 
patiënten populaties: 1) patiënten die in aanmerking komen voor ICD implantatie, maar tijdens 
follow-up geen baat hebben van de behandeling; en 2) vroegtijdige identificatie van patiënten die 
overlijden aan plotselinge hartdood maar volgens de huidige richtlijnen niet in aanmerking komen 





Ondanks de vooruitgang in het voorkomen en behandelen van cardiovasculaire ziekte blijft 
plotselinge hartdood in de Westerse wereld een belangrijk maatschappelijk gezondheidsprobleem. 
In de Verenigde Staten alleen al sterven elk jaar tussen de 180.000 en 460.000 personen aan 
plotselinge hartdood, waarvan het overgrote deel buiten het ziekenhuis plaatsvindt.1 Sinds de 
introductie van de ICD hebben vele studies het gunstige effect aangetoond voor de primaire 
preventie van plotselinge hartdood. Het overlevingsvoordeel is bestudeerd in een patiënten 
populatie die volgens de huidige risicoparameters een verhoogd risico hebben op plotselinge 
hartdood. De huidige parameters die gebruikt worden om het risico op plotselinge hartdood in te 
schatten zijn: leeftijd, geslacht, roken, hoog cholesterol, lichamelijke activiteit, hypertensie, QRS 
lengte, nierfunctie en (LVEF).2 Het is daarom ook logisch dat patiënten met positieve 
risicofactoren voor het ontwikkelen van aritmieën een significant overlevingsvoordeel laten zien. 
De internationale richtlijnen, met LVEF als belangrijkste risico stratificatie methode, adviseren 
ICD therapie aan een breed scala van patiënten met hartziekte. Een groot deel van de populatie 
met een verhoogd risico op plotselinge hartdood  heeft daarom een indicatie voor ICD 
behandeling. Echter, het grootste deel van de gevallen van plotselinge hartdood treedt op in 
patiënten die niet op de hoogte zijn van hun hartziekte. Omdat dit een heel groot deel is, zal ICD 
behandeling relatief weinig invloed hebben op de incidentie van plotselinge hartdood in de 
algehele bevolking. Zonder nieuwe parameters voor de tijdige identificatie van patiënten met een 
hoog risico op plotseling hartdood, kan het overlijden van deze patiënten niet worden voorkomen. 
Om de incidentie van plotselinge hartdood significant te verminderen, zijn dus meer specifieke 








Overlijden voor het krijgen van een eerste terechte ICD therapie 
Sinds de toevoeging van primaire preventie in de internationale richtlijnen is het gunstige effect 
aangetoond dat ICD therapie heeft op patiënten die risico lopen op het krijgen van een 
levensbedreigende ventriculaire aritmie. In 2008 is het aantal ICD’s dat geïmplanteerd werd 
gestegen naar een geschatte hoeveelheid van 275.000.3 Desondanks gaat het overlevingsvoordeel 
van de behandeling met een ICD gepaard met ongunstige gebeurtenissen zoals onterechte shocks 
en pocket gerelateerde infecties.4 Zoals eerder al beschreven, bestaat er in de algehele bevolking 
een onbekende subgroep die voordeel zou kunnen hebben van behandeling met een ICD. Deze 
subgroep moet echter nog geïdentificeerd worden. Aan de andere kant is de incidentie van 
terechte therapie binnen de huidige populatie die een indicatie heeft voor ICD behandeling, 
relatief laag. Een deel overlijdt zelfs voor het krijgen van een eerste terechte therapie. Koller et al. 
analyseerden de incidentie van terechte ICD therapie en sterfte en definieerde “non-benefit” als 
overlijden voor het krijgen van een eerste terechte therapie. De studie liet tijdens een follow-up 
van 7 jaar zien dat 11% overleed vóór het krijgen van een eerste terechte therapie.5 In dit 
proefschrift is in 900 primaire preventie ICD patiënten met ischemische hartziekte het risico op 
“non-benefit” in kaart gebracht, waaruit bleek dat een groep te identificeren is die een 5-jaars 
cumulatieve incidentie van non-benefit (overlijden voor een eerste terechte therapie) heeft van 
50%. Hieruit zou geconcludeerd kunnen worden dat deze patiënten, ondanks dat zij een indicatie 
hebben voor ICD behandeling, geen baat hebben van de behandeling. Desalniettemin lopen deze 
patiënten nog wel het risico op het krijgen van onterechte shocks of pocket gerelateerde infecties, 
wat het belang benadrukt om deze onbekende subgroep tijdig te identificeren. Exclusie van deze 
patiënten voor ICD behandeling zou de indicatie stelling voor het implanteren van deze dure 
behandelingsmethode verbeteren en daarbij het algehele voordeel dat patiënten hebben, binnen de 
populatie die baat heeft van behandeling met een ICD, verhogen. Toekomstig wetenschappelijk 




dit moment geen indicatie heeft voor ICD behandeling, maar wellicht wel baat hiervan zou 
kunnen hebben. Deze patiënten zouden heroverwogen moeten worden voor ICD implantatie als 
ze voor implantatie al geïdentificeerd zouden kunnen worden. De in dit proefschrift ontwikkelde 
risico scores zouden bij de identificatie van deze patiënten kunnen helpen.  
 
Toen dr Mirowski zijn idee introduceerde over het voorkomen van plotselinge hartdood werd hier 
direct kritiek op geuit. Dertig jaar later is de kritiek verschoven naar de toepasbaarheid en 
effectiviteit van ICD therapie. Elke dag groeit de patiënten populatie die in aanmerking komt voor 
ICD behandeling. Daarom zou onderzoek wat in de toekomst nog gaat plaatsvinden zich moeten 
richten op de individuele persoon. Dit met als doel de patiënten populatie die geen baat heeft van 
ICD behandeling te verminderen. Daarnaast moeten nieuwe baseline parameters geïdentificeerd 
worden om risicostratificatie te verbeteren. Ten slotte moeten technologische ontwikkelingen 
plaatsvinden om de negatieve aspecten van ICD behandeling terug te dringen. De era van de ICD 
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De artikelen die in dit proefschrift zijn beschreven, zijn tot stand gekomen op de afdeling 
cardiologie van het Leids Universitair Medisch Centrum. Graag wil ik iedereen bedanken 
die een bijdrage heeft geleverd aan het tot stand komen van dit proefschrift. Enkele 
personen wil ik hiervoor in het bijzonder noemen. 
 
Allereerst wil ik Prof. dr. Schalij bedanken voor het vertrouwen dat hij in mij had en de 
kans die hij mij heeft gegeven om het promotietraject gedurende mijn co-schappen te 
doorlopen.  
 
Beste Jan Willem. Het is lastig om in woorden uit te drukken hoe dankbaar ik jou ben. 
Wat was het een fijne samenwerking, wat heb je me goed begeleid. Bedankt voor alles. 
 
Beste Hans. Wat fijn dat, op het moment dat Jan Willem de kliniek in ging, jij het stokje 
vanuit ‘de tuin’ overnam. Het was heel fijn om een aanspreekpunt te hebben daar. Dank 
voor alle tijd en moeite die jij in mij hebt gestoken. 
 
Lieve Pap en Mam. Wat is het fijn om ouders te hebben zoals jullie! Altijd tonen jullie 
weer de interesse, altijd zijn jullie weer benieuwd naar de vorderingen. Of dingen nu 
goed of verkeerd gaan, jullie zullen altijd achter mij blijven staan. Het is zo fijn om te 
weten dat ik altijd op jullie onvoorwaardelijke steun kan rekenen. Pap en Mam, zonder 
jullie was dit niet gelukt. 
 
Lieve Roeland en Stephanie. Zo verschillend als we zijn, zo goed dat we het kunnen 
vinden met zijn drieën. Wat fijn om een broer en zus als jullie te hebben. Dank voor alle 
interesse die jullie getoond hebben gedurende het promotietraject.  
 
Lieve Esther. Wat had ik nu zonder jou gemoeten. Altijd heb je aan mijn zijde gestaan 




momenten even nodig had. Altijd kon ik bij je komen voor advies, of juist voor gewoon 
een lach. Altijd lukte het jou weer om in mijn geslotenheid, de openheid te creëren. Jij 









De auteur van dit proefschrift werd geboren op 4 september 1983 in Utrecht. In 2002 
behaalde hij zijn VWO eindexamen aan het STEBO te Utrecht, na in 2000 geslaagd te 
zijn van zijn HAVO eindexamen aan Het Nieuwe Lyceum te Bilthoven. Na een jaar 
Domeingerichte Economie gedaan te hebben aan de Universiteit van Utrecht begon hij in 
2003 met de studie Geneeskunde aan de Universiteit van Amsterdam. Tijdens zijn studie 
is hij gestart met onderzoek te doen naar implanteerbare cardioverter defibrillatoren in het 
Leids Universitair Medisch Centrum. Tijdens zijn co-schappen is hij hiermee door 
gegaan wat heeft geleid tot een promotieonderzoek onder leiding van Prof. Dr. M.J. 
Schalij en Dr. C.J.W. Borleffs. De resultaten hiervan staan beschreven in dit proefschrift.  
 Per 1 oktober 2011 is hij begonnen als AGNIO op de cardiologie afdeling van het 
Onze Lieve Vrouwe Gasthuis. Hij heeft een relatie met Esther Koele.  
 
 
 
 
